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ABSTRACT OF DISSERTATION 
RATIONAL DESIGN, SYNTHESIS, AND CHARACTERIZATION OF NOVEL 
mPGES-1 INHIBITORS AS NEXT GENERATION OF ANTI-INFLAMMATORY 
DRUGS 
    Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are currently 
widely used as fever and pain relief in patients with arthritis and other inflammatory 
symptoms. NSAIDs effect by inhibiting cyclooxygenase-1 (COX-1) and/or 
cyclooxygenase-2 (COX-2). COX isozymes (COXs) are key enzymes in the 
biosynthesis of prostaglandin H2 (PGH2) from arachidonic acid (AA). It is now clear 
that prostaglandin E2 (PGE2), one of the downstream products of PGH2, is the main 
mediator in both chronic and acute inflammation. Microsomal prostaglandin E synthase 
(mPGES-1) is the terminal enzyme of COX-2 in the PGE2 biosynthesis pathway. 
Different from other two constitutively expressed PGE2 synthase (PGES), mPGES-2 
and cPGES, mPGES-1 is induced by pro-inflammatory stimuli and responsible for the 
production of PGE2 related to inflammation, fever and pain. For these reasons, selective 
inhibition of mPGES-1 is expected to suppress inflammation induced PGE2 production 
and, therefore, will exert anti-inflammatory activity while avoid the side effects of 
COXs inhibitors, such as gastrointestinal (GI) toxicity, and cardiovascular events.  
    A combination of computational and experimental approaches was used to 
discovery mPGES-1 inhibitors with new scaffolds. The methods used include 
molecular docking, molecular dynamic simulation, molecular mechanics-Poisson-
Boltzmann surface area (MM-PBSA) binding free energy calculation, and in vitro 
activity assays. Our large-scale structure-based virtual screening was performed on 
compounds in the NCI libraries, containing a total of ~260,000 compounds. 7 
compounds have been determined for their IC50 values (about 300 nM to 8000 nM). 
What’s more, these new inhibitors of mPGES-1 identified from virtual screening did 
not shown significant inhibition against COX isozymes even at substantially high 
concentrations (e.g. 100 µM).  
    Rational methodology for drug design and organic synthesis were applied to 
generate three series of mPGES-1 inhibitors with different scaffolds. In total, about 200 
compounds were synthesized and tested for their in vitro inhibition against human 
mPGES-1. Compounds with high potency against human mPGES-1 were further 
screened for their inhibition against mouse mPGES-1 and selectivity of human mPGES-
1 over COXs. Several compounds were identified as submicromolar inhibitors against 
human mPGES-1 with high selectivity over COXs.  
    In general, we have successfully identified a library of compounds as potent 
mPGES-1 inhibitors without significant inhibition against COXs. Structure information 
and in vitro activity evaluation data generated from the virtual screening and the library 
of compounds will be used to guide future design and synthesis of the mPGES-1 
inhibitors. 
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Chapter 1: mPGES-1 inhibitors as next generation of anti-inflammatory drugs 
1.1 PGE2 as an inflammation mediator  
Prostaglandin E2 (PGE2) is a crucial prostaglandin (PG) produced by most 
mammalian tissues and regulate in multiple biological activities under both normal 
physiological conditions and pathological processes.1 The function of PGE2 as a 
mediator for fever and pain in the inflammation has drawn most attentions.2-6 The 
biosynthesis of PGE2 is initiated from the release of arachidonic acid (AA) from the 
phospholipid membranes by phospholipase A2 (PLA2), followed by a serial of 
enzymatic transformations known as the biosynthetic pathway of PGE2.3 In the first 
step of this pathway, AA is transformed to PGH2 by COX-1 or COX-2 via an unstable 
peroxide intermediate PGG2. Next, PGH2 is converted to PGE2 by PGE synthase 
(PGES).7 PGE2 is a pro-inflammatory mediator, which can trigger fever and pain, the 
two main characteristics of inflammation.8 The PGE2 production can be induced by 
stimuli of pro-inflammation like TNF-α9, interleukin-1β (1L-1β) and 
lipopolysaccharide (LPS).10 Moreover, PGE2 is also involved in multiple types of 
cancers. It has been found to regulate crucial steps in cancer development by decreasing 
the level of apoptosis, inducing metastasis, increasing angiogenesis in the tumor and 
stimulating tumor cells proliferation.11 In spite of all these bad effects of PGE2, the 
positive aspect of constructive PGE2 cannot be ignored.12 Reported studies in PGE2-
receptor-deficient mice have also revealed the role of PGE2 in normal physiological 
functions, including suppressing of type I allergy, inducing bone formation, and 
protection against inflammatory bowel disease etc.13  
1.2 Problems of current anti-inflammatory drugs 
   Since the synthesis of Aspirin by Bayer in 1897, non-selective cyclooxygenase 
(COX)-1 and COX-2 inhibitors are the mainstays to treat inflammatory symptoms.14 
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The physiological roles of COX-1 and COX-2 are different. As a constitutively 
expressed enzyme, COX-1 catalyzes the biosynthesis of cytoprotective PGs, whereas 
COX-2 is mainly responsible for the synthesis of PGs involved in the inflammation. 
Different from COX-1, COX-2 can be induced by inflammatory stimuli.15 Aspirin, 
ibuprofen, indomethacin, and other traditional non-selective, non-steroidal anti-
inflammatory drugs (NSAIDs) function by inhibiting both COX-1 and COX-2. The 
history of COX non-specific NSAIDs is associated with an increasing risk of 
gastrointestinal side effects. To cope with the limitations of traditional NSAIDs, the 
COX-2 selective inhibitors were developed as an attempt to eliminate the 
gastrointestinal toxicity as well as achieve the anti-inflammatory benefit of NSAIDs.16 
COX-2 specific inhibitors were introduced as medications for pain and fever since 1997. 
They were so successful that almost half of the prescriptions written for NSAIDs in the 
United States in 2004 were COX-2 specific inhibitors.17 However, several COX-2 
inhibitors were taken off the pharmaceutical market of U.S. and other countries in 2004 
and 2005 due to multiple kinds of severe side effects.18 These side effects include 
increased likelihood of cardiovascular diseases, ulcers, and bleeding within the 
gastrointestinal tract. The cause for these side effects is that the PGH2 is also a precursor 
to a number of other prostaglandins, including PGI2, PGJ2 PGD2, PGF2α and TXA2. 
Among these prostaglandins, TXA2 and PGI2 are pivotal in maintaining the normal 
functions of cardiovascular system. TXA2 has a physiological function in 
vasoconstriction and pro-thrombosis. On the contrary, as the antagonist of TXA2, PGI2 
has the effect of vasodilatation and antiplatelet. The balance between TXA2 and PGI2 
is crucial to maintain the normal functions of cardiovascular system. COX-2 specific 
inhibitors like rofecoxib will disrupt this balance, consequentially resulted in disruption 
of the normal function of cardiovascular system.19-22  
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1.3 mPGES-1 as target for next generation of anti-inflammatory drugs 
   Protein mPGES-1 is a member of Membrane-Associated Proteins in Eicosanoid and 
Glutathione metabolism (MAPEG) superfamily. The MAPEG family includes six 
human proteins: microsomal glutathione transferase 1 (MGST1), MGST2, MGST3, 
MGST-like1 (MGST1-L1), 5-lipoxygenase-activating protein (FLAP) and leukotriene 
C4 (LTC4). All of the members from this family are small proteins with similar 3D 
structures and have molecular weights around 14-18 kDa.23 mPGES-1, microsomal 
PGE synthase-2 (mPGES-2), and cytosolic PGE synthase (cPGES) are three enzymes 
in human that are involved in the biosynthesis of PGE2.23 Different from mPGES-1 
which is induced by pro-inflammation, mPGES-2 and cPGES are constitutively 
expressed.24 Distinct from mPGES-1, mPGES-2 does not need glutathione (GSH) as a 
cofactor.24 mPGES-2 could couple with both COX enzymes, whereas cPGES only 
couples with COX-1. Taking together, mPGES-2 and cPGES provide the basal level of 
PGE2 (also known as constitutive PGE2) for physiological homeostasis. Constitutive 
PGE2 is not induced by inflammatory stimulus. Protein mPGES-1 is a stimuli-
dependent and pro-inflammatory enzyme. It preferentially consume PGH2 from COX-
2 as substrate to produce PGE2 related to inflammation.24 Moreover, the knockout 
studies in various animal models confirmed the involvement of mPGES-1 in diseases 
including pain hypersensitivity,25 pyresis,26 atherosclerosis,27 arthritis,28 cardiac 
ischemia,29 Alzheimer’s disease,30 and induced hydronephrosis.31 Increased mPGES-1 
expression in human is also related to inflammatory pathologies, e.g. Alzheimer’s 
disease,32 cancer,33 bowel inflammation,34 atherosclerosis,35 myositis,36 and 
osteoarthritis.37-39 Inhibition of the PGE2 production could attenuate the inflammatory 
syndromes in many diseases.40 Given the reports that mPGES-1 knockout mice have 
normal behavior and can reproduce normally, mPGES-1 specific inhibitors are expected 
to have negligible adverse side effects.41 All of these studies indicated that mPGES1, 
as the terminal synthase of biosynthesis pathway of inflammatory related PGE2, has 
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great potential to be a promising target for next generation of anti-inflammatory drugs.42  
1.4 Reported mPGES-1 inhibitors and their problems 
   Scientific research regarding mPGES-1 inhibitors are booming in recent years 
because mPGES-1 inhibitors have the potential to become the next generation of anti-
cancer and anti-inflammatory drugs.43 The efforts of identifying mPGES-1 inhibitors 
started from structural modification of the mPGES-1 substrate (PGH2).43 However, the 
stable analogues of PGH2 only showed minimal to moderate inhibition against human 
mPGES-1. LTC4 is a weak inhibitor of mPGES-1,44 but it can act as a strong, GSH-
competitive inhibitor of MGST-1.45 Some stable analogs of the substrate (PGH2), such 
as U-44069 and U-46619, show no inhibition at all, whereas another stable analog (U-
51605) exhibits weak inhibition against human mPGES-1 with IC50 around 10 μM. 
Whereas arachidonic acid and its analogs are stronger inhibitors of mPGES-1, with IC50 
as low as 300 nM.44, 46 Several COX-2 inhibitors could act as weak inhibitors of 
mPGES-1 43, celecoxib (IC50 = 22 ± 3 µM), valdecoxib (IC50 = 75 ± 19 µM) and 
lumiracoxib (IC50=33±4μM), for instance. But not all the coxibs are active against 
mPGES-1. Etoricoxib and rofecoxib failed to inhibit mPGES-1 even at very high 
concentrations (up to 200µM).47 MK-886 is a potent 5-lipoxygenase-activating protein 
(FLAP) inhibitor and a moderate human mPGES-1 inhibitor synthesized by Merck.48 
Derived from MK-886, compound 1 depicted in Figure 1.1 is a specific inhibitor of 
human mPGES-1 with selectivity of at least 100-fold over recombinant human mPGES-
2, TXA2 synthase, and FLAP.48 Andrea Wiegard et al. reported in 2012 that pyrazole 
alkalotic acid derivatives could act as inhibitors against human mPGES-1.49 The 
structural optimization made around this scaffold did not lead to obvious improvement 
in the inhibitory activity.49 Gianluigi Lauro et al. identified a group of mPGES-1 
inhibitors (Compound 15, 20 and 21 in Figure 1.1) with unprecedented chemical core 
by employing the fragment virtual screening.50 However, with IC50 values all above 1 
µM, none of these compounds was proved to be potent mPGES-1 inhibitors.50  
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   In summary, although there have been an increasing number of papers reporting 
inhibitors against human mPGES-1, most of the reported mPGES-1 inhibitors have not 
shown in vivo activities. In particular, none of human mPGES-1 inhibitors has an 
equally potent inhibitory activity against mouse mPGES-1, which has impeded the 
usage of wild-type mouse model in preclinical studies. Hence, no mPGES-1 inhibitor 
has been proven clinically useful.  
 
 
Figure 1.1 Some reported mPGES-1 inhibitors (IC50 / µM) 
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1.5 Reported animal experiments of mPGES-1 inhibitors and their problems 
 
Figure 1.2 Structure of MF63 
   MF63, 2-(6-Chloro-1H-phenanthro [9, 10-d]imidazol-2-yl)-isophthalonitrile, is a 
potent human mPGES-1 inhibitor identified by Merck Frosst Canada in 2008,51 with 
IC50 = 1.3 nM against human mPGES-1. However, MF63 did not significantly inhibit 
mouse or rat mPGES-1, which makes the animal study of MF63 in wide-type mice or 
rats impossible. To solve this problem, Xu et al. performed an animal experiment using 
KI (knock-in) mouse.51 They found that MF63 can effectively reduce the PGE2 levels 
in brains and air pouches of the knock-out/knock-in mice.51 Although the technologies 
of knock-out/knock-in mouse provide us with valuable scientific research tools and win 
the Nobel Prize in physiology or medication in 2007, these technologies have their own 
limitations.52 In particular, the loss/change of gene activities might result in alternation 
in the phenotype of the mouse52 and the emerging of the flanking allele problems.53 A 
human mPGES-1 inhibitor that can also inhibit mouse mPGES-1 will help to avoid the 
problems of the knock-out/knock-in mouse model in the preclinical studies.  
   Based on the discussion above, most currently available NSAIDs have severe side 
effects because they block the synthesis of all the PGH2 downstream prostaglandins. As 
a downstream enzyme of prostaglandins metabolism, mPGES-1 is a promising target 
for the next generation of anti-inflammatory drugs. But the development of anti-
inflammatory drugs targeting mPGES-1 is seriously hindered by the lack of mPGES-1 
specific inhibitors that can potently inhibit both human and mouse mPGES-1 enzymes. 
Therefore, the identification of dual inhibitors against both human and mouse mPGES-
1 with novel scaffolds is significant. Our ultimate aim is to develop mPGES-1 specific 
inhibitors as next generation of anti-inflammatory agents. To achieve this aim, we need 
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to identify human and mouse mPGES-1 dual inhibitors to make the preclinical studies 
more feasible.  
   In conclusion. The absence of feasible animal models could preclude the preclinical 
studies. New inhibitors that can potently inhibit both human and mouse mPGES-1 
enzymes will make preclinical studies more feasible and avoid the problems occurred 
in the knock-in/knock-out mouse models. However, so far, no potent dual inhibitor 
against both human and mouse mPGES-1 enzymes has been reported. Although several 
compounds were reported to inhibit both human and mouse mPGES-1 enzymes, their 
dual inhibition was insignificant.5, 54, 55 For these reasons, the design and synthesis of 
dual inhibitors against mouse and human mPGES-1 enzymes are significant. In this 
study, we are using a combined approach of the structure-based virtual screening, de 
novo drug design, and in vitro activity assays to identify dual inhibitors of human and 
mouse mPGES-1 enzymes with novel scaffolds.  
 
1.6 Aims of this study 
Aim 1: To identify/predict new inhibitors of human mPGES-1 by performing 
virtual screening 
   The NCI, ENZO and SPECS compound libraries were filtered by using a multistep 
virtual screening protocol. A recently available, more computationally expensive but 
more accurate method was used to estimate the binding free energy for each compound 
binding with human mPGES-1, and the compounds are ranked according the estimated 
binding free energies. The top-ranked compounds were ordered for in vitro activity 
assays in Aim 3.  
Aim 2: To design and synthesize novel inhibitors of human mPGES-1 by carrying 
out de novo design and organic synthesis 
   In order to generate potent dual inhibitors against both human and mouse mPGES-
1 enzymes, the known potent mPGES-1 inhibitors were selected as hints or leads for 
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further structural optimization through de novo design. Our de novo drug design was 
based on the 3D structures of both human and mouse mPGES-1 enzymes, particularly 
the common amino-acid residues.  
Aim 3: To examine the compounds obtained in Aims 1 and 2 for their in vitro 
inhibitory activities against human and mouse mPGES-1 enzymes by using 
competitive ELISA assays 
   The enzyme activity assays were performed to determine the inhibitory activities of 
the compounds against both human and mouse mPGES-1 enzymes. 
A combination of computational and experimental approaches were used to achieve 
our aims. The methods to be used include large-scale structure-based virtual screening, 
molecular dynamic simulation, molecular mechanics Poisson-Boltzmann surface area 
(MM-PBSA) binding free energy calculation, molecular docking, organic synthesis, 
and in vitro activity assays.  
 
1.7 Experimental sections related to the aims 
Experimental section for Aim 1: To identify/predict new inhibitors of human 
mPGES-1 by performing virtual screening 
 Our lab started to study the detailed 3D structure and mechanism of mPGES-1 and 
identify its inhibitors long before any of the X-ray crystal structures of human mPGES-
1 was reported.1, 40, 56-58 The very first crystal structure of mPGES-1 (PDB code 
3DWW), which was determined by electron crystallography, was published by Caroline 
Jegerschold et al in 2008.59 It was a low-resolution structure (3.5 Å resolution) 
representing an inactive, closed protein conformation in which the binding site is not 
accessible to substrate PGH2. Recent years were marked by a burst of crystal structures 
of mPGES-1-GSH-inhibitor complexes. In 2013, two high-resolution structures were 
published: 4AL0 with no inhibitor, 4AL1 binding with 48T (a GSH-analog acting as a 
GSH-competitive inhibitor).60 One year later, Li et al. published a 2.08 Å resolution 
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crystal structure (4BPM) with LVJ acting as a GSH non-competitive inhibitor. Also in 
2014, another crystal structure of mPGES-1 also with LVJ as the ligand (4WAB) was 
released by Weinert et al, but their study focused on the method of crystallization of 
membrane proteins rather than the structure of mPGES-1.61 Early in 2015, the crystal 
structures of mPGES-1 with four different ligands were published by Luz et al: 4DZ 
(4YL0), 4U8 (4YL1), 4U9 (4YL3) and 4DV (4YK5).62 The recent development in 
understanding of the 3D structure will make our structure-based virtual screening 
possible and more reliable.  
 
 
Figure 1.3 Cristal structure of human mPGES-1 (a) The binding pocket of mPGES-
1 with GSH and LVJ (yellow for 4BPM; pink for 3DWW represent closed state), (b) 
Structure of LVJ by Chemdraw. (c) Restore docking by autodock. (GSH is in Green, 
crystal structure of LVJ in white. docking result in cyan)  
 
   The X-ray crystal structure of mPGES-1 with a GSH non-competitive inhibitor, 
4BPM, was used for virtual screening in this study. In 4BPM, LVJ binds to the catalytic 
pocket by “hydrophobic effect” and hydrogen bonding between the hydroxyl group of 
Ser127 and the nitrogen of benzimidazole. The N (blue in Figure 1.3b) of LVJ acts as a 
hydrogen bond acceptor. The tertiary butyl of LVJ is inserted into a hydrophobic 
chamber of the binding pocket.63 Although the AutoDock Vina program64 was able to 
give a prediction of the binding conformation of the LVJ (Figure 1.3c), we failed to 
rank the LVJ amongst the best inhibitors of human mPGES-1 in a validation study, 
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indicating that the score function of the AutoDock Vina is not very accurate. Taking the 
limitation of capacity of wet experiment into consideration, it is only practical to take a 
very small fraction of the best-ranking compounds for the assays. Therefore, rather than 
ranking all the compounds based on the binding score generated by the AutoDock like 
He Shan et al. did 65, we used a more sophisticated and accurate approach to estimate 
the binding energies. Our virtual screening approach will be similar to that published 
previously.1, 66 Our virtual screening first focused on compounds available in the NCI, 
SPECS and ENZO libraries. All of the compounds will be docked into the binding 
pocket one by one using the AutoDock Vina,64 followed by energy-minimizations, 
molecular dynamics (MD) simulation, and MM-PBSA binding free energy calculations 
using the Amber 12 program suite.67, 68  
   In Chapter 2, compounds with novel scaffolds were identified to have inhibitory 
activities against human mPGES-1 enzyme. Some of these inhibitors could be used as 
lead compounds for further development of potent mPGES-1 inhibitors with novel 
scaffolds.  
Experimental section for Aim 2: To design and synthesize novel inhibitors of 
human mPGES-1 by carrying out de novo design and organic synthesis 
No X-ray crystal structure of mouse mPGES-1 is available so far. Depicted in Figure 
1.4 is a homologous model of mouse mPGES-1 generated by using human mPGES-1 
structure (4BPM) as a template. The reliability of the mouse mPGES-1 structure is 
guaranteed by the high sequence similarity (0.82)62 between mouse and human 
mPGES-1 and the high GMQE (Global Model Quality Estimation) score (0.87).69, 70 
The difference in key residues, such as #52 (which is R in human and K in mouse), #53 
(which is H in human and K in mouse) and #124 (which is P in human and R in mouse), 
may explain why some potent human mPGES-1 inhibitors like MF63 and LVJ have 
very little or no inhibition towards mouse mPGES-1.  
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Figure 1.4 The similarity of human and mouse mPGES-1. (Mouse mPGES-1 
structure was created by homologous modeling on swissmodel.expasy.org) (a) 3D 
structures of mouse mPGES-1 (cyan) and human mPGES-1 (yellow), (b) The sequence 
comparison: Mouse mPGES-1 as Target; Human mPGES-1 as 4bpm.1.A  
 
 
Figure 1.5 Proposed Binding mode of compounds with human mPGES-1 (4BPM). 
(left) mPGES-1 & v04, (right) mPGES-1 & py31.  
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Scheme 1.1 The structural modification of representative compounds from three 
serials: from compound 31 to v04 (Group 1 in Chapter 3), from compound 31 to py56 
(Group 2 in Chapter 4), from compound 1765 to zh48 (Group 3 in Chapter 5).   
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Scheme 1.2 Synthesis route for representative compounds 
Reagents and conditions: (a) DMF, K2CO3, reflux; (b) EtOH, reflux, catalytic 
amount of acetic acid; (c) DMF, K2CO3, reflux; (d) EtOH, reflux, catalytic amount 
concentrate chloride acid; (e) DMF/POCl3, 0℃-100℃, basified with K2CO3 solution; 
(f) EtOH or EtOH/water, reflux. (g) MeOH, reflux, catalytic amount of acetic acid; (h) 
DMF, K2CO3, reflux; (i) EtOH, reflux; (j) EtOH, acetic acid, reflux. 
 
Group 1 (Chapter 3) was derived from compound 31, an mPGES-1 inhibitor 
discovered by previous lab members. compound 31 has IC50 values of 3.5 μM against 
human mPGES-1. More importantly, it is an mPGES-1 specific inhibitor, which shows 
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no inhibition against COX-2. Figure 4, 5 and 6 in the corresponding reference indicate 
the proposed binding mode: as a hydrophilic group of compound 31, the hydrophilic 
carboxylic acid functional group could insert into the polar cavity of the active site 
formed by Ser127, Thr131, Arg126 and Tyr130. The hydrophobic end could insert into 
the nonpolar cavity formed by Val124, Ile32 and Ala138. The “bridge” between the 
polar “head” and nonpolar “tail”, phenyl ring, might interact by π-π stacking with the 
aromatic ring of Tyr130. Based on this binding model, in a preliminary study, we 
designed the scaffold of compounds Group 1 (Chapter3). The scaffold of these 
compounds is composited of a hydrophobic and hydrophilic end. The hexane ring on 
the hydrophobic end might have no specific effect except for “hydrophobic interaction”. 
Therefore, we replaced it with inexpensive straight-chain paraffin. The active 
methylene compounds were used to substitute the 2, 4-thiazolidinedione functional 
group as the hydrophilic group.  
Group 2 (Chapter 4) was derived from the same lead compound, compound 3 
published by our lab in 2011.1 Vilsmeier-Haach reaction was applied to synthesis of the 
hydrophobic end of compounds in another serial (Group 2).71 The reactant for the 
Vilsmeier-Haach reaction, 4-chloro-[2-[1-[4-(butoxy)phenyl]ethylidene]hydrazinyl, 
(4A-Cl-1 in scheme 1) is unstable in solid state, its powder will deteriorate within one 
day in air, so it has to be dried and dissolved in DMF upon preparation. The DMF 
solution of 4A-Cl-1 was previously cooled with ice bath. POCl3 was added dropwise to 
the reaction mixture which will be warmed to room temperature and then heated at 100 
degree Celsius for about 3-4 hours. After cooling the reaction mixture to 0 degree 
Celsius, saturated K2CO3 solution was added slowly to the mixture with vigorous 
stirring. After the solution turned from acidic to basic, the precipitate was filtered and 
washed with water several times. The pure final product was obtained by 
recrystallization of the precipitate with ethanol.  
Group 3 (Chapter 5) compounds were derived from the compound 17, which was 
published by Shan H, et al. in 2013.65   
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Group 4 was derived from Group 1 with Biginelli reaction.72 Specifically, these 
compounds containing a dihydropyrimidine as a hydrophilic group were derived from 
the scaffold skeleton of the Group 1. However, due to low potency against human 
mPGES-1, we gave up the scaffold of Group 4.  
   So far, about 200 compounds have been synthesized (58 compounds in Chapter3, 56 
compounds in Chapter4 and 91 compounds in Chapter 5). Their structures have been 
confirmed by 1H-NMR and 13C-NMR (Appendix I, table I-1, I-2 and I-3), then by 
HPMS (Appendix II, table II-1, II-2 and II-3). SAR was discussed based on the in vitro 
activity data. Possible binding modes were predicted based on the SAR and structures 
of the compounds. Various new compounds could be design and synthesized based on 
these results.73-75   
Experimental section for Aim 3: To examine the compounds obtained in aims 
1 and 2 for their in vitro inhibitory activities against human and mouse mPGES-1 
enzymes by using competitive ELISA assays 
The inhibitory activities of the compounds from virtual screening and organic 
synthesis were analyzed by in vitro cell-free activity assays using mPGES-1 enzymes 
expressed in Human Embryonic Kidney 293 (HEK293) cells.1 Crude microsomal 
human or mouse enzyme and compounds were added to 1.5 ml microfuge tubes. Tubes 
containing only mPGES-1 were used as blank control, and tubes contain only buffer 
were used as negative control. The volume of reaction mixture before reaction was 96 
μl, containing 100 mM potassium phosphate with pH 7.2, 5μl of 50 mM GSH, 1 μl of 
100 μg/ml enzyme preparation (except for negative controls), and compound in 1 μl 
DMSO. To ensure that the results were comparable, we also added 1 μl DMSO without 
compounds to the tubes of blank controls, negative controls, and positive controls. The 
lipophilic compound might form colloid-like aggregates, and in turn appear to ‘inhibit’ 
human or mouse mPGES-1 without specific interaction with the enzymes. Adding 
detergent triton-X100 (0.1%) in the reaction buffer helps to rule out the nuisance 
inhibition, which is relevant for highly lipophilic compounds.49 The substrate PGH2 
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was purchased from Cayman Chemical Inc. It is stable in -80 ℃ in acetone solution for 
six month. The substrate was diluted with DMF into a 50 μg/ml (0.14 mM) solution 
before use. During the reactions, the solution of substrate was put on dry ice all the time 
to avoid non-enzyme degradation of the substrate. The reaction mixtures containing 
enzyme and compounds were incubated at room temperature for 20 minutes. Then the 
substrate PGH2 (in DMF/Acetone solution, 4 μl) was added to initiate the reaction. After 
60 seconds, 10 μl of SnCl2 (40 mg/ml in EtOH) was added to terminate the reaction by 
reducing the remaining substrate PGH2 into PGF2α. The cross reactivity of PGF2α and 
PGD2 (Product of the non-enzymatic conversion of PGH2) with the PGE2 antibody is 
less than 0.01% (manual of Prostaglandin E2 ELISA Kit, Cayman Chemical). Therefore, 
the PGD2 and PGF2α will have little interference on the subsequent PGE2 ELISA. The 
reaction mixture was put on ice, diluted by enzyme immunoassay (EIA) buffer for the 
determination of product concentrations. In order to eliminate the interference of the 
non-enzymatic conversion of PGH2 to PGE2, the negative control tests were performed 
every time under the same conditions. Tubes for the positive controls had the same 
enzyme concentration, but a sufficiently long reaction time (longer than 20 minutes) 
was used to completely convert the substrate to PGE2. Tubes containing the same 
concentration of enzyme but without the inhibitor was used as the blank controls, which 
will also be performed every time. Mean of the PGE2 concentrations in the blank 
controls was used as the standard (100%), whereas mean of the PGE2 concentrations in 
negative controls will serve as 0%. The inhibition rate of the compound was calculated 
as a ratio, equal to the 100% minus the percentage of the remaining activity of enzyme. 
   A competitive Enzyme-linked Immunosorbent Assay (ELISA) was used to 
determine the PGE2 level quantitatively. PGE2-HRP (PGE2-horseradish peroxidase 
conjugate) and product PGE2 competed for a limited amount of PGE2 antibody. One 
day before the ELISA, the 96-well high-binding EIA microplate was coated with 
protein A (Thermo Fisher Scientific, Lot number 1469040A) in order to attach PGE2-
antibody (Sigma: P5164 or a gift from Dr. Hsin-Hsiung Tai) to the microplate. As far 
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as we know, no commercial PGE2-HRP conjugate is available. To solve this problem, 
the PGE2-HRP conjugate synthesized by Dr. Hsin-Hsiung Tai years ago, which was 
used in our initial preliminary studies in this project.76, 77 We synthesized the PGE2-
HRP conjugate according to the procedure depicted in Scheme 3.1 (with HRP from 
Sigma) for further studies in this project. As shown in Scheme 1.3, to activate the 
carboxylic group of PGE2, the DMF solution of PGE2 was incubated at room 
temperature with 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
(EDC) to activate the carboxyl group of PGE2 by converting PGE2 to PGE2-O-
acylisourea ester, which is very reactive and unstable. The PGE2 O-acylisourea ester 
then react with N-hydroxysuccinimide (NHS) to form the semi-stable PGE2-NHS ester. 
After 2 hours, the solution of horseradish peroxidase (HRP) in a buffer with 100mM 
NaHCO3 was added. The condensation reaction occulted between PGE2-NHS and the 
naked amino groups on HRP. The mixture was incubated at 4 ℃ in the dark overnight. 
G-25 column equilibrated with PBS buffer was used to purify the crude mixture. The 
whole purification process will be performed in the 4 ℃ cold room. Phenol solution 
was added to the PBS buffer as antioxidant and sanitizer. The product was tested for 
activity before lyophilization. The lyophilized PGE2-HRP conjugate should be a water 
soluble, yellow to pink powder. The powder was stored in -20 ℃ before use. According 
to our experiences, this conjugate could be kept active for many years under -20 ℃.  
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Scheme 1.3 Synthesis of PGE2-HRP conjugate  
 
In this dissertation, some of the compounds obtained from Aims 1 and 2 have been 
analyzed first at single concentrations of 10 µM and 1 µM against human mPGES-1. 
Then, the promising inhibitors have been assayed further for their IC50 values against 
human and mouse mPGES-1 enzymes. Tested IC50 curves were depicted in Figure 3.1, 
Figure 3.2, Figure 4.1, Figure 4.2 and Figure 5.1. Inhibition rates and IC50 data were 
summarized in Table 3.1, Table 4.1 and Table 5.1. The in vitro data showed that some 
of the compounds could potently inhibit human mPGES-1. In addition, some of them 
also showed potent inhibitory activity against mouse mPGES-1. These results 
demonstrated that our strategy for designing dual inhibitors against both human and 
mouse mPGES-1 enzyme is feasible.  
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Chapter 2: Selective Inhibitors of Human mPGES-1 from Structure-Based 
Computational Screening 
   Summary: Human mPGES-1 is recognized as a promising target for next generation 
of anti-inflammatory drugs. Although various mPGES-1 inhibitors have been reported 
in literatures, few have entered clinical trials and none has been proven clinically useful 
so far. There are clearly unmet demands for novel inhibitors of mPGES-1 with new 
scaffolds as the next generation anti-inflammatory therapeutics. Here, we report the 
identification of a series of new, potent and selective inhibitors of human mPGES-1 
with diverse scaffolds through combined computational and experimental studies. The 
computationally modeled binding structures of these new inhibitors with mPGES-1 
provide some interesting clues for the rational design of modified structures of the 
inhibitors to more favorably bind with mPGES-1. The main data discussed in this 
Chapter have been published.78  
2.1 Introduction  
Prostaglandin E2 (PGE2) is known as the principal pro-inflammatory prostanoid and 
plays an important role in nociception.79 The biosynthesis of PGE2 starts from 
arachidonic acid (AA) which is converted by cyclooxygenase COX-1 or COX-2 to 
prostaglandin H2 (PGH2).80 PGH2 is then converted to PGE2 by the prostaglandin E 
synthase (PGES) enzymes,81 including microsomal PGES-1 (mPGES-1), an inducible 
enzyme.82 It is known that mPGES-1 and COX-2 together83, 84 play a key role in a 
number of inflammation-related diseases.85-91 Hence, human mPGES-1 is recognized 
as a promising target for next generation of drugs to treat the inflammation-related 
diseases.92  
There are a number of non-steroidal anti-inflammatory drugs (NSAIDs) available 
for current clinical practice. The available NSAIDs inhibit COX-1 and/or COX-2.93 All 
of the available COX-1/2 inhibitors have significant adverse side effects.94 The serious 
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side effects led to withdrawal of rofecoxib (Vioxx), a selective COX-2 inhibitor. 
Therefore, people are interested in developing novel, improved anti-inflammatory 
drugs.93 Through the action of the COX inhibitors, all prostaglandins downstream of 
PGH2 cannot be produced, resulting in a variety of problems. For example, blocking 
the production of prostaglandin-I2 (PGI2) will cause significant cardiovascular 
problems.95 Inducible enzyme mPGES-1 is a more promising target for anti-
inflammatory drugs, because the mPGES-1 inhibition will only block the PGE2 
production without affecting the production of PGI2 and other prostaglandins, as 
confirmed by the gene knock-out studies.96, 97 Thus, mPGES-1 inhibitors are expected 
to retain the anti-inflammatory effect of COX inhibitors, but without the side effects 
caused by the COX inhibition.  
Although various mPGES-1 inhibitors have been reported,98-118 few have entered 
clinical trials119 and none has been proven clinically useful so far due to various 
problems of the compounds. The development of new inhibitors of mPGES-1 with 
different scaffolds as the next generation therapeutics for inflammation-related diseases 
is in high demand. Here, we report the identification of a set of new, potent and selective 
inhibitors of human mPGES-1 with various scaffolds through combined computational 
and experimental studies.  
2.2 Results and Discussion  
   Our virtual screening was based on the X-ray crystal structure (PDB ID: 4BPM)120 
of human mPGES-1 and performed on the Development Therapeutics Program (DTP) 
Release 4 compound library including ~265,000 compounds available at the National 
Cancer Institute (https://cactus.nci.nih.gov/download/nci/). The virtual screening 
procedure used to screen the compounds in the library is similar to that we previously 
used to identify small-molecule inhibitors of various protein targets.121, 122 First, the 
~265,000 compounds were screened by performing receptor-rigid docking using 
AutoDock Vina,123 leading to identification of top-100,000 compounds. Then, each of 
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the top-100,000 compounds was further optimized using a four-step procedure 
(including 2,000 steps of energy-minimization, 20 ps of molecular dynamic simulation, 
4,000 steps of energy-minimization, and then Molecular Mechanics/Poisson-
Boltzmann Surface Area (MM/PBSA) binding energy calculation using AMBER 12 
software package)124, 125 similar to the known binding estimation after refinement 
(BEAR) protocol.126, 127 The top-40 compounds were selected according to the 
ascending order of the MM/PBSA binding energies. 
   The computationally selected 40 compounds were tested for their inhibitory activity 
against human mPGES-1. Our protocol for the protein preparation and in vitro activity 
assays were the same as what we described previously.128-130 All of the 40 compounds 
were assayed first for their inhibitory activity at a concentration of 10 µM. Then, the 
most active compounds were tested further for the dose-dependent inhibition in order 
to determine their IC50 values (Table 2.1) against mPGES-1. Finally, the most promising 
compounds were also assayed for their inhibitory activities against COX-1/2 (mixed 
COX-1 and COX-2) in order to know their selectivity for mPGES-1 over COX-1/2. 
The COX-1/2 assays were performed by using the COX (ovine/human) Inhibitor 
Screening Assay Kit (Item No. 560131) ordered from Cayman Chemical Company 
(Ann Arbor, MI). According to the kit, the COX activity assay utilizes the competition 
between prostaglandins (PGs) and a PG tracer, i.e. a PG-acetylcholinesterase (PG-
AChE) conjugate, for a fixed amount of PG antiserum.131, 132  Following the assay 
using the kit, we used a mixture of COX-1 and COX-2 (denoted as COX-1/2) with 
equal amount of each enzyme. The efficacies of tested compounds were determined as % 
inhibition against the COX enzymes at the concentration of 100 µM. All of the enzyme 
activity assays were carried out in triplicate.  
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Figure 2.1 Molecular structures of the top-7 inhibitors of human mPGES-1 identified. 
(Some atoms with the numbering as superscripts are mentioned in the text for 
convenience of the discussion) 
 
   According to the activity assays, all of the computationally selected 40 compounds 
showed significant inhibitory activity against human mPGES-1, with 10% to 100% 
inhibition at a concentration of 10 µM (see Table 2.1). Molecular structures of the most 
active compounds (top-7) are depicted in Figure 2.1, and those of the remaining 
compounds are provided in Experimental Section. 
 
Table 2.1 In vitro inhibitory activities of the newly identified mPGES-1 inhibitors 
Compound %Inhibition of 
mPGES-1 at 10 µMa 
IC50 (nM) for 
mPGES-1b 
%Inhibition of 
COX-1/2 at 100 µMc 
1 99 276 ± 60 14 ±13 
2 98 284 ± 81 8 ± 20 
3 99 370 ± 79 1 ± 3 
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4 100 439 ± 84 9 ± 22 
5 94 664 ± 106 0 ± 3 
6 100 889 ± 186 37 ± 4 
7 75 917 ± 99 15 ± 2 
8 71 N.D. N.D. 
9 70 N.D. N.D. 
10 70 N.D. N.D. 
11 69 N.D. N.D. 
12 65 N.D. N.D. 
13 65 N.D. N.D. 
14 64 N.D. N.D. 
15 59 N.D. N.D. 
16 59 N.D. N.D. 
17 59 N.D. N.D. 
18 57 N.D. N.D. 
19 53 N.D. N.D. 
20 50 N.D. N.D. 
21 49 N.D. N.D. 
22 49 N.D. N.D. 
23 48 N.D. N.D. 
24 47 N.D. N.D. 
25 46 N.D. N.D. 
26 46 N.D. N.D. 
27 46 N.D. N.D. 
28 44 N.D. N.D. 
29 43 N.D. N.D. 
30 40 N.D. N.D. 
31 37 N.D. N.D. 
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32 36 N.D. N.D. 
33 32 N.D. N.D. 
34 30 N.D. N.D. 
35 29 N.D. N.D. 
36 28 N.D. N.D. 
37 26 N.D. N.D. 
38 25 N.D. N.D. 
39 15 N.D. N.D. 
40 10 N.D. N.D. 
aThe % inhibition of the compounds at a concentration of 10 µM against human 
mPGSE-1. 
bThe determined IC50 against human mPGES-1 based on the data depicted in Figure 2.2  
cThe % inhibition of the compound at a concentration of 100 µM against the COX-1/2 
(mixed COX-1 and COX-2). The enzyme mixture contained equal amounts of COX-1 
and COX-2 in terms of their enzyme activities. In this way, when a compound can 
significantly inhibit either COX-1 or COX-2, it will show the significant inhibitory 
effects against the mixed COX-1 and COX-2. 
 
 
Figure 2.2 Dose-dependent inhibition of human mPGES-1 by compounds 1 to 7: plots 
of the remaining enzyme activity vs the inhibitor concentration 
 
   Based on the activity data summarized in Table 2.1, compounds 1 to 7 at a 
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concentration of 10 M inhibited the mPGES-1 activity by at least 75%. All of these 
compounds showed nanomolar IC50 values, 276 to 917 nM. Depicted in Figure 2.2 are 
their dose-response curves. The data in Table 2.1 also revealed that all of the top-7 
compounds are highly selective for mPGES-1 over COX-1/2, as these compounds at a 
very high concentration (100 µM) showed no significant inhibition against COX-1 or 
COX-2, except for compound 6. Even for compound 6, the inhibition at 100 µM was 
only ~37%, suggesting that IC50 > 100 µM for compound 6 against COX-1/2.  
   Depicted in Figure 2.3 are the energy-minimized structures of human mPGES-1 
binding with the top-7 compounds. In general, each of these compounds binds with the 
enzyme at the substrate-binding site and fit the binding site well. Figure 2.3(A) depicts 
the overall complex of the enzyme with 1, and Figure 2.3(B) shows the structural detail 
of the binding site, showing that the main scaffold of 1 binds very well with the 
hydrophobic groove of the substrate-binding site of mPGES-1. The extended 
hydrocarbon side chain has hydrophobic interaction with the protein environment. 
   As shown in Figure 2.3(C), 2,4-dinitrobenzyl group of compound 2 stays in the 
bottom of the substrate-binding pocket of mPGES-1. The thiazole and dichlorobenzyl 
groups have the hydrophobic interaction with the protein. Compound 3 fits very well 
into the substrate-binding site of mPGES-1, as seen in Figure 2.3(D) showing a 
hydrogen bond (HB) between the NH group (including N9) and the hydroxyl oxygen 
on the side chain of residue T131. Compound 4 is huge in size, but it fits well in the 
substrate-binding site as seen in Figure 2.3(E). It is interesting to know that the binding 
site of the enzyme can accommodate a ligand as large as compound 4.  
   As shown in Figure 2.3(F), there are two HBs between the protein and compound 5. 
One HB is between N22 of 5 and the hydroxyl group of S127 side chain, and the other 
forms between and O12 of 5 and the hydroxyl group of T131 side chain. In addition, 
the benzyl rings of 5 have the hydrophobic interaction with the protein.  
   Figure 2.3(G) shows that, unlike the other compounds discussed above, compound 
6 binds with the protein on the upper part of the substrate-binding groove of mPGES-
 
26 
 
1, with a HB between N7 of 6 and the hydroxyl group of S127 side chain. As seen in 
Figure 2.3(H), compound 7 occupies the substrate-binding pocket with both of the 
phenyltriazolothiadiazole rings. N30 of compound 7 forms a HB with the hydroxyl 
group of Y130 side chain. 
 
Figure 2.3 Energy-minimized structures of human mPGES-1 binding with the 
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identified inhibitors (1 to 7 depicted in Figure 2.1): (A) and (B) Compound 1; (C) 2; 
(D) 3; (E) 4; (F) 5; (G) 6; (H) 7. The protein is shown in cyan cartoon, and the key 
residues are shown in green ball-and-stick models. The ligand is shown in orange ball-
and-stick models. Important polar interactions are shown in dashed lines.  
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Figure 2.4 Molecular structures of remaining compounds (8 to 40 listed in Table 2.1) 
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2.3 Conclusions 
   Overall, the diverse binding structures of these highly selective inhibitors with 
mPGES-1 depicted in Figure 2.3 provide some interesting clues concerning how to 
design modified structures of the inhibitors to more favorably bind with mPGES-1. 
Based on the structures in Figure 2.3, each inhibitor has some unique interaction with 
the protein. A more potent inhibitor/ligand could be designed to have more of these 
favorable protein-ligand interactions.  
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Chapter 3: Design, synthesis and characterization of 2-cyano-3-phenylacrylic 
acid derivatives as human and mouse mPGES-1 dual inhibitors 
   Summary: A series of 2-cyano-3-phenylacrylic acid derivatives were designed, 
synthesized, and evaluated as novel dual inhibitors against both human and mouse 
mPGES-1. Compounds v20 and v27 displayed IC50 values of 50 nM and 51 nM against 
human mPGES-1, respectively. The structure-activity relationship was discussed. 
Further binding mode analysis revealed that v20, as the most potent inhibitor against 
both human and mouse mPGES-1 of these 2-cyano-3-phenylacrylic acid derivatives, 
could form hydrogen bonds with Arg52 and His53 of human mPGES-1, while it will 
also form a hydrogen bond with Lys52 of mouse mPGES-1. These hydrogen bonds are 
necessary for maintaining the bioactivities of the compounds in this series. This also 
explains why compounds with carboxyl groups showed much higher potency than their 
corresponding ester derivatives. The most potent human mPGES-1 inhibitors also 
showed inhibition activities against mouse mPGES-1. This will make the pre-clinical 
experiments with wild-type mouse disease models feasible.  
3.1 Introduction  
   So far, three PGE2 synthases have been identified: mPGES-1, mPGES-2, cPGES. 
Among them, mPGES-2 and cPGES are the constitutively expressed forms of PGE2 
synthases, while mPGES-1 is an inducible membrane-bonded isoform of PGE2 
synthases.133 Since the discovery of mPGES-1 in the late 1990s, mPGES-1 has emerged 
as a strategic target for the treatment of PGE2-related acute and chronic disorders,134, 135 
for example, Hypoxia,136 arthritis,137-139 tendon disease,140 myotonic dystrophy,141 
human abdominal aortic aneurysm,142 Alzheimer’s disease,143 ischemic 
excitotoxicity,144 brain ischemic injury,144 inflammation related pain and fever.18, 145 
Interestingly, the PGE2 inhibition was reported to be able to enhance the antiviral 
immunity.146 The significance of mPGES-1 in rapidly proliferating cells such as tumor 
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cells makes it an ideal target for pharmacological intervention against cancer.147-149 
The traditional anti-inflammatory drugs (or traditional NSAIDs) reduce PGE2 level 
by blocking the COXs (COX isozymes).150 However, administration of COXs 
inhibitors for an extended period would cause numerous adverse effects, that preventing 
them from being utilized widely.151 The major concern related to the usage of traditional 
NSAIDs are renal, cardiovascular and gastrointestinal side effects.152, 153 For this reason, 
there is an urgent need to develop alternative of traditional NSAIDs as next generation 
of anti-inflammatory drugs.154 Therefore, the discovery of novel mPGES-1 inhibitors 
could be a valuable pharmacological approach while avoid the side effects of the 
traditional NSAIDs at the same time.155  
Despite a great number of potent human mPGES-1 inhibitors have been reported, 
almost all of them failed to show inhibitory activity against mouse mPGES-1, which 
made the preclinical trials in the inflammation disease model of wild-type (WT) mice 
impossible.55 The lack of mouse mPGES-1 inhibitory activity is due to the structural 
differences between the human and mouse mPGES-1.156 In this Chapter, we will present 
a new class of human and mouse mPGES-1 dual inhibitors designed starting from a 
previously identified hit, i.e. compound 3 (see Scheme 1.1).1 Some of the presented 2-
cyano-3-phenylacrylic acid derivatives were able to inhibit both human and mouse 
mPGES-1 in sub-micromole level.  
3.2 Results and Discussions  
3.2.1 Inhibitory activities against human and mouse mPGES-1 
   The experimental studies to discover mPGES-1 inhibitors in our lab were carried 
out by employing cell-free mPGES-1 activity assays protocol as described before.1 The 
reaction was initiated by exogenous addition of the substrate PGH2 in the reaction 
buffer that contains mPGES-1 and inhibitor. The direct conversion of PGE2 from PGH2 
can be determined by ELISA. The reported mPGES-1 inhibitor MK886 was used as 
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the reference compounds.157-162  
   All synthesized conjugates of 2-cyano-3-phenylacrylic acid derivatives (v01-v58) 
were evaluated for their in vitro human mPGES-1 inhibition activity in a concentration-
dependent manner. The results of inhibitory activities (IC50 values) are presented in 
Table 3.1 in nanomolar (nM) concentrations.  
 
Table 3.1 Structures and activities for 2-cyano-3-phenylacrylic acid analogs v01 ~ 
v58 
ID Structures 
IC50 (against 
human mPGES-
1)/nMa 
IC50 (against 
mouse mPGES-
1)/nM 
v01 
 
8739 ± 1169 N.D.b 
v02 
 
4817 ± 511 N.D. 
v03 
 
4749 ± 489 N.D. 
v04 
 
285 ± 40 754 ± 73 
v05 
 
135 ± 16 776 ± 217 
v06 
 
89 ± 12 716 ± 120 
v07 
 
6225± 502 N.D. 
v08 
 
5241 ± 429 N.D. 
v09 
 
3518 ± 471 N.D. 
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v10 
 
136 ± 13  1390 ± 255 
v11 
 
376 ± 31 N.D. 
v12 
 
998 ± 196 N.D. 
v13 
 
181 ± 33 1632 ± 250 
v14 
 
1008 ± 262 N.D. 
v15 
 
83 ± 14 357 ± 52 
v16 
 
1297 ± 232 N.D. 
v17 
 
1865 ± 350 N.D. 
v18 
 
74 ± 8 572 ± 83 
v19 
 
2270 ± 350 N.D. 
v20 
 
50 ± 9 270 ± 64 
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v21 
 
5633 ± 987 N.D. 
v22 
 
348 ± 100 1771 ± 241 
v23 
 
1448 ± 192 N.D. 
v24 
 
294 ± 60 N.D. 
v25 
 
242 ± 30 N.D. 
v26 
 
905 ± 177 N.D. 
v27 
 
51 ± 10 390 ± 84 
v28 
 
4374 ± 915 N.D. 
v29 
 
110 ± 29 3724 ± 683 
v30 
 
2883 ± 687 N.D. 
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v31 
 
1095 ± 212 N.D. 
v32 
 
356 ± 123 N.D. 
v33 
 
4283 ± 1404 N.D. 
v34 
 
2210 ± 450 N.D. 
v35 
 
531 ± 116 N.D. 
v36 
 
256 ± 33 7291 ± 2546 
vx 
 
>30000 N.D. 
v37 
 
541 ± 82 N.D. 
v38 
 
5414 ± 818 N.D. 
v39 
 
10811 ± 1038 N.D. 
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v40 
 
1451 ± 152 N.D. 
v41 
 
1455 ± 119 N.D. 
v42 
 
4140 ± 858 N.D. 
v43 
 
439 ± 104 N.D. 
v44 
 
2772 ± 577 N.D. 
v45 
 
456 ± 42 N.D. 
v46 
 
2084 ± 440 N.D. 
v47 
 
272 ± 56 N.D. 
v48 
 
6992 ± 1190 N.D. 
v49 
 
2383 ± 274 N.D. 
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v50 
 
112 ± 12 6733 ± 2194 
v51 
 
152 ± 26 1807 ± 584 
v52 
 
3083 ± 1203 N.D. 
v53 
 
1441 ± 666 N.D. 
v54 
 
3477 ± 1428 N.D. 
v55 
 
1504 ± 213 N.D. 
v56 
 
1636 ± 283 N.D. 
v57 
 
17796 ± 5680 N.D. 
v58 
 
98 ± 19 1814 ± 540 
aData are expressed as means ± SD of single determinations obtained in triplicate. 
bN.D. = not determined 
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Figure 3.1 Human mPGES-1 inhibitory activity of 2-cyano-3-phenylacrylic acid 
derivatives. The inhibitor concentration is given in log scale.  
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Figure 3.2 Mouse mPGES-1 inhibitory activity of screened inhibitors 2-cyano-3-
phenylacrylic acid derivatives. The inhibitor concentration is given in log scale. 
 
3.2.2 SAR study  
 
Scheme 3.1. Compound 3,1 the starting compound for 2-cyano-3-phenylacrylic acid 
derivatives  
 
   Compound 31 is the lead compound for the design and synthesis of 2-cyano-3-
phenylacrylic acid derivatives as mPGES-1 inhibitors. It is a human mPGES-1 inhibitor 
identified by a former member in our lab with IC50 value of 3.5 μM against human 
mPGES-1.1 In order to get compounds with more potency, derivatives of 2-cyano-3-
phenylacrylic acid were then explored (Table 3.1). In the in vitro study, Compounds 
v06 (89nM), v15 (83nM), v18 (74nM) and v50 (112nM) showed similar high activities 
against human mPGES-1, which suggest that the substitute on the phenyl group (X 
position in Scheme 3.2) probably had no apparent effect on the inhibitory activity. The 
esters have much lower activities than their corresponding acid. A case in point is that 
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v26 (905 nM) is a less potent inhibitor against human mPGES-1 than its corresponding 
acid v27 (51 nM).  
 
Scheme 3.2 The scaffold of 2-cyano-3-phenylacrylic acid derivatives  
 
   Table 3.1 highlighted the SAR for the 2-cyano-3-phenylacrylic acid derivatives 
moiety. These studies revealed that the inhibition activities of the 2-cyano-3-
phenylacrylic acid derivatives were very dependent on the nature and position of the 
substituents present on the R position and Y positions. Introducing a nitro group, cyano 
group or carboxylic group to the Y positions will strengthen the in vitro activity while 
an ester group (COOEt) or CONH2 group to the Y positions will weaken the in vitro 
activity, which implies that EWGs (electron-withdrawing groups) or electronegative 
groups are required at the Y positions for the activities. The above discussion indicates 
that for the 2-cyano-3-phenylacrylic acid scaffold, the electronegative substitutions for 
Y and the hydrophobic groups for R position are key factors for potent human and 
mouse mPGES-1 inhibitory activity.  
3.2.3 Off target tests 
   In inflammatory responses, cyclooxygenases (COXs) are expressed in resident and 
infiltrating cells of the inflammatory locus and involved in the biosynthesis of 
prostaglandins (PGs).163 COXs plays a significant role in the biosynthesis of PGs from 
arachidonic acid (AA).164 COXs inhibition could result in various side effects, for 
example, the COX-2 specific inhibitors are responsible for the dramatic risks in 
cardiovascular toxicity.165 For this reason, high selectivity will be important to the 
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success of a development candidate of next generation anti-inflammatory drugs, 
precluding the usage of a basic moiety mPGES-1 selective inhibitor design. mPGES-1 
selective inhibitors will have the effect of anti-inflammation while avoiding the side 
effects of the traditional NSAIDs.16 In our study, only inhibitors with IC50 values below 
100 nM were assayed for their COXs inhibitions.  
   The ‘COX (ovine / human) Inhibitor Screening Assay Kit’ (Cayman Chemical, Item 
No. 560131)131, 132 was used for this assay. Briefly, the compounds were incubated with 
purified COXs for 10 min at 37℃ on the water bath. The concentration for all the 
inhibitors was 100 µM. The reactions were initiated with the addition of AA. The 
reaction mixture was quickly vortexed and incubated for exactly two minutes at 37℃ 
(water bath), and then the reaction was stopped by adding saturated stannous chloride 
solution. The tubes were then removed from the water bath and vortexed, incubated for 
five minutes at room temperature. The reaction mixture should become cloudy at this 
time. Then the cloudy solution was diluted three thousand times. The level of 
prostaglandins (PGs) in the diluted solutions were then assayed by a 96-well plate, 
which was provided by this commercial kit. The inhibition rates were listed in Table 
3.2.  
 
 Table 3.2 Inhibition of the most potent mPGES-1 inhibitors against COXs 
Name 
%/Inhibition against 
COXs at 100 µM 
v06 28.6 ± 2.8 
v15 9.4 ± 5.4 
v18 2.0 ± 3.0 
v20 59.8 ± 1.2 
v27 44.1 ± 0.9 
v58 0.2 ± 1.7 
 
   The six tested compounds did not show significant inhibition against COXs at 100 
µM. This result indicates that these six compounds have high selectivity on mPGES-1 
over COXs. Based on the structural similarity of this compound set, we expect that 
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these 2-cyano-3-phenylacrylic acid derivatives are not significant inhibitors of COXs.  
 
3.2.4 Configuration analysis  
   To confirm that of the 2-cyano-3-phenylacrylic acid derivatives will adopt trans/E 
configuration rather than cis/Z configuration, four compounds, v01, v37, v38 and v44, 
with four different function groups were chosen to be optimized with Gaussian09.166 
The geometries of all compounds in this dissertation were fully optimized with the 
density functional theory (DFT) employing the Beck’s three-parameter hybrid 
exchange functional and the Lee-Yang-Parr correlation function (B3LYP) with the basis 
set of 6-31+G*. To evaluate the zero-point vibration energy and to confirm that the 
optimized structures were really global minima on the potential energy surface, the 
harmonic vibration-al were calculated at the same level of B3LYP/6-31+G* in water 
with SMD as solvation model. The SMD167 model was developed more recently 
compared with other self-consistent reaction field (SCRF) such as IEFPCM168 and 
CPCM,169, 170. A highlight for SMD is that it took more than two thousand experimental 
solvation free energies as training set for better predictions.167, 171, 172 For these reasons, 
the SMD is believed to be a more accurate method than other commonly applied 
solation models. Therefore, we choose SMD as the solvation model in our study.  
 
Table 3.3 Theoretical Relative Gibbs Free Energies of Z configuration to E 
configuration (in water) 
Name  
Theoretical Relative Gibbs Free Energies (ΔGZ-E  
kcal/mole) of Z configuration in water* 
v01  2.9 
v37  5.6 
v38  4.3 
v44  7.6 
ΔGZ-E=G(Z configuration) - G(E configuration) 
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   In this study, we set the Gibbs free energy of the E configuration as zero point. 
Based on the above calculation, the E configurations are more stable than the 
corresponding Z configuration for the calculated compounds. Therefore, all of these 2-
cyano-3-phenylacrylic acid derivatives should adapt the E configuration.  
3.2.5 Binding mode analysis 
   In order to study the inhibition mechanism of this series of derivatives, we applied 
molecular docking to predict the binding mode of compounds v20 with human and 
mouse mPGES-1.  
 
Figure 3.3 predicted binding mode of v20 with human (left) and mouse (right) 
mPGES-1  
 
   The hydrogen bonds between the carboxyl group of v20 and the residues on the loop 
(R52 and H53 for human mPGES-1; K52 and R53 for mouse mPGES-1) are of great 
importance for the inhibitory activates against human and mouse mPGES-1. 
Replacement of the carboxyl group with other groups such as esters will result in 
significant loss of inhibitory activity. Flexibility of this compound makes it possible to 
bind with both human and mouse mPGES-1.  
 
53 
 
3.3 Conclusions  
   In conclusion, a series of 2-cyano-3-phenylacrylic acid derivatives have been 
identified as human mPGES-1 inhibitors. Amongst them, several compounds were 
identified as dual inhibitors against both human and mouse mPGES-1. Six compounds 
showed IC50 less than 100 nM. The most potent human mPGES-1 inhibitors are v20 
and v27, with IC50 values of 51 and 50 nM against human mPGES-1 respectively. 
What’s more, with IC50 values both below 400 nM, they are also potent mouse mPGES-
1 inhibitors. Their activities against the mouse mPGES-1 will avoid the possible 
troubles of the KI/KO mouse and make the future animal study with mouse disease 
models feasible. The SAR studies and binding mode investigation demonstrate that for 
this 2-cyano-3-phenylacrylic acid scaffold, the cyano substitution and carboxylic 
substitution for Y position, the bigger hydrophobic groups are favorable for improving 
in vitro inhibitory activities. On the other hand, the ester structure and the amide group 
at Y position and the phenyl group for R are not favorable for high activities. The 
presented SAR indicates that further decoration of the phenyl group in the middle may 
provide us more potent dual inhibitors against human and mouse.  
3.4 Experimental section 
3.4.1 Chemistry  
   1H NMR and 13C NMR spectra were recorded on 400 or 500 MHz spectrometers 
using tetramethylsilane (TMS) as the internal standard. Chemical shifts are reported in 
parts per million (ppm) downfield from TMS. The spin multiplicities are described as 
s (singlet), d (doublet), dd (double doublet), t (triplet), q (quartet), or m (multiplet). 
Coupling constants are calculated and reported in Hertz (Hz). Analytical thin layer 
chromatography (TLC) was performed on commercial available precoated silica gel 
60- F254 (0.5 mm) glass plates. Visualization of the spots on TLC plates was achieved 
either by exposure to iodine vapor or UV light. Column chromatography was performed 
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using silica gel of 100–200 mesh. Moisture sensitive reactions were carried out using 
standard syringe septum Techniques and under inert atmosphere of nitrogen. All 
solvents and reagents were used without further purification. All evaporation of 
solvents was carried out under reduced pressure on rotary evaporator below 70 °C. The 
names of all the compounds given in the experimental section were taken from the 
ChemDraw.173  
   The high performance mass spectrometer (HPMS) used in this study was AB 
SCIEX triple TOFTM-5600 (AB SCIEX,Redwood City, CA, U.S.A.). All the 
compounds were run in positive ion and high sensitivity mode under the conditions and 
settings as described before.174 The positive ions were generated in the source using 
nitrogen as the source gases. Source gas temperature was set at 500 ◦C. Ion spray voltage 
floating (ISVF) was set to 3000 V. The Analyst® TF 1.7 software package (AB SCIEX, 
Redwood City, CA, U.S.A.) was used for instrument control and HPMS data acquisition. 
The Multi-Quant TM3.0 software (AB SCIEX, Redwood City, CA, U.S.A.) was used 
for quantitative analysis.174 
3.4.2 General method for the synthesis of target compounds 
  The reaction of substituted hydroxyl aldehydes and different halogenated 
hydrocarbons give the alkylated aldehydes, which were further converted to their 
corresponding target compounds (v01 ~ v58). The synthesis of the starting materials 
and representative target compounds is illustrated in Scheme 3.3.  
 
Scheme 3.3 Reagents and conditions for the synthesis of v18  
(a) DMF, K2CO3, 80℃, 80% ~ 90%; (b) Malononitrile, acetic acid, EtOH, reflux, 40% 
~ 80%. 
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3.4.3 Structural information of representative target compounds  
 
 
Figure 3.4 1H NMR and 13C NMR for representative compound v18 
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   The 1H NMR and 13C NMR spectrum of representative compound v18 in CDCl3 is 
shown in Figure 3.4. In this figure, all 1H NMR peaks and 1H-1H coupling are well 
resolute, and could be assigned to the molecular structure. c-H: δ 7.67 (d, J = 2.1 Hz, 
1H), e-H: 7.60 (s, 1H), d-H: 7.50 (d, J = 2.1 Hz, 1H), a-H: 4.16 (t, J = 6.6 Hz, 2H), b-
H: 3.91 (s, 3H), a-H: 1.98 – 1.69 (m, 2H), a-H: 1.58 – 1.41 (m, 2H), a-H: 1.39 – 1.16 
(m, 8H), a-H: 0.89 (t, J = 8.7, 5.0 Hz, 3H).  
   Structures, Names, 1H NMR and 13C NMR data for all of the 58 2-cyano-3-
phenylacrylic acid derivatives were summarized in Appendix I, Table I-1. Calculated 
and found molecular weights of protonated target compounds were summarized in 
Appendix II, Table II-1.
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Chapter 4: Design and synthesis 1, 3-Diphenylpyrazole derivatives as human 
mPGES-1 inhibitors 
   Summary: Human mPGES-1 has emerged as prospective target in the exploration 
of next-generation of anti-inflammatory drugs, as specific mPGES-1 inhibitors are 
expected to discriminatively suppress the production of induced PGE2 without blocking 
the normal biosynthesis of other prostanoids including homeostatic PGE2. Therefore, 
this therapeutic approach is believed to be able to reduce the adverse effects associated 
with the application of traditional non-steroidal anti-inflammatory drugs (tNSAIDs) 
and selective COX-2 inhibitors (coxibs). Identified from structure-based virtue 
screening, the lead was used in the design of novel inhibitors based on the binding mode 
with the enzyme structure. We recently developed a class of benzylidenebarbituric acid 
derivatives as inhibitors against both human and mouse mPGES-1. In order to further 
identify potent inhibitors with novel chemical scaffolds, as continued efforts, we 
thereby report the synthesis and in vitro evaluation of 5-((1,3-diphenyl-1H-pyrazol-4-
yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-trione (py20) and related 1, 3-
Diphenylpyrazole derivatives as potent mPGES-1 inhibitors. 
4.1 Introduction 
   In the eicosanoid pathway, arachidonic acid (AA) is converted to prostaglandin H2 
(PGH2) by the action of cyclooxygenases (COX-1 and COX-2).175-177 PGH2 serves as 
common precursor for various biologically active prostanoids, such as thromboxane A2 
(TXA2), PGD2, PGI2, PGF2α and PGE2, depending on different distal synthases.19, 43, 178 
Among these prostanoids, PGE2, well recognized as an important inflammatory 
mediator, is isomerized from PGH2 catalyzed by three distinct synthases (mPGES-1, 
mPGES-2 and cPGES).177, 179-181 Unlike the other two constitutively expressed enzymes, 
the expression of mPGES-1, similar to that of COX-2, is highly inducible in response 
to pro-inflammatory stimuli.177, 182 
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   As two generations of anti-inflammatory drugs, tNSAIDs and coxibs represent the 
mainstream for the treatment of inflammation-related symptoms by either non-
selectively inhibiting COX isozymes or selectively inhibiting COX-2, respectively.165, 
183, 184 However, both of these two categories of drugs inhibit the biosynthesis of all 
downstream prostanoids and so their application is associated with considerable 
adverse effects.185-189 tNSAIDs trigger gastrointestinal (GI) ulceration because of the 
interference with COX-1-derived protective function in GI tract.16, 153, 190, 191 Coxibs, as 
a class of specific COX-2 inhibitors,192 on the other hand, break the internal balance of 
vasodilative PGI2 and vasoconstrictive TXA2 and thus result in cardiovascular risk.193-
195 Since PGE2 is the major inducible PG in inflammation, inhibiting mPGES-1 is 
recognized as a prospective candidate therapeutic approach in the development of the 
next generation of anti-inflammatory drugs.26, 28, 43, 196 
   We recently developed a series of benzylidenebarbituric acid derivatives as 
inhibitors against both human and mouse mPGES-1 enzymes. As we carefully analyzed 
the binding mode of these compounds with human mPGES-1 crystal structure (PDB: 
4BPM)120 it is observed that there is still substantial unoccupied area in the active 
pocket. We decided to introduce pyrazole core not only because of its existence in many 
bioactive molecules, but also its versatility for multi-functionalization.71, 197-202 Thus, a 
series of 5-( (1,3-diphenyl-1H-pyrazol-4-yl) methylene) pyrimidine-2,4,6(1H,3H,5H) -
trione derivatives and other structurally related compounds were designed and 
synthesized. A number of these compounds were active against both human and mouse 
mPGES-1 enzymes and selective over COX isozymes. 
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4.2 Results and Discussions 
4.2.1 Lead compound 
 
Scheme 4.1 From Compound 31 to py56, structural similarity between the lead 
compound and the most potent human mPGES-1 inhibitor in this Chapter.  
 
   Compound 3 is a human mPGES-1 inhibitor identified by Zhan et al. in 2011 
through structure-based virtual screening.1 With IC50 of 3.5 µM, it is a moderate human 
mPGES-1 inhibitor.  
4.2.2 Inhibitory activity against human and mouse mPGES-1 
   The synthesized compounds were tested by employing cell-free mPGES-1 activity 
assays as described in Chapter 1. 
 
Table 4.1 Structures and activities for 1, 3-Diphenylpyrazoles analogs py01-py56 
ID 
(code) 
Structures of Pyrazole 
compounds.  
IC50/nM or 
(%Inhibition)c 
Against human 
mPGES-1a 
IC50/nM or 
(%Inhibition) 
Against mouse 
mPGES-1 
py01 
(10a) 
 
282 ± 83 (12.0 ± 2.9) 
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py02 
 
296 ± 68 (20.6 ± 4.2) 
py03 
 
190 ± 68 (30.3 ± 3.2) 
py04 
(11a) 
 
83 ± 30 (47.9 ± 5.2) 
py05 
 
209 ± 42 (45.8 ± 8.5) 
py06 
 
90 ± 15 (29.2 ± 2.3) 
py07 
 
197 ± 32 (4.3 ± 20.8) 
py08 
 
97 ± 15 (4.6 ± 21.6) 
py09 
 
806 ± 162 (15.9 ± 22.8) 
py10 
(10b) 
 
(51.0 ± 10.0) N.D.b 
py11 
 
(53.9 ± 6.8) N.D. 
 
61 
 
py12 
 
(77.1 ± 3.9) N.D. 
py13 
(11b) 
 
(63.7 ± 1.4) N.D. 
py14 
 
(54.9 ± 1.7) N.D. 
py15 
 
(52.2 ± 4.7) N.D. 
py16 
 
(48.8 ± 3.6) N.D. 
py17 
 
(47.3 ± 7.9) N.D. 
py18 
 
(39.0 ± 6.6) N.D. 
py19 
(4b) 
 
265 ± 96 (27.6 ± 4.7) 
py20 
(8) 
 
212 ± 34 2573 ± 628 
 
62 
 
py21 
(4c) 
 
169 ± 41 357 ± 75 
py22 
(4d) 
 
285 ± 65 (45.6 ± 2.2) 
py23 
 
323 ± 52 2157 ± 188 
py24 
(4e) 
 
361 ± 51 740 ± 108 
py25 
 
375 ± 127 (20.8 ± 4.2) 
py26 
(4f) 
 
294 ± 83 (23.9 ± 9.8) 
py27 
(4g) 
 
598 ± 142 (-4.4 ± 9.2) 
py28 
(4a) 
 
337 ± 85 (18.4 ± 9.2) 
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py29 
(5b) 
 
95 ± 16 (46.4 ± 8.7) 
py30 
 
92 ± 20 1264 ± 138 
py31 
(5c) 
 
56 ± 10 445 ± 83 
py32 
(5d) 
 
52 ± 15 1769 ± 1158 
py33 
 
113 ± 23 1126 ± 131 
py34 
(5e) 
 
92 ± 19 316 ± 30 
py35 
 
188 ± 31 (49.8 ± 14.5) 
py36 
(5f) 
 
93 ± 14 (55.6 ± 25.4) 
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py37 
(5g) 
 
797 ± 160 (24.5 ± 5.0) 
py38 
(5a) 
 
561 ± 192  (2.6 ± 5.9) 
py39 
 
(30.3 ± 6.4) N.D. 
py40 
 
(29.1 ± 1.5) N.D. 
py41 
 
(15.5 ± 7.2) N.D. 
py42 
 
(6.8 ± 2.5) N.D. 
py43 
 
(-1.9 ± 2.5) N.D. 
py44 
 
(-2.2 ± 1.1) N.D. 
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py45 
(10c) 
 
(31.9 ± 21.2) N.D. 
py46 
(11c) 
 
(14.1 ± 14.1) N.D. 
py47 
 
(23.5  ± 6.8) N.D. 
py48 
 
(37.1  ± 2.3) N.D. 
py49 
(10d) 
 
1593 ± 557 N.D. 
py50 
(11d) 
 
1394 ± 303 N.D. 
py51 
 
4932 ± 1161 N.D. 
py52 
 
1036 ± 293 N.D. 
py53 
(11e) 
 
1729 ± 666 N.D. 
py54 
 
1878 ± 426 N.D. 
 
66 
 
py55 
 
41 ± 5 (35.4 ± 3.4) 
py56 
(11f) 
 
36 ± 11 (37.0 ± 16.1) 
aData are expressed as means ± SD of single determinations obtained in triplicate. 
bn.d. = not detected. cThe % inhibition of the compound at a concentration of 10 µM 
against mPGES-1 (IC50 values were determined if the compounds caused in 70 % or 
higher inhibition). 
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Figure 4.1 Human mPGES-1 inhibitory activity of 1, 3-Diphenylpyrazoles derivatives. 
The inhibitor concentration is given in log scale. 
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Figure 4.2 Mouse mPGES-1 inhibitory activity of 1, 3-Diphenylpyrazoles derivatives.  
The inhibitor concentration is given in log scale. 
 
4.2.3 Off target testing  
   The selectivity of newly obtained 1,3-Diphenylpyrazoles derivatives on human 
mPGES-1 over COXs was tested for ten most potent compounds that showed IC50 
values below 100 nM. The assay was carried out by employing the same protocol as 
described in section 3.2.3.  
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Table 4.2 Inhibition of the most potent mPGES-1 inhibitors against COXs 
Name 
%/Inhibition at 100 
µM 
py04 18.9 ± 0.1 
py08 17.2 ± 0.0 
py29 1.0 ± 4.5 
py30 16.0 ± 4.1 
py31 4.4 ± 8.6 
py32 0.7 ± 5.4 
py34 -2.0 ± 0.2 
py36 11.1 ± 16.3 
py55 6.8 ± 6.4 
py56 1.2 ± 28.6 
 
   The six compounds tested show no significant inhibition against COXs at 100 µM. 
This result indicates that these six compounds have high selectivity on mPGES-1 over 
COXs. Based on the structural similarity of this compound set, we could expect that the 
presented 1, 3-Diphenylpyrazoles derivatives will show no significant inhibition 
against COXs.  
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4.2.4 SAR study  
 
Scheme 4.2 The scaffold of 1, 3-Diphenylpyrazoles derivatives.  
 
   Table 4.3 and 4.4 highlights the SAR for the 1, 3-Diphenylpyrazoles derivatives. 
These studies reveal that the inhibition of the 1, 3-Diphenylpyrazoles derivatives was 
totally depend on the nature and position of the substituents present on the X position 
and Z position in Scheme 4.2.  
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 Table 4.3 SAR on the substitution of central pyrazole ring 
 
Compound R2 X Y 
IC50
a for human 
mPGES-1 (µM) 
IC50 for mouse 
mPGES-1 (µM) 
(4a) py28 H Cl O 0.337±0.085 n.d.b (18.4±9.2)c 
(4b) py19 EtO Cl O 0.265±0.096 2.57±0.63 
(4c) py21 nC4H9O Cl O 0.169±0.041 0.357±0.075 
(4d) py22 nC6H13O Cl O 0.285±0.065 n.d. (45.6±2.2) 
(4e) py24 nC8H17O Cl O 0.361±0.051 0.740±0.108 
(4f) py26 nC10H21O Cl O 0.294±0.083 n.d. (23.9±9.8) 
(4g) py27 BnO Cl O 0.598±0.142 n.d. (-4.4±9.2) 
(5a) py38 H Cl S 0.561±0.192 n.d. (2.6±5.9) 
(5b) py29 EtO Cl S 0.095±0.016 n.d. (46.4±8.7) 
(5c) py31 nC4H9O Cl S 0.056±0.010 0.445±0.083 
(5d) py32 nC6H13O Cl S 0.052±0.015 1.77±1.16 
(5e) py34 nC8H17O Cl S 0.092±0.019 0.316±0.030 
(5f) py36 nC10H21O Cl S 0.093±0.014 n.d. (55.6±25.4) 
(5g) py37 BnO Cl S 0.797±0.160 n.d. (24.5±5.0) 
(8) py20 nC4H9O H O 0.212±0.034 2.57±0.63 
(9) py30 nC4H9O H S 0.092±0.020 1.26±0.14 
aData are expressed as means ± SD of single determinations obtained in triplicate. bn.d. 
= not detected. cThe % inhibition of the compound at a concentration of 10 µM against 
mPGES-1 (IC50 values were determined if the compounds caused in 70 % or higher 
inhibition). 
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   The length and shape of the aliphatic side chain were investigated in the SAR study. 
We fixed the substituent at pyrazole-1-position as 4-chlorophenyl and variate the side 
chain on 3-phenyl. From the in vitro data shown in Table 4.3, it was observed as 
compared to that without an side chain (1a), compounds with linear side chains (4b~4f 
and 5b~5f) generally more potent against human mPGES-1, while benzyl substitution 
(4g and 5g), however, did not improve the inhibitory efficacy. Linear side chains with 
4 or 6 carbons yielded compounds with highest potency, while longer side chains, such 
as octyl or decyl did not give a better inhibition. Another fact was that compounds with 
2-thiobarbituric acid “heads” were generally more potent as compared to those with 
barbituric acid ones. We also changed the substituent in pyrazole-1-position from 4-
chlorophenyl to phenyl group. In this case, 1c was used as starting substituted 
acetophenone. Followed the similar protocol as shown in Scheme 2, 8 and 9 were 
prepared. These compounds (8 and 9) were slightly less potent than those with 4-
chlorophenyl substituent (4c and 5c, respectively).  
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Table 4.4 SAR on the polar head 
 
Compound R 
 
IC50
a for human 
mPGES-1 (µM) 
IC50 for mouse 
mPGES-1 (µM) 
(10a) py01 Et 
 
0.283±0.083 n.d.b (12.0±2.9) c 
(10b) py10 Et 
 
n.d. (51±10) n.d. 
(10c) py45 Et 
 
n.d. (32±21) n.d. 
(10d) py49 Et 
 
1.59±0.56 n.d. 
(10e) py52 Et 
 
1.04±0.29 n.d. 
(10f) py55 Et 
 
0.041±0.005 n.d. (35±3.4) 
(11a) py04 nBu 
 
0.083±0.034 n.d. (48±5.2) 
(11b) py13 nBu 
 
n.d. (64±1.4) n.d. 
(11c) py46 nBu 
 
n.d. (14±14) n.d. 
(11d) py50 nBu 
 
1.39±0.30 n.d. 
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(11e) py53 nBu 
 
1.73±0.67 n.d. (35±3.4) 
(11f) py56 nBu 
 
0.036±0.011 n.d. (37±16) 
aData are expressed as means ± SD of single determinations obtained in triplicate. bn.d. 
= not detected. cThe % inhibition of the compound at a concentration of 10 µM against 
mPGES-1 (IC50 values were determined if the compounds caused in 70 % or higher 
inhibition). 
 
   With these (2-thio)barbituric acid derivatives in hand, we broadened the structural 
abundance with pyrazole core by coupling 1H-pyrazole-4-carbaldehyes (3b and 3d) 
with various activated methylene compounds such as malononitrile, 2- 2-cyano-3-
phenylacrylic acid and 2,4-thiazolidinedione. As shown in Table 4.4, compounds with 
malononitrile and 2-cyanoacetamide “heads” (10b, 10c and 11b, 11c) were not active 
against human mPGES-1 while that with 2- 2-cyano-3-phenylacrylic acid (10a and 11a) 
showed submicromolar potency. It was noted that the compounds 10f and 11f, obtained 
from the coupling of 3b and 3d with 2,4-thiazolidinedione acetic acid, were capable of 
inhibiting human mPGES-1 with low nanomolar potency (IC50 = 0.041 ± 0.005 µM and 
0.036 ± 0.011 µM, respectively).  
For the in vitro evaluation of these compounds, we conducted the first single 
concentration screening at 10 µM against human mPGES-1. Compounds caused 
significant inhibition ( > 70 %) were tested for IC50 values against human mPGES-1. 
These compounds were than screened against the mouse enzyme at a concentration of 
10 µM. Similarly, those caused an inhibition greater than 70 % was determined IC50 
values against mouse mPGES-1. Generally, the inhibitory efficacy against mouse 
mPGES-1 of these compounds were lower as compared to the human enzyme. Yet some 
of the compounds did inhibit both enzymes with submicromolar potency, such as 5c 
(IC50 = 0.056 ± 0.010 µM and 0.445 ± 0.083 µM for human and mouse mPGES-1, 
respectively) and 5e (IC50 = 0.092 ± 0.019 µM and 0.316 ± 0.030 µM, respectively)  
The inhibition against COX isozymes was also evaluated for some of the most potent 
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compounds (IC50 < 0.100 µM against human mPGES-1). As shown in Table 3, at a 
concentration as high as 100 µM, compounds 5b~5f, 9, 10f, 11a and 11f resulted in 
inhibition less than 20 %.  
4.2.5 Configuration analysis 
   To confirm the possible ‘E’ ‘Z’ configuration of the 2-cyano-3-phenylacrylic Acid 
derivatives, py01, py45, py47, py49, py52, and py55 were optimized by Gaussian09 
at the DFT B3LYP 6-31G* level.166 SMD167 model was applied in this study as 
described in Section 3.2.4.  
 
Table 4.5 Theoretical Relative Gibbs Free Energies of Z configuration to E 
configuration (in water)  
Name  
Theoretical Relative Gibbs Free Energies (ΔG*， 
kcal/mole) of Z configuration in water* 
py01  2.4 
py45  4.5 
py47  4.6 
py49  -1.3 
py52  -5.7 
py55  -4.8 
*ΔG = G(Z configuration) - G(E configuration) 
 
 
Scheme 4.3 The intro-molecular steric hindrance of py55 (E configuration)  
 
   The E configuration is thermodynamically unstable due to the intro-molecular steric 
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hindrance (Scheme 4.3). This is confirmed by the calculated Gibbs free energy 
difference between E and Z configuration. We can speculate that all the compounds 
containing thiazolidine-2, 4-dione group (py49 ~ 51, py55 and py56) or 2-
thioxothiazolidin-4-one group (py52 ~ py54) will adapt Z configuration, otherwise, will 
adapt E configuration.  
4.2.6 Binding mode analysis 
   To further study the inhibition mechanism of this series of derivatives, the binding 
modes of compounds py56 and py32 were simulated by molecular docking. The 
predicted binding mode are depicted in Figure 4.1 
 
 
Figure 4.3 predicted binding modes of py56 (left) and py32 (right) with human 
mPGES-1 
 
   In both binding modes the substituted pyrazole scaffold are located at the same place 
of the enzyme, with the 4-hexoxyphenyl group located in the shallow hydrophobic 
groove and the chlorophenyl group inserted into the upper pocket of mPGES-1. 
Including the chlorine on the 1H-phenyl ring slightly improves the activity since it will 
have higher occupancy of the pocket. Introduction of a bulkier hydrophobic side chain 
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on the 3-phenyl ring also mildly increases its activity, although insignificant. 
Substitution of either 2-thioxothiazolidin-4-one or the 3-carboxymethylthiazolidine-
2,4-dione groups are crucial for the activities. The carboxylic oxygen on py56 can build 
hydrogen bonds with the NH groups on the R52 side chain while the carbonyl oxygen 
on py32 can also build hydrogen bonds with the same set of atoms on R52. Any 
modification on the carboxyl group of py56 will lower its activity. Swapping the sulfur 
with an oxygen on py32 also lowers the activity since it will have a smaller size and 
less non-polar contacts with nearby residues. Introduction of methyl groups on py32 
will totally eliminate the activity of the compounds due to huge steric hindrance. 
4.3 Conclusions 
   There is growing interest in identifying mPGES-1 inhibitors as new therapeutic 
agents. Herein we report the design, synthesis, and characterization a novel class of 1, 
3-Diphenylpyrazole derivatives as human mPGES-1 inhibitors. In particular, 
compound (Z)-2-(5-((1-(4-chlorophenyl)-3-(4-(hexyloxy) phenyl)-1H-pyrazol-4-yl) 
methylene)-2, 4-dioxothiazolidin-3-yl) acetic acid, (py56) showed the most significant 
inhibition against human mPGES-1 with IC50 of 36 nM. Moreover, some of the 
compounds that showed inhibitions against human mPGES-1 also show inhibition 
against mouse mPGES-1, which indicates that further optimization based on the SAR 
could result in more potent duel inhibitors of human and mouse mPGES-1. 
4.4 Experimental section 
4.4.1 General method for the synthesis of target compounds 
   The reaction of substituted hydroxyl aldehydes and different halogenated 
hydrocarbons give the alkylating aldehydes, which were further converted to their 
corresponding target compounds (py01 ~ py56). The synthesis of the starting materials 
and representative target compounds is illustrated in Scheme 4.4, Scheme 4.5 and 
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Scheme 4.6. 
   The synthesis of this series of compounds followed a straightforward multi-step 
protocol, as shown in Scheme 1. 4-Alkyloxyacetophenone (1b ~ 1g), obtained from the 
reaction of 4-hydroxyacetophenone and alkyl bromide, or acetophenone (1a) was 
condensed with 4-chlorophenylhydrazine in reflux ethanol containing 5 % glacial acetic 
acid. The ethylidene hydrazine (2a ~ 2g) was formed as precipitate at room temperature 
and filtered off. The next step was Vilsmeier-Haack-Arnold ring closing formylation, 
by treating 2a ~ 2g with POCl3/DMF. The produced 1H-pyrazole-4-carbaldehyde 
intermediate (3a ~ 3g) was coupled with barbituric acid or 2-thiobarbituric acid in 
refluxing EtOH/H2O (4:1) to afford the final product (4a ~ 4g or 5a ~ 5g). 
 
 
Scheme 4.4 Reagents and conditions: (a) K2CO3 (2.00 equiv.), DMF, 80 oC; (b) 5 % 
glacial AcOH in EtOH, reflux; (c) POCl3 (4.00 equiv.), DMF, 0 oC~60 oC; (d) 
EtOH/H2O (4:1, v/v), reflux.  
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Scheme 4.5 Reagents and conditions: (a) 5 % glacial AcOH in EtOH, reflux; (b) POCl3 
(4.00 equiv.), DMF, 0 oC~60 oC; (c) EtOH/H2O (4:1, v/v), reflux. 
 
 
Scheme 4.6 Reagents and conditions: (a) NH4OAc (2.00 equiv.), glacial AcOH, 100 oC. 
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4.4.2 Structural information for target compounds 
 
 
Figure 4.4 1H NMR and 13C NMR for representative compound py56, with d6-DMSO 
as solvent  
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   The 1H NMR and 13C NMR spectrum of representative compound py56 in d6-
DMSO for group 2 is shown in Figure 4.4. All 1H NMR peaks and 1H-1H coupling are 
well resolved, and can be assigned to the molecular structure of py56. 1H NMR (400 
MHz, d6-DMSO) δ p-H: 8.78 (s, 1H), o-H: 7.63 (s, 1H), h, g, i, j, l, m, n-H:8.06 (d, J = 
8.8 Hz, 2H), 7.69 (s, 1H), 7.61 – 7.47 (m, 3H), 7.09 (d, J = 8.7 Hz, 2H), q-H: 4.36 (s, 
2H), f-H: 4.03 (t, J = 6.5 Hz, 2H), e-H: 1.82 – 1.64 (m, 2H), b, c, d-H: 1.48 – 1.28 (m, 
6H), a-H: 0.88 (t, J = 6.8 Hz, 3H).  
   Structures, Names, 1H NMR and 13C NMR data for 1, 3-Diphenylpyrazole 
derivatives were listed in Table I-2 of Appendix I. Calculated and measured molecular 
weights of the protonated target compounds (MH)+ were summarized in Appendix II, 
Table II-2. 
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Chapter 5: Design, synthesis and characterization of hydrazide derivatives as a 
novel class of selective human mPGES-1 inhibitors  
   Summary: In this Chapter, we present the design, synthesis and biological 
evaluation of a series of hydrazide compounds as human mPGES-1 inhibitors. Some of 
these derivatives exhibited excellent in vitro mPGES-1 inhibition efficacy. Selectivity 
test revealed that the most potent compounds have high selectivity of human mPGES-
1 over COX-1/2 enzymes. Among the 91 compounds reported in this chapter, six 
compounds, including the most potent human mPGES-1 inhibitor within this 
dissertation, showed IC50 values below 100 nM.  
5.1 Introduction  
   For treating inflammation-associated symptoms, traditional NSAIDs and COX-2 
selective coxibs have been developed as two generation of anti-inflammatory drugs.203 
However, as both of them shut down the production of all prostanoid downstream of 
PGH2, their clinical application are associated with considerable adverse effects.16, 189 
In recent two decades, the inhibition of mPGES-1 was suggested as candidate 
therapeutic approach in the development of next generation of anti-inflammatory 
drugs.204, 205 The mPGES-1 inhibitors block the production of only inflammation related 
PGE2 and thus do not render the side effects resulted from the interference of other 
prostanoids.198, 199 Therefore, great efforts have been depicted in the development and 
identification of novel mPGES-1 inhibitors. The hydrazide appears as pharmacophore 
various pharmaceutical agents such as antibiotics.206, 207  
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Scheme 5.1 The two reported hydrazide derivatives as human mPGES-1 inhibitors65  
 
   The hydrazides were first associated with human mPGES-1 in 2013.65 By using the 
active conformation structural model and virtual screening, Shan H, et al. successfully 
identified two hydrazide derivatives (compound 12 and compound 17 in Figure 5.1) 
with IC50 value at submicromolar level (Figure 5.1).65 However, due to the limited 
chemical abundance of hydrazide derivatives reported, we decided to prepare more 
compounds in light of the structure of compound 17. As selective inhibition of 
mPGES-1 by small-molecule inhibitors has been proved to be clinically validated as a 
rational and a safer alternative strategy of traditional NSAIDs for inflammations.208, 209 
Novel hydrazide derivatives capable of inhibiting mPGES-1 are synthesized and 
evaluated.  
5.2 Results and Discussions  
5.2.1 Inhibition against human mPGES-1  
  All newly synthesized derivatives of hydrazide were evaluated for their human 
mPGES-1 inhibitions in a concentration-dependent manner. The inhibitory potency 
(%/inhibition at 10 µM and 1 µM) are presented in Table 5.1. Ten of the compounds 
which showed inhibition greater than 80% at 1 µM were further determined for their 
IC50 values against human mPGES-1. Compound zh86 in Table 5.1 is the same 
compound with the compound 17 reported by Shan H et al.65 Its IC50 determined by 
our in vitro mPGES-1 bioassay kit (170 ± 51 nM) is in the same order of magnitude 
with the reported IC50 value of 0.10 ± 0.01 µM.65 However, the solubility of this 
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compound was very poor due to the amount of hydrophobic Benzyl groups. To get 
novel hydrazides with higher potency inhibition and possibly better aqueous solubility, 
we synthesize a serious of structurally related compounds. Six of the compounds were 
determined with IC50 against human mPGES-1 lower than 100 nM. Particularly, zh89 
was the most potent human mPGES-1 inhibitor, with an IC50 value of 27 nM.  
 
5.2.2 Inhibition against mouse mPGES-1  
  The top 10 most potent human mPGES-1 inhibitors were further screened for their 
inhibition against mouse mPGES-1 at the concentration of 10 µM. Unfortunately, most 
of them failed to inhibit the mouse enzyme at 10 µM (Table 5.1). However, zh48 was 
capable of inhibiting the mouse enzyme by 58.5% at 10 µM.  
 
Table 5.1 Structures and activities against human or mouse mPGES-1 for 
hydrazine analogs zh01-zh91 
ID Structures 
%/ 
Inhibition 
against 
human 
mPGES-1 
at 10µM 
%/ 
Inhibition 
against 
human 
mPGES-1 
at 1µM 
IC50 against 
human 
mPGES-1 / nMa 
(%/ Inhibition 
against mouse 
mPGES-1 at 
10µM) 
zh01 
 
5.3 ± 4.4 -1.0 ± 6.1 N.D.b 
zh02 
 
24.6 ± 18.7 11.4 ± 4.2 N.D. 
zh03 
 
98.4 ± 0.6 82.0 ± 1.5 
46.5 ± 14.9 
(15.1 ± 41.1) 
zh04 
 
83.2 ± 2.2 42.5 ± 13.0 N.D. 
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zh05 
 
91.0 ± 1.6 71.8 ± 3.4 N.D. 
zh06 
 
88.7 ± 1.7 66.0 ± 1.6 N.D. 
zh07 
 
35.2 ± 20.7 2.4 ± 2.7 N.D. 
zh08 
 
15.6 ± 3.4 4.2 ± 13.0 N.D. 
zh09 
 
57.6 ± 3.6 20.6 ±21.6 N.D. 
zh10 
 
7.3 ± 4.1 5.5 ± 1.5 N.D. 
zh11 
 
87.3 ± 0.8 68.5 ± 7.0 N.D. 
zh12 
 
59.0 ± 1.9 21.8 ± 5.7 N.D. 
zh13 
 
63.9 ± 14.9 6.7 ± 10.8 N.D. 
zh14 
 
65.0 ± 12.5 19.0 ± 3.7 N.D. 
zh15 
 
71.1 ± 3.7 50.3 ± 3.6 N.D. 
zh16 
 
63.2 ± 11.9 38.9 ± 0.6 N.D. 
zh17 
 
16.1 ± 6.6 10.4 ± 14.8 N.D. 
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zh18 
 
60.2 ± 15.7 19.1 ± 17.5 N.D. 
zh19 
 
27.5 ± 9.3 1.5 ± 0.5 N.D. 
zh20 
 
71.2 ± 7.0 44.9 ± 9.1 N.D. 
zh21 
 
71.6 ± 5.8 33.4 ± 7.4 N.D. 
zh22 
 
47.9 ± 9.4 8.3 ± 15.6 N.D. 
zh23 
 
44.3 ± 14.7 3.8 ± 8.5 N.D. 
zh24 
 
31.8 ± 15.8 2.9 ± 10.3 N.D. 
zh25 
 
3.9 ± 9.6 5.8 ± 8.8 N.D. 
zh26 
 
34.8 ± 4.6 10.0 ± 5.9 N.D. 
zh27 
 
71.1 ± 6.7 55.6 ± 12.3 N.D. 
zh28 
 
24.6 ± 9.2 6.0 ± 20.8 N.D. 
zh29 
 
80.7 ± 9.5 47.6 ± 15.0 N.D. 
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zh30 
 
28.6 ± 4.4 1.8 ± 1.1 N.D. 
zh31 
 
24.0 ± 6.4 -1.4 ± 13.9 N.D. 
zh32 
 
45.1 ± 3.0 5.2 ± 24.6 N.D. 
zh33 
 
33.4 ± 4.0 9.6 ± 10.2 N.D. 
zh34 
 
8.3 ± 15.9 5.2 ± 6.4 N.D. 
zh35 
 
81.5 ± 8.6 57.3 ± 16.3 N.D. 
zh36 
 
92.9 ± 11.7 52.6 ± 8.0 N.D. 
zh37 
 
92.9 ± 1.1 81.6 ± 5.8 
120.3 ± 35.2 
(0 ± 27.9) 
zh38 
 
58.7 ± 3.8 7.4 ± 7.6 N.D. 
zh39 
 
53.7 ± 2.2 5.6 ± 7.5 N.D. 
zh40 
 
70.8 ± 10.4 51.0 ± 7.2 N.D. 
zh41 
 
59.0 ± 0.4 27.6 ± 8.0 N.D. 
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zh42 
 
96.1 ± 2.3 87.3 ± 3.0 
37.5 ± 8.8 
(21.6 ± 25.4) 
zh43 
 
81.7 ± 1.4 67.4 ± 6.6 N.D. 
zh44 
 
79.7 ± 4.1 67.0 ± 8.9 N.D. 
zh45 
 
5.5 ± 9.4 4.3 ± 2.6 N.D. 
zh46 
 
85.8 ± 8.7 72.7 ± 5.1 N.D. 
zh47 
 
82.4 ± 5.1 59.1 ± 5.3 N.D. 
zh48 
 
92.5 ± 6.2 81.2 ± 14.1 
30.8 ± 7.0 
(58.5 ± 4.4) 
zh49 
 
85.9 ± 3.9 80.0 ± 5.2 
183.9 ± 54.1 
(30.4 ± 16.9) 
zh50 
 
54.8 ± 5.6 13.3 ± 12.5 N.D. 
zh51 
 
53.6 ± 3.2 7.0 ± 13.1 N.D. 
zh52 
 
102.0 ± 0.9 72.8 ± 1.2 N.D. 
zh53 
 
85.4 ± 9.7 61.1 ± 5.6 N.D. 
zh54 
 
96.6 ± 2.6 75.0 ± 5.1 N.D. 
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zh55 
 
83.8 ± 7.7 68.2 ± 5.8 N.D. 
zh56 
 
100.5 ± 2.6 66.0 ± 3.8 N.D. 
zh57 
 
11.6 ± 10.4 -1.0 ± 4.9 N.D. 
zh58 
 
94.7 ± 9.5 66.9 ± 7.2 N.D. 
zh59 
 
60.1 ± 6.6 34.7 ± 14.7 N.D. 
zh60 
 
84.4 ± 4.7 81.1 ± 5.3 
314.4 ± 92.3 
(46.0 ± 6.7) 
zh61 
 
93.1 ± 7.9 61.6 ± 17.4 N.D. 
zh62 
 
52.1 ± 23.6 23.0 ± 9.3 N.D. 
zh63 
 
93.1 ± 6.4 61.3 ± 6.2 N.D. 
zh64 
 
27.5 ± 20.9 9.2 ± 43.0 N.D. 
zh65 
 
91.2 ± 10.9 77.0 ± 5.6 N.D. 
zh66 
 
46.2 ± 15.2 16.8 ± 23.3 N.D. 
 
93 
 
zh67 
 
59.6 ± 13.7 9.8 ± 11.9 N.D. 
zh68 
 
23.4 ± 10.1 3.5 ± 5.0 N.D. 
zh69 
 
76.3 ± 1.3 20.3 ± 5.0 N.D. 
zh70 
 
102.1 ± 0.5 78.3 ± 15.5 N.D. 
zh71 
 
86.0 ± 13.5 77.4 ± 4.5 N.D. 
zh72 
 
98.3 ± 11.8 72.1 ± 7.1 N.D. 
zh73 
 
29.5 ± 7.7 13.7 ± 4.8 N.D. 
zh74 
 
52.6 ± 7.2 17.9 ± 4.2 N.D. 
zh75 
 
11.8 ± 7.8 2.4 ± 17.6 N.D. 
zh76 
 
86.1 ± 14.7 67.1 ± 11.6 N.D. 
zh77 
 
76.9 ± 10.2 52.2 ± 10.7 N.D. 
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zh78 
 
86.0 ± 2.3 70.4 ± 5.7 N.D. 
zh79 
 
67.4 ± 11.0 51.9 ± 8.7 N.D. 
zh80 
 
59.4 ± 22.9 53.6 ± 12.7 N.D. 
zh81 
 
85.6 ± 11.5 47.6 ± 9.8 N.D. 
zh82 
 
65.1 ± 19.0 39.4 ± 42.3 N.D. 
zh83 
 
32.1 ± 23.3 11.3 ± 14.6 N.D. 
zh84 
 
22.6 ± 5.4 8.7 ± 18.0 N.D. 
zh85 
 
14.4 ± 21.3 48.2 ± 3.1 N.D. 
zh86 
 
92.4 ± 3.4 75.3 ± 2.7 
169.9 ± 50.6 
(30.0 ± 4.5) 
zh87 
 
96.5 ± 1.5 83.5 ± 1.8 
29.0 ± 5.8 
(1.1 ± 31.9) 
zh88 
 
89.6 ± 5.8 80.6 ± 1.3 
60.9 ± 10.1 
(25.1 ± 23.3) 
 
95 
 
zh89 
 
98.3 ± 5.9 95.8 ± 4.2 
27.3 ± 10.1 
(45.2 ± 16.2) 
zh90 
 
67.9 ± 2.6 20.4 ± 14.0 N.D. 
zh91 
 
55.3 ± 3.6 4.3 ± 3.9 N.D. 
aIC50 value was determined from single determination by triplet. 
bN.D.: Not determined. 
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Figure 5.1 In vitro activity of the hydrazide derivatives against human mPGES-1. The 
inhibitor concentration is given in log scale. 
 
5.2.3 Structure-activity relationships (SAR) of hydrazide derivatives 
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Scheme 5.2 Scaffold for the hydrazide derivatives 
 
   The above results revealed that the inhibition against human mPGES-1 was highly 
related to the function groups at the Y positions. Hydrogen bond acceptors such as 
carboxyl group or nitro group are required for the maintenance of inhibitory potency. 
Replacement of the nitro group or carboxyl group by other hydrophobic groups such as 
halogens, methoxide groups will lead to significant decreased or even caused 
completely loss in potency. We also changed the size and shape of the hydrophobic 
groups at the R position. The compound with short hydrophobic group (such as zh25 ~ 
zh32) and the benzyl group (such as zh59 ~ zh81) slightly impaired the inhibitory 
efficacy as compared to larger hydrophobic substitutions. On the other hand, the 
compounds that with three benzyl groups (zh87 ~ zh89) are generally more potent 
human mPGES-1 inhibitors, despite their low solubility. Indicating that the compounds 
with multiple benzyl groups (zh86 ~ zh91) might adapt a different binding mold with 
the rest of the compounds (zh01 ~ zh85) of the hydrazide derivatives, as will be 
discussed later in the computational part.  
5.2.4 Selectivity of human mPGES-1 over COXs 
   Inhibition at 100 µM was tested for six most potent compounds (IC50 value below 
100nM) in order to investigate their cross-reactivity against COXs. The assay was 
carried out following the same protocol as described in Chapter 3, section 3.2.3. 
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Table 5.2 Inhibitions of potent mPGES-1 inhibitors against COXs 
Name %/Inhibition at 100 μM 
zh03 -1.7 ± 5.5 
zh42 3.8 ± 3.0 
zh48 5.9 ± 3.1 
zh87* 25.2 ± 5.7 
zh88* 25.8 ± 0.0 
zh89* 18.9 ± 9.8 
*Solubility of these compounds are lower than 100 µM. Data in this table are tested at 
their highest aqueous solubility.  
 
   None of these potent mPGES-1 inhibitors showed significant potent inhibition 
against COXs, even at very high concentrations (e.g. 100 µM) or at their highest 
solubility in the reaction buffer. The six tested hydrazide derivatives are highly selective 
for mPGES-1 over COXs, as these compounds at a very high concentration (100 µM) 
showed no significant inhibition against COX-1 or COX-2.  
5.2.5 Configuration analysis  
   To provide theoretical support that ‘E’ configuration will be more stable than the ‘Z’ 
configuration for this group of compounds, zh01 was optimized by Gaussian09 at the 
DFT B3LYP 6-31+G* level,166 and SMD167 model was applied in this study as 
described in Section 3.2.4.  
   The calculated Gibbs free energy of Z configuration zh01 is higher than the 
corresponding E configuration by 1.7 kcal/mole. None of the ninety-one hydrazide 
derivatives could have intro-molecular steric hindrance like the E configuration of py49 
~ py56 in Chapter 4. For this reason, the hydrazide derivatives should all adopt the 
energetic-favorable, less steric hindrance E configuration.  
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5.2.6 Molecular modeling study 
  Molecular docking studies were performed on the two selected compounds zh89 and 
zh42 to authenticate the obtained experimental in vitro activities against human 
mPGES-1. The selected compounds were successfully docked in the PGH2 binding site 
of mPGES-1 (PDB ID: 4bpm) using the Autodock Vina program.210  
 
Figure 5.2 Predicted binding mode of compound zh89 (left) and zh42 (right) with 
human mPGES-1  
 
  The predicted binding models for compounds zh89 and zh42 is depicted in Figure 
5.2. Compounds zh89 and zh42 adopted similar binding modes. The hydrogen bonds 
with the human mPGES-1 “upper reign” (R52 and H53) are crucial for the maintenance 
of the inhibitory efficacy. The binding mode could explain why hydrogen bond acceptor 
is required to maintain the activities. The hydrophobic side chains of both compounds 
locate in the hydrophobic pocket formed by Y110, I32, etc. Compound zh89, with three 
bulky benzyl groups, tends to interact R52 with hydrogen bonding while zh42 interacts 
with H53 due to the smaller size of linear side chain. Furthermore, the binding mode 
could also explain why compounds in this chapter shown relatively poor inhibitory 
activity against the mouse mPGES-1, as in mouse mPGES-1 structure, K52 and R53 
are the mutant amino acid residue instead of R52 and H53 in the human enzyme. These 
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mutants interference the hydrogen bonding between the compounds with the 
corresponding pocket in the mouse enzyme structure. 
5.3 Conclusions 
   In conclusion, based on the SAR and binding model with the crystal structure of 
human mPGES-1 (PDB: 4BPM), novel selective human mPGES-1 inhibitors with 
hydrazide scaffold have been designed, synthesized, and biologically evaluated 
inhibition rates (%) were determined against human mPGES-1 in a cell-free assay. In 
total, we synthesized 91 hydrazide derivatives. The most potent compounds against 
human mPGES-1 (Inhibition > 80% at 1µM) were further determined for their IC50 
values. For the six compounds with IC50 values less than 100nM, inhibition against 
mouse mPGES-1 and the cross-reactivity against COXs were also investigated. 
Compound zh89 showed IC50 value of 27 ± 10 nM against human mPGES-1. 
Furthermore, the top-six active compounds showed no significant inhibition against 
COXs. Overall, the results presented in this chapter suggest that hydrazide derivatives 
represent promising human mPGES-1 selective inhibitors for the development of next 
generation of NSAIDs.  
5.4 Experimental Section  
5.4.1 Materials and Methods  
   Following the same methods as described before, 1H NMR and 13C NMR spectra 
were recorded on 400 spectrometers using tetramethylsilane (TMS) as the internal 
standard. The HPMS protocol used in previous chapters was also successfully applied 
in this chapter.  
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5.4.2 Organic synthesis 
 
Scheme 5.3 Synthesis of compounds zh48 Reagents and conditions:  
(a) MeOH, reflux, catalytic amount of acetic acid;  
(b) DMF, K2CO3, 80℃; (d) EtOH, reflux; (e) EtOH, acetic acid, reflux.  
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5.4.3 Structural information for target compounds  
 
 
Figure 5.3 1H NMR and 13C NMR for representative compound zh48 
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   The 1H NMR and 13C NMR spectrum of representative compound zh48 in d6-
DMSO is shown in Figure 5.3. All 1H NMR peaks and 1H-1H coupling are well 
resolved, and can be assigned to the molecular structure of zh48. 1H NMR (400 MHz, 
d6-DMSO) δ l-H: 13.10 (s, 1H), g-H: 11.89 (s, 1H), f-H: 8.49 (s, 1H), b, c, d, e, f, I j, 
k-H: 8.01 (d, J = 8.0 Hz, 2H), 7.91 (d, J = 8.5 Hz, 2H), 7.83 (d, J = 7.5 Hz, 2H), 7.05 
(d, J = 8.7 Hz, 2H), a-H: 4.03 (t, J = 6.4 Hz, 2H), 1.86 – 1.59 (m, 2H), 1.48 – 1.36 (m, 
2H), 1.36 – 1.16 (m, 8H), 0.85 (t, J = 6.6 Hz, 3H). 
   Structures, Names, 1H NMR and 13C NMR data for hydrazide derivatives are listed 
in Table I-3 of Appendix I. Calculated and measured molecular weights of the 
protonated targets compounds (MH)+ were summarized in Appendix II, Table II-3.  
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Chapter 6: Concluding Remarks and Future Plan 
6.1 Summary of the major conclusions obtained from this investigation 
Inhibition of mPGES-1 has emerged as an attractive approach for the treatment of 
a number of inflammation related diseases. Although many reported compounds 
exhibited submicromolar inhibitory concentrations against human mPGES-1, none of 
them have been proved clinically useful. This fact forced the scientific community to 
develop new mPGES-1 inhibitors with different scaffolds.  
In summary, we have identified new inhibitors of human mPGES-1 by applying 
structure-based virtual screening. We have designed and evaluated three classes of 
human mPGES-1 inhibitors with different chemical scaffolds. Some of the synthesized 
compounds also showed potent inhibitory efficacy against mouse mPGES-1, which 
potently facilitate the preclinical animal studies with mouse disease models.  
1) Novel human mPGES-1 inhibitors were identified by applying a virtual 
screening protocol and then in vitro assay. The protocol is a combination of flexible 
docking, large-scale structure-based virtual screening, energy minimization, molecular 
dynamics (MD) simulation, and MM/PBSA binding free energy calculation.  
2) We have successfully developed about two hundred of compounds as candidates 
for human mPGES-1 inhibitors. They can be divided into three groups based on the 
scaffolds. Six compounds of Group 1 (Chapter 3), while ten compounds of Group 2 
(Chapter 4) and six compounds of Group3 (Chapter 5) showed efficacy inhibitory 
activity against human mPGES-1 with IC50 values below 100nM.  
3) In addition to the human mPGES-1, we also determined the inhibition against 
mouse mPGES-1 for the most potent human mPGES-1 inhibitors 
4) Cross-activity assays with COXs demonstrated that the most potent mPGES-1 
inhibitors did not cause significant inhibition against COXs.  
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6.2 Future plan concerning rational design of mPGES-1 inhibitors as next 
generation of anti-inflammatory drugs 
1) To further identify mPGES-1 inhibitors with novel scaffolds as new leads by 
employing our virtual screening protocol to screen compounds in other libraries such 
as the SPECS and ZINC libraries.  
2) To further characterize the detailed pharmacological and toxicological profiles 
of the identified mPGES-1 inhibitors, such as the in vivo effectiveness, selectivity of 
mPGES-1 over other enzymes in the AA metabolism pathway, and 
pharmacokinetic/pharmacodynamic (PK/PD) profiles.  
3) The most potent mPGES-1 inhibitors derived from structural optimization will 
be used as drug candidates for appropriate animal studies.   
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Appendix I. Structures, Names, 1H NMR and 13C NMR data for synthesized compounds 
Table I-1. Structures, Names, 1H NMR and 13C NMR data for 2-cyano-3-phenylacrylic acid derivatives (Chapter 3) 
V Structure. 1H NMR 13C NMR 
v01  
(E)-ethyl 2-cyano-3-(4-(hexyloxy)-3-
nitrophenyl)acrylate 
1H NMR (400 MHz, cdcl3) δ 8.42 – 8.21 (m, 2H), 
8.14 (s, 1H), 7.19 (d, J = 9.6 Hz, 1H), 4.36 (q, J = 
7.1 Hz, 2H), 4.19 (t, J = 6.4 Hz, 2H), 1.90 – 1.76 
(m, 2H), 1.53 – 1.42 (m, 2H), 1.42 – 1.27 (m, 
7H), 0.89 (t, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 162.06, 
155.60, 151.70, 139.77, 135.45, 129.04, 
123.48, 115.22, 114.90, 102.78, 70.35, 
62.85, 31.28, 28.62, 25.35, 22.44, 14.10, 
13.91. 
v02  
(E)-ethyl 2-cyano-3-(4-(heptyloxy)-
3-nitrophenyl)acrylate 
1H NMR (400 MHz, cdcl3) δ 8.43 – 8.25 (m, 2H), 
8.15 (s, 1H), 7.23 – 7.08 (m, 1H), 4.57 – 4.31 (m, 
2H), 4.20 (t, J = 6.4 Hz, 2H), 2.01 – 1.72 (m, 2H), 
1.55 – 1.10 (m, 11H), 0.89 (t, J = 6.5 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 162.07, 
155.62, 151.70, 139.80, 135.36, 129.13, 
123.49, 115.23, 114.88, 102.82, 70.36, 
62.87, 31.61, 28.81, 28.68, 25.66, 22.52, 
14.11, 14.01. 
v03  
(E)-ethyl 2-cyano-3-(3-nitro-4-
(octyloxy)phenyl)acrylate 
1H NMR (400 MHz, cdcl3) δ 8.51 – 8.25 (m, 2H), 
8.15 (s, 1H), 7.19 (d, J = 8.7 Hz, 1H), 4.38 (q, J = 
7.2 Hz, 2H), 4.20 (t, J = 6.4 Hz, 2H), 1.96 – 1.72 
(m, 2H), 1.55 – 1.14 (m, 13H), 0.88 (t, J = 6.9 
Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 162.08, 
155.62, 151.70, 139.80, 135.35, 129.14, 
123.49, 115.23, 114.88, 102.82, 70.36, 
62.87, 31.71, 29.11, 29.08, 28.67, 25.70, 
22.59, 14.11, 14.04. 
v04 
 
2-(4-(hexyloxy)-3-nitrobenzylidene) 
1H NMR (400 MHz, cdcl3) δ 8.29 (d, J = 2.4 Hz, 
1H), 8.23 (dd, J = 8.9, 2.4 Hz, 1H), 7.71 (s, 1H), 
7.23 (d, J = 9.0 Hz, 1H), 4.23 (t, J = 6.4 Hz, 2H), 
1.87 (dt, J = 14.3, 6.4 Hz, 2H), 1.55 – 1.42 (m, 
13C NMR (101 MHz, cdcl3) δ 156.62, 
156.60, 139.80, 135.23, 128.91, 122.82, 
115.25, 113.35, 112.41, 82.33, 70.69, 
31.26, 28.57, 25.32, 22.44, 13.92. 
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malononitrile 2H), 1.42 – 1.23 (m, 4H), 0.90 (t, J = 7.1 Hz, 3H). 
v05  
2-(4-(heptyloxy)-3-nitrobenzylidene) 
malononitrile 
1H NMR (400 MHz, cdcl3) δ 8.28 (d, J = 2.4 Hz, 
1H), 8.24 (dd, J = 8.9, 2.4 Hz, 1H), 7.70 (s, 1H), 
7.23 (d, J = 9.0 Hz, 1H), 4.23 (t, J = 6.4 Hz, 2H), 
1.94 – 1.82 (m, 2H), 1.54 – 1.42 (m, 2H), 1.42 – 
1.23 (m, 6H), 0.89 (t, J = 6.9 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 156.59, 
139.80, 135.19, 128.93, 122.82, 115.24, 
113.34, 112.40, 82.35, 70.69, 31.60, 
28.78, 28.62, 25.62, 22.51, 14.01. 
v06  
2-(3-nitro-4-(octyloxy)benzylidene) 
malononitrile 
1H NMR (400 MHz, cdcl3) δ 8.51 – 8.13 (m, 2H), 
7.92 – 7.54 (m, 1H), 7.43 – 7.06 (m, 1H), 4.55 – 
4.04 (m, 2H), 1.92 (ddd, J = 24.2, 15.3, 8.5 Hz, 
2H), 1.74 – 1.05 (m, 11H), 1.05 – 0.61 (m, 3H). 
13C NMR (101 MHz, cdcl3) δ 156.60, 
156.55, 139.81, 135.14, 128.96, 122.81, 
115.23, 113.32, 112.38, 82.38, 70.69, 
31.69, 29.07, 28.61, 25.66, 22.59, 14.05. 
v07  
(E)-ethyl 2-cyano-3-(4-
(pentyloxy)phenyl)acrylate 
1H NMR (400 MHz, cdcl3) δ 8.15 (s, 1H), 8.07 – 
7.89 (m, 2H), 7.05 – 6.72 (m, 2H), 4.36 (q, J = 
7.2 Hz, 2H), 4.03 (t, J = 6.6 Hz, 2H), 1.81 (dd, J 
= 8.0, 6.8 Hz, 2H), 1.54 – 1.28 (m, 7H), 0.93 (t, J 
= 7.1 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 163.43, 
163.15, 154.41, 133.63, 124.08, 116.25, 
115.16, 99.01, 68.43, 62.35, 28.67, 28.05, 
22.36, 14.18, 13.95. 
v08  
(E)-ethyl 2-cyano-3-(4-
(hexyloxy)phenyl)acrylate 
1H NMR (400 MHz, cdcl3) δ 8.14 (s, 1H), 7.97 
(d, J = 8.8 Hz, 2H), 6.96 (d, J = 8.8 Hz, 2H), 4.35 
(q, J = 7.1 Hz, 2H), 4.02 (t, J = 6.5 Hz, 2H), 1.96 
– 1.63 (m, 2H), 1.56 – 1.16 (m, 9H), 0.90 (t, J = 
6.7 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 163.43, 
163.12, 154.38, 133.62, 124.07, 116.24, 
115.15, 99.00, 68.44, 62.33, 31.47, 28.94, 
25.58, 22.53, 14.17, 13.97. 
v09 
 
1H NMR (400 MHz, cdcl3) δ 8.13 (s, 1H), 7.96 
(d, J = 9.0 Hz, 2H), 6.95 (d, J = 8.9 Hz, 2H), 4.34 
(qd, J = 7.1, 0.9 Hz, 2H), 4.01 (t, J = 6.5 Hz, 2H), 
13C NMR (101 MHz, cdcl3) δ 163.42, 
163.10, 154.36, 133.61, 124.06, 116.22, 
115.14, 98.99, 68.44, 62.32, 31.69, 
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(E)-ethyl 2-cyano-3-(4-
(heptyloxy)phenyl)acrylate 
1.90 – 1.70 (m, 2H), 1.57 – 1.17 (m, 11H), 0.88 
(t, J = 7.0, 6.0 Hz, 3H). 
28.97, 28.95, 25.86, 22.54, 14.16, 14.02. 
v10  
2-(4-(heptyloxy)benzylidene) 
malononitrile  
1H NMR (400 MHz, cdcl3) δ 8.10 – 7.77 (m, 2H), 
7.63 (s, 1H), 7.12 – 6.83 (m, 2H), 4.05 (t, J = 6.5 
Hz, 2H), 1.97 – 1.72 (m, 2H), 1.57 – 1.13 (m, 
8H), 0.89 (d, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 164.51, 
158.87, 133.46, 123.75, 115.52, 114.50, 
113.41, 78.12, 68.73, 31.69, 28.93, 28.91, 
25.83, 22.55, 14.04. 
v11  
(E)-2-cyano-3-(4-
(heptyloxy)phenyl)acrylamide 
1H NMR (400 MHz, cdcl3) δ 8.22 (s, 1H), 8.01 – 
7.83 (m, 2H), 7.10 – 6.84 (m, 2H), 6.65 (s, 1H), 
6.43 (s, 1H), 4.01 (t, J = 6.6 Hz, 2H), 1.96 – 1.66 
(m, 2H), 1.55 – 1.19 (m, 8H), 0.88 (t, J = 6.9 Hz, 
3H). 
13C NMR (101 MHz, cdcl3) δ 163.24, 
162.83, 153.38, 133.31, 124.17, 117.74, 
115.16, 99.15, 68.43, 31.70, 28.98, 28.96, 
25.87, 22.55, 14.03. 
v12 
 
(E)-ethyl 3-(3-bromo-4-(hexyloxy)-5-
methoxyphenyl)-2-cyanoacrylate 
1H NMR (400 MHz, cdcl3) δ 8.07 (s, 1H), 7.78 
(d, J = 2.1 Hz, 1H), 7.63 – 7.50 (m, 1H), 4.37 (q, 
J = 7.1 Hz, 2H), 4.11 (t, J = 6.6 Hz, 2H), 3.91 (s, 
3H), 1.79 (dd, J = 8.3, 6.8 Hz, 2H), 1.59 – 1.26 
(m, 9H), 0.97 – 0.75 (m, 3H). 
13C NMR (101 MHz, cdcl3) δ 162.30, 
153.66, 153.11, 150.24, 129.96, 127.73, 
118.07, 115.56, 111.86, 102.26, 73.98, 
62.73, 56.20, 31.52, 30.12, 25.47, 22.57, 
14.14, 14.02. 
v13 
 
2-(3-bromo-4-(hexyloxy)-5-
methoxybenzylidene) malononitrile 
1H NMR (400 MHz, cdcl3) δ 7.67 (s, 1H), 7.59 
(d, J = 3.8 Hz, 1H), 7.53 – 7.46 (m, 1H), 4.26 – 
4.13 (m, 2H), 3.91 (s, 3H), 1.87 – 1.72 (m, 2H), 
1.52 (s, 2H), 1.43 – 1.25 (m, 4H), 0.91 (t, J = 3.6 
Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 157.81, 
153.74, 151.51, 130.04, 126.99, 118.28, 
113.56, 112.75, 111.18, 81.70, 74.26, 
56.24, 31.48, 30.12, 25.44, 22.55, 14.00. 
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v14 
 
(E)-ethyl 3-(3-bromo-4-(heptyloxy)-
5-methoxyphenyl)-2-cyanoacrylate 
1H NMR (400 MHz, cdcl3) δ 8.06 (s, 1H), 7.76 (s, 
1H), 7.55 (d, J = 1.4 Hz, 1H), 4.51 – 4.26 (m, 
2H), 4.10 (t, J = 6.6 Hz, 2H), 3.90 (s, 3H), 1.92 – 
1.70 (m, 2H), 1.57 – 1.19 (m, 11H), 0.87 (t, J = 
6.1 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 162.28, 
153.65, 153.08, 150.22, 129.94, 127.73, 
118.06, 115.54, 111.87, 102.24, 73.96, 
62.71, 56.19, 31.75, 30.16, 28.99, 25.76, 
22.58, 14.13, 14.05. 
v15  
2-(4-(decyloxy)-3-nitrobenzylidene) 
malononitrile 
1H NMR (400 MHz, cdcl3) δ 8.28 (d, J = 2.2 Hz, 
1H), 8.26 – 8.18 (m, 1H), 7.70 (s, 1H), 7.23 (d, J 
= 8.9 Hz, 1H), 4.23 (t, J = 6.4 Hz, 2H), 1.94 – 
1.78 (m, 2H), 1.56 – 1.42 (m, 2H), 1.42 – 1.15 
(m, 13H), 0.87 (t, J = 6.7 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 156.60, 
156.58, 139.81, 135.17, 128.93, 122.82, 
115.24, 113.33, 112.39, 82.36, 70.69, 
31.83, 29.45, 29.41, 29.24, 29.12, 28.62, 
25.66, 22.63, 14.07. 
v16 
 
(E)-ethyl 3-(3-bromo-5-methoxy-4-
(pentyloxy)phenyl)-2-cyanoacrylate 
1H NMR (400 MHz, cdcl3) δ 8.09 (s, 1H), 7.79 
(d, J = 2.1 Hz, 1H), 7.63 – 7.49 (m, 1H), 4.38 (q, 
J = 7.1 Hz, 2H), 4.12 (t, J = 6.7 Hz, 2H), 3.92 (s, 
3H), 1.94 – 1.69 (m, 2H), 1.54 – 1.32 (m, 7H), 
0.93 (t, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 162.33, 
153.69, 153.14, 150.26, 129.99, 127.75, 
118.10, 115.57, 111.86, 102.29, 73.98, 
62.74, 56.22, 29.84, 27.95, 22.40, 14.15, 
14.00. 
v17 
 
(E)-ethyl 3-(3-bromo-5-methoxy-4-
(octyloxy)phenyl)-2-cyanoacrylate 
1H NMR (400 MHz, cdcl3) δ 8.08 (s, 1H), 7.79 
(d, J = 1.3 Hz, 1H), 7.57 (dd, J = 1.6, 0.5 Hz, 
1H), 4.47 – 4.26 (m, 2H), 4.11 (t, J = 6.6 Hz, 2H), 
3.92 (d, J = 0.5 Hz, 3H), 1.97 – 1.68 (m, 2H), 
1.55 – 1.12 (m, 13H), 0.88 (t, J = 6.6 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 162.32, 
153.68, 153.13, 150.26, 129.99, 127.74, 
118.09, 115.57, 111.86, 102.27, 74.00, 
62.73, 56.21, 31.79, 30.16, 29.29, 29.21, 
25.81, 22.62, 14.14, 14.07. 
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v18 
 
2-(3-bromo-5-methoxy-4-
(octyloxy)benzylidene) malononitrile 
1H NMR (400 MHz, cdcl3) δ 7.67 (d, J = 2.1 Hz, 
1H), 7.60 (s, 1H), 7.50 (d, J = 2.1 Hz, 1H), 4.16 
(t, J = 6.6 Hz, 2H), 3.91 (s, 3H), 1.98 – 1.69 (m, 
2H), 1.58 – 1.41 (m, 2H), 1.39 – 1.16 (m, 8H), 
0.89 (t, J = 8.7, 5.0 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 157.82, 
153.74, 151.51, 130.03, 127.00, 118.28, 
113.57, 112.76, 111.20, 81.69, 74.26, 
56.25, 31.78, 30.16, 29.25, 29.19, 25.77, 
22.62, 14.06. 
v19  
(E)-ethyl 3-(3-bromo-5-methoxy-4-
(octadecyloxy)phenyl)-2-
cyanoacrylate 
1H NMR (400 MHz, cdcl3) δ 8.09 (s, 1H), 7.80 
(d, J = 1.8 Hz, 1H), 7.58 (d, J = 1.9 Hz, 1H), 4.38 
(q, J = 7.1 Hz, 2H), 4.12 (t, J = 6.6 Hz, 2H), 3.92 
(s, 3H), 1.98 – 1.69 (m, 2H), 1.54 – 1.44 (m, 2H), 
1.40 (t, J = 7.1 Hz, 3H), 1.37 – 1.16 (m, 28H), 
0.88 (t, J = 6.7 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 162.33, 
153.69, 153.13, 150.28, 130.01, 127.74, 
118.09, 115.56, 111.84, 102.28, 74.01, 
62.73, 56.21, 31.89, 30.16, 29.67, 29.63, 
29.59, 29.55, 29.33, 25.81, 22.66, 14.14, 
14.08. 
v20  
(E)-3-(3-bromo-5-methoxy-4-
(octadecyloxy)phenyl)-2-
cyanoacrylic acid 
1H NMR (400 MHz, dmso) δ 8.11 (s, 1H), 7.85 
(s, 1H), 7.73 (s, 1H), 7.24 (s, 1H), 4.01 (t, J = 6.2 
Hz, 2H), 3.84 (s, 3H), 1.81 – 1.57 (m, 2H), 1.42 
(s, 2H), 1.21 (s, 28H), 0.83 (t, J = 6.6 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 163.37, 
153.53, 150.31, 148.33, 129.38, 126.91, 
117.53, 114.54, 73.46, 56.57, 31.75, 
30.05, 29.50, 29.47, 29.44, 29.40, 29.35, 
29.17, 29.12, 25.76, 22.54, 14.33. 
v21 
 
1H NMR (400 MHz, cdcl3) δ 8.14 (s, 1H), 7.78 
(d, J = 2.1 Hz, 1H), 7.45 (dd, J = 8.4, 2.2 Hz, 
1H), 6.92 (d, J = 8.5 Hz, 1H), 4.37 (q, J = 7.2 Hz, 
2H), 4.11 (t, J = 6.8 Hz, 2H), 3.93 (s, 3H), 1.86 
13C NMR (101 MHz, cdcl3) δ 163.14, 
154.71, 153.41, 149.46, 127.81, 124.27, 
116.39, 111.99, 111.85, 99.02, 68.81, 
62.36, 56.05, 30.88, 19.10, 14.19, 13.77. 
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(E)-ethyl 3-(4-butoxy-3-
methoxyphenyl)-2-cyanoacrylate 
(dt, J = 14.6, 6.8 Hz, 2H), 1.51 (dq, J = 14.8, 7.4 
Hz, 2H), 1.39 (t, J = 7.1 Hz, 3H), 0.99 (t, J = 7.4 
Hz, 3H). 
v22  
2-(4-butoxy-3-methoxybenzylidene) 
malononitrile 
1H NMR (400 MHz, cdcl3) δ 7.68 (d, J = 2.1 Hz, 
1H), 7.63 (s, 1H), 7.37 (dd, J = 8.5, 2.2 Hz, 1H), 
6.95 (d, J = 8.5 Hz, 1H), 4.13 (t, J = 6.7 Hz, 2H), 
3.93 (s, 3H), 2.13 – 1.70 (m, 2H), 1.57 – 1.44 (m, 
2H), 1.00 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 159.08, 
154.65, 149.72, 128.13, 123.95, 114.47, 
113.61, 111.89, 111.07, 78.05, 69.03, 
56.08, 30.81, 19.08, 13.75. 
v23  
(E)-ethyl 2-cyano-3-(4-(hexyloxy)-3-
methoxyphenyl)acrylate 
1H NMR (400 MHz, cdcl3) δ 8.13 (s, 1H), 7.78 
(d, J = 1.8 Hz, 1H), 7.44 (dd, J = 8.4, 2.0 Hz, 
1H), 6.91 (d, J = 8.4 Hz, 1H), 4.46 – 4.28 (m, 
2H), 4.09 (t, J = 6.8 Hz, 2H), 3.92 (s, 3H), 2.01 – 
1.70 (m, 2H), 1.54 – 1.26 (m, 9H), 0.89 (t, J = 6.8 
Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 163.01, 
154.58, 153.31, 149.36, 127.69, 124.18, 
116.27, 111.90, 111.77, 98.92, 69.01, 
62.23, 55.92, 31.35, 28.69, 25.39, 22.39, 
14.06, 13.85. 
v24  
2-(4-(hexyloxy)-3-
methoxybenzylidene) malononitrile 
1H NMR (400 MHz, cdcl3) δ 7.67 (d, J = 1.9 Hz, 
1H), 7.62 (s, 1H), 7.35 (dd, J = 8.4, 2.1 Hz, 1H), 
6.93 (d, J = 8.5 Hz, 1H), 4.11 (t, J = 6.8 Hz, 2H), 
3.92 (s, 3H), 1.94 – 1.72 (m, 2H), 1.53 – 1.40 (m, 
2H), 1.40 – 1.25 (m, 4H), 0.91 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 159.07, 
154.64, 149.72, 128.12, 123.95, 114.46, 
113.61, 111.90, 111.08, 69.35, 56.07, 
31.45, 28.75, 25.49, 22.50, 13.96. 
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v25  
(E)-2-cyano-3-(4-(hexyloxy)-3-
methoxyphenyl)acrylic acid 
1H NMR (400 MHz, dmso) δ 8.04 (s, 1H), 7.70 
(d, J = 2.1 Hz, 1H), 7.51 (dd, J = 8.5, 2.1 Hz, 
1H), 7.25 (s, 1H), 7.05 (d, J = 8.5 Hz, 1H), 4.05 
(t, J = 6.6 Hz, 2H), 3.83 (s, 3H), 1.80 – 1.69 (m, 
2H), 1.49 – 1.38 (m, 2H), 1.38 – 1.22 (m, 4H), 
0.89 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 165.49, 
164.46, 151.99, 151.04, 149.17, 125.73, 
125.32, 118.61, 117.19, 112.81, 112.78, 
79.56, 79.23, 78.90, 68.76, 55.90, 31.48, 
31.42, 28.96, 26.27, 25.68, 25.56, 22.50, 
14.26. 
v26  
(E)-ethyl 2-cyano-3-(4-(decyloxy)-3-
methoxyphenyl)acrylate 
1H NMR (400 MHz, cdcl3) δ 8.10 (s, 1H), 7.76 (s, 
1H), 7.42 (s, 1H), 6.90 (s, 1H), 4.34 (s, 2H), 4.06 
(s, 2H), 3.90 (s, 3H), 1.84 (s, 2H), 1.58 – 1.07 (m, 
17H), 0.85 (s, 3H). 
13C NMR (101 MHz, cdcl3) δ 162.95, 
154.50, 153.27, 149.29, 127.66, 124.11, 
116.22, 111.83, 111.72, 98.86, 68.98, 
62.17, 55.86, 31.69, 29.34, 29.14, 28.72, 
25.69, 22.49, 14.03, 13.92. 
v27  
(E)-2-cyano-3-(4-(decyloxy)-3-
methoxyphenyl)acrylic acid 
1H NMR (400 MHz, cdcl3) δ 8.21 (s, 1H), 7.84 
(d, J = 1.8 Hz, 1H), 7.49 (dd, J = 8.5, 1.8 Hz, 
1H), 6.95 (d, J = 8.5 Hz, 1H), 6.13 (s, 1H), 4.12 
(t, J = 6.8 Hz, 2H), 3.95 (s, 3H), 2.01 – 1.71 (m, 
2H), 1.59 – 1.13 (m, 14H), 0.88 (t, J = 6.8 Hz, 
3H). 
13C NMR (101 MHz, cdcl3) δ 170.53, 
167.83, 156.43, 154.11, 149.56, 128.73, 
123.97, 115.91, 112.03, 111.86, 97.65, 
69.24, 56.08, 31.84, 29.48, 29.28, 29.26, 
28.80, 25.82, 22.63, 14.07. 
v28  
(E)-2-cyano-3-(4-(decyloxy)-3-
methoxyphenyl)acrylamide 
1H NMR (400 MHz, cdcl3) δ 8.22 (s, 1H), 7.66 (t, 
J = 8.2 Hz, 1H), 7.44 (dd, J = 8.4, 2.1 Hz, 1H), 
6.88 (dd, J = 23.6, 8.6 Hz, 1H), 6.26 (s, 1H), 5.79 
(s, 1H), 4.07 (q, J = 7.1 Hz, 2H), 3.90 (d, J = 8.1 
Hz, 3H), 1.99 – 1.81 (m, 2H), 1.54 – 1.05 (m, 
14H), 0.86 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 162.58, 
153.82, 153.25, 149.45, 127.44, 124.31, 
117.89, 111.95, 111.85, 109.99, 98.99, 
69.15, 56.01, 31.85, 29.49, 29.30, 29.26, 
28.85, 25.84, 22.64, 14.08. 
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v29  
2-(4-(decyloxy)-3-
methoxybenzylidene) malononitrile 
1H NMR (400 MHz, cdcl3) δ 7.66 (s, 1H), 7.62 (s, 
1H), 7.43 – 7.32 (m, 1H), 6.93 (d, J = 8.5 Hz, 
1H), 4.23 – 4.02 (m, 2H), 3.92 (s, 3H), 2.03 – 
1.77 (m, 2H), 1.54 – 1.10 (m, 14H), 0.88 (t, J = 
6.0 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 159.07, 
154.65, 149.71, 128.13, 123.94, 114.47, 
113.61, 111.90, 111.07, 69.36, 56.07, 
31.85, 29.48, 29.46, 29.26, 28.78, 25.81, 
22.64, 14.07. 
v30  
(E)-ethyl 2-cyano-3-(4-(decyloxy)-3-
nitrophenyl)acrylate 
1H NMR (400 MHz, cdcl3) δ 8.33 (dd, J = 7.5, 
2.1 Hz, 2H), 8.15 (s, 1H), 7.23 – 7.08 (m, 1H), 
4.48 – 4.27 (m, 2H), 4.20 (t, J = 6.4 Hz, 2H), 2.01 
– 1.72 (m, 2H), 1.52 – 1.10 (m, 17H), 0.86 (t, J = 
6.9 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 162.06, 
155.61, 151.70, 139.78, 135.39, 129.09, 
123.49, 115.22, 114.89, 102.80, 70.36, 
62.86, 31.83, 29.46, 29.42, 29.24, 29.14, 
28.67, 25.69, 22.63, 14.11, 14.06. 
v31  
(E)-2-cyano-3-(4-(hexyloxy)-3-
methoxyphenyl) acrylamide 
1H NMR (400 MHz, cdcl3) δ 8.24 (s, 1H), 7.70 (s, 
1H), 7.59 – 7.39 (m, 1H), 6.94 (dd, J = 8.4, 2.6 
Hz, 1H), 6.29 (s, 1H), 5.85 (s, 1H), 4.11 (d, J = 
2.5 Hz, 2H), 4.01 – 3.86 (m, 3H), 1.88 (d, J = 4.9 
Hz, 2H), 1.48 (s, 2H), 1.35 (s, 4H), 1.04 – 0.73 
(m, 3H). 
13C NMR (101 MHz, cdcl3) δ 162.56, 
153.79, 153.22, 149.42, 127.42, 124.30, 
117.89, 111.92, 111.82, 99.00, 69.13, 
56.00, 31.47, 28.81, 25.51, 22.51, 13.96. 
v32 
 
2-(4-methoxy-3-
(pentyloxy)benzylidene) 
malononitrile 
1H NMR (400 MHz, cdcl3) δ 7.66 (s, 1H), 7.62 (s, 
1H), 7.36 (d, J = 8.3 Hz, 1H), 6.94 (d, J = 8.2 Hz, 
1H), 4.07 (d, J = 6.3 Hz, 2H), 3.97 (s, 3H), 2.11 – 
1.76 (m, 2H), 1.54 – 1.28 (m, 4H), 0.94 (t, J = 6.8 
Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 159.13, 
155.21, 149.08, 127.86, 124.19, 114.44, 
113.54, 111.99, 111.19, 78.25, 69.19, 
56.25, 28.57, 28.01, 22.39, 13.95. 
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v33  
(E)-ethyl 2-cyano-3-(4-(heptyloxy)-
3-methoxyphenyl) acrylate 
1H NMR (400 MHz, cdcl3) δ 8.12 (s, 1H), 7.77 
(d, J = 1.9 Hz, 1H), 7.52 – 7.34 (m, 1H), 6.91 (d, 
J = 8.5 Hz, 1H), 4.46 – 4.20 (m, 2H), 4.08 (t, J = 
6.8 Hz, 2H), 3.92 (s, 3H), 2.07 – 1.76 (m, 2H), 
1.56 – 1.14 (m, 11H), 0.87 (t, J = 6.6 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 163.01, 
154.55, 153.31, 149.35, 127.68, 124.15, 
116.25, 111.87, 111.76, 98.90, 69.00, 
62.21, 55.90, 31.54, 28.83, 28.72, 25.68, 
22.41, 14.05, 13.89. 
v34  
(E)-2-cyano-3-(3-methoxy-4-
(pentyloxy)phenyl) acrylamide 
1H NMR (400 MHz, cdcl3) δ 8.22 (s, 1H), 7.68 (s, 
1H), 7.44 (d, J = 8.6 Hz, 1H), 7.07 – 6.83 (m, 
1H), 6.26 (d, J = 45.8 Hz, 2H), 4.09 (t, J = 6.6 
Hz, 2H), 3.92 (d, J = 0.9 Hz, 3H), 2.01 – 1.75 (m, 
2H), 1.57 – 1.28 (m, 4H), 0.93 (t, J = 7.2, 6.3 Hz, 
3H). 
13C NMR (101 MHz, cdcl3) δ 162.84, 
153.72, 153.20, 149.42, 127.40, 124.32, 
117.86, 111.94, 111.87, 99.13, 69.11, 
56.00, 28.57, 27.97, 22.38, 13.94. 
v35  
2-(4-(pentyloxy)benzylidene) 
malononitrile 
1H NMR (400 MHz, cdcl3) δ 7.89 (d, J = 8.6 Hz, 
2H), 7.63 (s, 1H), 7.10 – 6.88 (m, 2H), 4.24 – 
3.96 (m, 2H), 2.03 – 1.73 (m, 2H), 1.52 – 1.30 
(m, 4H), 0.94 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 164.50, 
158.88, 133.46, 123.75, 115.51, 114.50, 
113.41, 78.10, 68.71, 28.60, 28.01, 22.35, 
13.94. 
v36  
2-(4-
(hexyloxy)benzylidene)malononitrile 
1H NMR (400 MHz, cdcl3) δ 7.95 – 7.77 (m, 2H), 
7.63 (d, J = 4.0 Hz, 1H), 7.11 – 6.86 (m, 2H), 
4.06 (d, J = 5.8 Hz, 2H), 1.93 – 1.64 (m, 2H), 
1.49 – 1.09 (m, 6H), 1.00 – 0.66 (m, 3H). 
13C NMR (101 MHz, cdcl3) δ 163.80, 
158.15, 132.75, 123.05, 114.81, 113.78, 
112.70, 77.44, 68.03, 30.75, 28.18, 24.85, 
21.82, 13.28. 
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-- 
 
4-butoxy-3-methoxybenzaldehyde 
1H NMR (400 MHz, cdcl3) δ 9.72 (t, J = 1.9 Hz, 
1H), 7.45 – 7.23 (m, 2H), 6.94 – 6.59 (m, 1H), 
4.20 – 3.91 (m, 2H), 3.81 (s, 3H), 1.86 – 1.65 (m, 
2H), 1.57 – 1.24 (m, 2H), 0.99 – 0.75 (m, 3H). 
13C NMR (101 MHz, cdcl3) δ 190.70, 
154.09, 149.72, 129.75, 126.63, 111.28, 
109.16, 68.70, 55.85, 30.87, 19.05, 
13.70. 
v37  
(E)-3-(4-butoxy-3-methoxyphenyl)-
2-cyanoacrylic acid 
1H NMR (400 MHz, cdcl3) δ 8.22 (s, 1H), 7.82 (t, 
J = 14.3 Hz, 1H), 7.49 (dd, J = 8.4, 2.1 Hz, 1H), 
7.11 – 6.81 (m, 1H), 4.26 – 4.04 (m, 2H), 3.95 (s, 
3H), 1.98 – 1.81 (m, 2H), 1.69 – 1.39 (m, 2H), 
1.00 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 156.46, 
154.14, 149.58, 128.75, 123.99, 115.91, 
112.05, 111.87, 97.66, 68.92, 56.09, 
30.85, 19.10, 13.77. 
v38  
(E)-3-(4-butoxy-3-methoxyphenyl)-
2-cyanoacrylamide 
1H NMR (400 MHz, cdcl3) δ 8.20 (s, 1H), 7.65 (t, 
J = 10.1 Hz, 1H), 7.54 – 7.36 (m, 1H), 6.87 (dd, J 
= 27.9, 8.1 Hz, 1H), 6.22 (d, J = 57.7 Hz, 2H), 
4.24 – 4.02 (m, 2H), 4.02 – 3.84 (m, 3H), 2.01 – 
1.65 (m, 2H), 1.65 – 1.34 (m, 2H), 0.96 (dd, J = 
7.7, 7.1 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 162.79, 
153.72, 153.21, 149.43, 127.39, 124.32, 
117.87, 111.94, 111.87, 99.13, 68.80, 
56.00, 30.89, 19.10, 13.77. 
v39  
(E)-ethyl 2-cyano-3-(4-
(cyclohexylmethoxy)-3-
methoxyphenyl)acrylate 
1H NMR (400 MHz, cdcl3) δ 8.13 (s, 1H), 7.77 
(d, J = 2.2 Hz, 1H), 7.44 (dd, J = 8.5, 2.2 Hz, 
1H), 6.90 (d, J = 8.5 Hz, 1H), 4.36 (q, J = 7.1 Hz, 
2H), 3.91 (d, J = 3.9 Hz, 3H), 3.87 (d, J = 6.2 Hz, 
2H), 1.99 – 1.63 (m, 6H), 1.38 (t, J = 7.1 Hz, 3H), 
1.33 – 0.93 (m, 5H). 
13C NMR (101 MHz, cdcl3) δ 163.16, 
154.72, 153.66, 149.54, 127.83, 124.19, 
116.40, 112.09, 111.96, 98.92, 74.41, 
62.34, 56.09, 37.25, 29.79, 26.39, 25.63, 
14.19. 
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v40 
 
2-(4-(cyclohexylmethoxy)-3-
methoxybenzylidene) malononitrile 
1H NMR (400 MHz, cdcl3) δ 7.65 (d, J = 2.1 Hz, 
1H), 7.61 (s, 1H), 7.35 (dd, J = 8.5, 2.2 Hz, 1H), 
6.92 (d, J = 8.5 Hz, 1H), 3.89 (d, J = 8.4 Hz, 5H), 
2.20 – 1.43 (m, 6H), 1.40 – 0.27 (m, 5H). 
13C NMR (101 MHz, cdcl3) δ 158.94, 
154.74, 149.62, 127.98, 123.69, 114.33, 
113.48, 111.84, 111.00, 77.67, 74.38, 
55.91, 37.07, 29.56, 26.16, 25.42. 
v41  
(E)-2-cyano-3-(4-
(cyclohexylmethoxy)-3-
methoxyphenyl)acrylamide 
1H NMR (400 MHz, dmso) δ 8.06 (s, 1H), 7.73 
(s, 1H), 7.62 (d, J = 2.1 Hz, 2H), 7.50 (dd, J = 
8.5, 2.1 Hz, 1H), 7.07 (d, J = 8.6 Hz, 1H), 3.81 
(d, J = 6.3 Hz, 2H), 3.77 (s, 3H), 1.92 – 1.48 (m, 
6H), 1.29 – 1.05 (m, 3H), 1.05 – 0.85 (m, 2H). 
13C NMR (101 MHz, dmso) δ 163.52, 
152.55, 151.01, 149.23, 125.98, 124.70, 
117.67, 113.02, 112.96, 103.04, 73.87, 
55.99, 37.33, 29.59, 26.43, 25.60. 
v42  
(E)-ethyl 2-cyano-3-(3-methoxy-4-
(pentyloxy)phenyl)acrylate 
1H NMR (400 MHz, cdcl3) δ 8.11 (s, 1H), 7.76 (d, 
J = 2.0 Hz, 1H), 7.52 – 7.36 (m, 1H), 7.00 – 6.72 
(m, 1H), 4.50 – 4.22 (m, 2H), 4.07 (t, J = 6.8 Hz, 
2H), 3.91 (s, 3H), 2.02 – 1.78 (m, 2H), 1.56 – 
1.27 (m, 7H), 0.91 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 162.77, 
154.32, 153.07, 149.11, 127.46, 123.93, 
116.03, 111.64, 111.52, 98.66, 68.77, 
62.00, 55.70, 28.23, 27.63, 22.03, 13.84, 
13.59. 
v43 
 
2-(3-methoxy-4-
1H NMR (400 MHz, cdcl3) δ 7.67 (d, J = 2.1 Hz, 
1H), 7.62 (s, 1H), 7.35 (dd, J = 8.4, 2.2 Hz, 1H), 
6.99 – 6.88 (m, 1H), 4.11 (t, J = 6.8 Hz, 2H), 3.92 
(s, 3H), 2.08 – 1.81 (m, 2H), 1.54 – 1.31 (m, 4H), 
0.94 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 159.08, 
154.64, 149.71, 128.13, 123.95, 114.47, 
113.61, 111.89, 111.07, 69.33, 56.08, 
28.50, 27.94, 22.36, 13.93. 
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(pentyloxy)benzylidene) 
malononitrile 
v44  
(E)-2-methoxy-4-(2-nitrovinyl)-1-
(pentyloxy)benzene 
1H NMR (400 MHz, cdcl3) δ 8.06 – 7.89 (m, 1H), 
7.60 – 7.48 (m, 1H), 7.21 – 7.10 (m, 1H), 7.00 (s, 
1H), 6.94 – 6.85 (m, 1H), 4.07 (td, J = 6.8, 2.1 
Hz, 2H), 3.95 – 3.53 (m, 3H), 2.00 – 1.74 (m, 
2H), 1.51 – 1.25 (m, 4H), 0.94 (t, J = 6.0 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 152.51, 
149.74, 139.39, 134.95, 124.59, 122.45, 
112.35, 110.60, 69.07, 56.06, 28.60, 
27.98, 22.38, 13.93. 
v45  
(E)-2-cyano-3-(3-methoxy-4-
(pentyloxy)phenyl)acrylic acid 
1H NMR (400 MHz, cdcl3) δ 8.22 (s, 1H), 7.84 
(d, J = 1.1 Hz, 1H), 7.49 (d, J = 8.6 Hz, 1H), 6.95 
(d, J = 8.5 Hz, 1H), 4.12 (t, J = 6.8 Hz, 2H), 3.95 
(s, 2H), 2.02 – 1.77 (m, 2H), 1.62 – 1.26 (m, 3H), 
0.94 (t, J = 7.0 Hz, 2H). 
13C NMR (101 MHz, cdcl3) δ 168.20, 
156.47, 154.12, 149.55, 128.76, 123.97, 
115.88, 112.03, 111.85, 97.67, 69.21, 
56.08, 28.52, 27.94, 22.37, 13.93. 
v46 
 
(E)-ethyl 3-(4-(benzyloxy)-3-
methoxyphenyl)-2-cyanoacrylate 
1H NMR (400 MHz, cdcl3) δ 8.12 (s, 1H), 7.80 
(d, J = 2.1 Hz, 1H), 7.48 – 7.29 (m, 6H), 6.96 – 
6.91 (m, 1H), 5.23 (s, 2H), 4.36 (q, J = 7.2 Hz, 
2H), 3.94 (s, 3H), 1.38 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 163.03, 
154.59, 152.77, 149.68, 135.87, 128.71, 
128.69, 128.22, 127.50, 127.19, 124.76, 
116.31, 112.87, 112.12, 99.44, 70.81, 
62.42, 56.07, 14.19. 
v47 
 
1H NMR (400 MHz, cdcl3) δ 7.68 (s, 1H), 7.61 (s, 
1H), 7.47 – 7.28 (m, 6H), 6.96 (d, J = 6.9 Hz, 
1H), 5.26 (s, 2H), 3.94 (d, J = 1.2 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 159.04, 
153.97, 149.93, 135.48, 128.79, 128.39, 
127.81, 127.21, 124.40, 114.37, 113.52, 
112.89, 111.23, 78.52, 70.97, 56.10. 
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2-(4-(benzyloxy)-3-
methoxybenzylidene) malononitrile 
v48 
 
(E)-3-(4-(benzyloxy)-3-
methoxyphenyl)-2-cyanoacrylamide 
1H NMR (400 MHz, cdcl3) δ 8.22 (s, 1H), 7.71 
(d, J = 2.0 Hz, 1H), 7.47 – 7.28 (m, 6H), 6.95 (d, 
J = 8.5 Hz, 1H), 6.29 (s, 1H), 6.03 (s, 1H), 5.24 
(s, 2H), 3.95 (s, 3H). 
13C NMR (101 MHz, cdcl3) δ 162.56, 
153.65, 152.56, 149.64, 135.87, 128.73, 
128.24, 127.19, 127.10, 124.81, 117.79, 
112.92, 111.95, 99.50, 70.82, 56.02. 
v49 
 
(E)-ethyl 3-(4-(benzyloxy)-3-
nitrophenyl)-2-cyanoacrylate 
1H NMR (400 MHz, dmso) δ 8.65 (d, J = 2.2 Hz, 
1H), 8.42 (s, 1H), 8.36 (dd, J = 9.0, 2.3 Hz, 1H), 
7.69 (d, J = 9.0 Hz, 1H), 7.52 – 7.15 (m, 5H), 
5.43 (s, 2H), 4.31 (q, J = 7.1 Hz, 2H), 1.30 (t, J = 
7.1 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 162.09, 
154.66, 152.89, 139.79, 136.81, 135.72, 
129.03, 128.76, 128.46, 128.01, 124.29, 
116.77, 115.98, 102.58, 71.56, 62.85, 
14.41. 
v50 
 
2-(3-ethoxy-4-
(pentyloxy)benzylidene) 
malononitrile 
1H NMR (400 MHz, cdcl3) δ 7.64 (d, J = 2.1 Hz, 
1H), 7.59 (s, 1H), 7.32 (dd, J = 8.5, 2.2 Hz, 1H), 
6.91 (d, J = 8.5 Hz, 1H), 4.14 – 4.04 (m, 4H), 
1.94 – 1.79 (m, 2H), 1.51 – 1.15 (m, 7H), 0.92 (t, 
J = 7.1 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 159.16, 
154.98, 149.06, 128.10, 123.93, 114.53, 
113.62, 112.38, 112.12, 69.30, 64.73, 
28.46, 27.98, 22.35, 14.53, 13.96. 
v51 
 
1H NMR (400 MHz, cdcl3) δ 7.64 (s, 1H), 7.18 (s, 
2H), 4.12 (t, J = 5.6 Hz, 2H), 3.89 (s, 6H), 1.76 
(s, 2H), 1.51 – 1.20 (m, 4H), 0.92 (d, J = 5.1 Hz, 
3H). 
13C NMR (101 MHz, cdcl3) δ 159.45, 
153.62, 143.56, 125.75, 114.06, 113.25, 
108.33, 80.18, 73.99, 56.29, 29.79, 
27.83, 22.38, 14.01. 
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2-(3,5-dimethoxy-4-
(pentyloxy)benzylidene) 
malononitrile 
v52  
(E)-2-cyano-3-(4-(hexyloxy)-3-
nitrophenyl) acrylamide 
1H NMR (400 MHz, cdcl3) δ 8.37 (d, J = 2.2 Hz, 
1H), 8.26 (s, 1H), 8.21 (dd, J = 8.9, 2.2 Hz, 1H), 
7.19 (d, J = 8.9 Hz, 1H), 6.36 (s, 1H), 6.07 (s, 
1H), 4.20 (t, J = 6.4 Hz, 2H), 2.05 – 1.76 (m, 2H), 
1.59 – 1.41 (m, 2H), 1.41 – 1.28 (m, 4H), 0.90 (t, 
J = 6.9 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 161.45, 
155.46, 150.89, 139.87, 135.51, 128.48, 
123.62, 116.67, 114.82, 102.82, 70.32, 
31.30, 28.64, 25.37, 22.46, 13.94. 
v53  
(E)-ethyl 3-(3-bromo-4-
(hexadecyloxy)-5-methoxyphenyl)-2-
cyanoacrylate 
1H NMR (400 MHz, cdcl3) δ 8.09 (s, 1H), 7.80 
(d, J = 2.0 Hz, 1H), 7.58 (d, J = 2.0 Hz, 1H), 4.38 
(q, J = 7.1 Hz, 2H), 4.12 (t, J = 6.6 Hz, 2H), 3.92 
(s, 3H), 1.96 – 1.67 (m, 2H), 1.56 – 1.08 (m, 
30H), 0.88 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 162.36, 
153.72, 153.18, 150.29, 130.05, 127.77, 
118.13, 115.61, 111.85, 102.28, 74.03, 
62.77, 56.24, 31.94, 30.20, 29.71, 29.67, 
29.63, 29.60, 29.38, 25.85, 22.71, 14.18, 
14.14, -0.00. 
v54 
 
(E)-ethyl 2-cyano-3-(4-
(hexadecyloxy)-3-nitrophenyl) 
acrylate 
1H NMR (400 MHz, cdcl3) δ 8.43 – 8.25 (m, 2H), 
8.15 (s, 1H), 7.19 (d, J = 8.8 Hz, 1H), 4.47 – 4.27 
(m, 2H), 4.20 (t, J = 6.4 Hz, 2H), 1.97 – 1.72 (m, 
2H), 1.57 – 1.06 (m, 32H), 0.87 (dd, J = 6.9, 6.5 
Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 162.07, 
155.62, 151.69, 139.81, 135.34, 129.15, 
123.50, 115.22, 114.88, 102.83, 70.36, 
62.87, 31.89, 29.65, 29.62, 29.60, 29.52, 
29.44, 29.32, 29.16, 28.68, 25.70, 22.65, 
14.11, 14.08. 
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v55  
(E)-ethyl 2-cyano-3-(3-nitro-4-
(octadecyloxy)phenyl) acrylate 
1H NMR (400 MHz, cdcl3) δ 8.40 – 8.25 (m, 2H), 
8.15 (s, 1H), 7.23 – 7.12 (m, 1H), 4.45 – 4.27 (m, 
2H), 4.20 (t, J = 6.4 Hz, 2H), 2.03 – 1.74 (m, 2H), 
1.54 – 1.13 (m, 34H), 0.87 (t, J = 6.9 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 162.06, 
155.62, 151.69, 139.80, 135.34, 129.14, 
123.50, 115.22, 114.88, 102.82, 70.36, 
62.86, 31.89, 29.67, 29.62, 29.60, 29.52, 
29.44, 29.33, 29.16, 28.68, 25.70, 22.65, 
14.11, 14.08. 
v56  
(E)-2-cyano-3-(3-nitro-4-
(octadecyloxy)phenyl) acrylamide 
1H NMR (400 MHz, cdcl3) δ 8.18 (s, 1H), 7.63 
(dd, J = 10.4, 2.0 Hz, 2H), 6.33 (s, 1H), 6.09 (s, 
1H), 4.11 (t, J = 6.6 Hz, 2H), 3.91 (s, 3H), 1.96 – 
1.70 (m, 2H), 1.57 – 1.41 (m, 2H), 1.41 – 1.12 
(m, 26H), 0.87 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, cdcl3) δ 161.74, 
153.67, 152.25, 150.08, 129.38, 127.86, 
118.27, 117.04, 111.98, 102.35, 73.99, 
56.15, 31.90, 30.16, 29.67, 29.64, 29.63, 
29.60, 29.56, 29.34, 25.82, 22.67, 14.10.. 
v57 
 
(E)-ethyl 2-cyano-3-(3,5-dimethoxy-
4-(pentyloxy)phenyl)acrylate 
1H NMR (400 MHz, cdcl3) δ 8.13 (s, 1H), 7.75 
(d, J = 2.1 Hz, 1H), 7.46 (dd, J = 8.4, 2.1 Hz, 
1H), 6.91 (d, J = 8.5 Hz, 1H), 4.36 (q, J = 7.1 Hz, 
2H), 4.08 (dd, J = 11.9, 6.4 Hz, 4H), 1.86 (dd, J = 
14.0, 6.4 Hz, 4H), 1.52 – 1.26 (m, 11H), 0.93 (td, 
J = 7.1, 2.2 Hz, 6H).  
13C NMR (101 MHz, cdcl3) δ 154.84, 
153.91, 127.60, 124.25, 113.71, 112.20, 
98.83, 69.05, 62.34, 28.68, 28.59, 28.16, 
28.08, 22.42, 22.38, 13.98. 
v58  
2-(3,4-bis(pentyloxy)benzylidene) 
malononitrile 
1H NMR (400 MHz, cdcl3) δ 7.65 (s, 1H), 7.19 (s, 
2H), 4.12 (t, J = 6.8 Hz, 2H), 3.89 (s, 6H), 1.84 – 
1.64 (m, 2H), 1.53 – 1.23 (m, 4H), 0.92 (t, J = 7.2 
Hz, 3H).  
13C NMR (101 MHz, cdcl3) δ 159.45, 
153.62, 143.56, 125.75, 114.06, 113.25, 
108.33, 80.18, 73.99, 56.29, 29.79, 
27.83, 22.38, 14.01. 
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Table I-2. Structures, Names, 1H NMR and 13C NMR data for 1, 3-Diphenylpyrazole derivatives (Chapter 4)  
 Structures of Pyrazole compounds.  
NMR 
1H NMR 13C NMR 
py01  
(E)-3-(1-(4-chlorophenyl)-3-(4-
ethoxyphenyl)-1H-pyrazol-4-yl)-2-
cyanoacrylic acid 
1H NMR (400 MHz, dmso) δ 13.84 (s, 1H), 
9.16 (s, 1H), 8.06 (s, 1H), 7.96 (d, J = 8.8 
Hz, 2H), 7.65 (d, J = 8.7 Hz, 2H), 7.55 (d, J 
= 8.5 Hz, 2H), 7.11 (d, J = 8.6 Hz, 2H), 4.11 
(q, J = 13.6, 6.7 Hz, 2H), 1.36 (t, J = 6.8 Hz, 
3H). 
13C NMR (101 MHz, dmso) δ 163.57, 
159.73, 155.27, 145.15, 137.57, 132.34, 
130.47, 129.98, 129.76, 122.82, 121.49, 
116.65, 115.14, 114.63, 101.60, 63.49, 
14.84. 
py02  
(E)-3-(3-(4-butoxyphenyl)-1-phenyl-
1H-pyrazol-4-yl)-2-cyanoacrylic acid 
1H NMR (400 MHz, dmso) δ 13.93 – 13.33 
(m, 1H), 9.13 (s, 1H), 8.06 (s, 1H), 7.90 (d, 
J = 7.5 Hz, 2H), 7.69 – 7.50 (m, 4H), 7.44 
(t, J = 7.1 Hz, 1H), 7.10 (d, J = 7.7 Hz, 2H), 
4.04 (t, J = 5.7 Hz, 2H), 1.84 – 1.35 (m, 
4H), 0.94 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 163.44, 
159.63, 154.89, 144.79, 138.57, 130.23, 
129.85, 129.27, 127.96, 122.80, 119.59, 
116.72, 114.94, 114.25, 101.53, 67.35, 
30.72, 18.76, 13.72. 
py03  
(E)-3-(3-(4-butoxyphenyl)-1-(4-
chlorophenyl)-1H-pyrazol-4-yl)-2-
cyanoacrylic acid 
1H NMR (400 MHz, dmso) δ 13.77 (s, 1H), 
9.12 (s, 1H), 8.04 (s, 1H), 7.92 (d, J = 8.9 
Hz, 2H), 7.68 – 7.58 (m, 2H), 7.51 (d, J = 
8.6 Hz, 2H), 7.08 (d, J = 8.6 Hz, 2H), 4.02 
(t, J = 6.3 Hz, 2H), 1.77 – 1.39 (m, 4H), 
0.94 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 163.37, 
159.68, 155.01, 144.90, 137.30, 132.11, 
130.21, 129.73, 129.42, 122.58, 121.18, 
116.44, 114.92, 114.39, 101.31, 67.35, 
30.72, 18.76, 13.71. 
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py04  
(E)-3-(1-(4-chlorophenyl)-3-(4-
(hexyloxy)phenyl)-1H-pyrazol-4-yl)-2-
cyanoacrylic acid 
1H NMR (400 MHz, dmso) δ 13.83 (s, 1H), 
9.13 (s, 1H), 8.04 (s, 1H), 7.93 (d, J = 7.5 
Hz, 2H), 7.62 (d, J = 7.5 Hz, 2H), 7.52 (d, J 
= 7.4 Hz, 2H), 7.08 (d, J = 7.4 Hz, 2H), 4.01 
(t, 2H), 1.82 – 1.17 (m, 8H), 1.36 (d, J = 
44.7 Hz, 6H), 0.87 (t, 3H). 
13C NMR (101 MHz, dmso) δ 163.36, 
159.67, 155.01, 144.90, 137.31, 132.11, 
130.20, 129.73, 129.43, 122.58, 121.19, 
116.44, 114.92, 114.39, 101.32, 67.64, 
31.02, 28.63, 25.20, 22.11, 13.93. 
py05  
(E)-2-cyano-3-(3-(4-(octyloxy)phenyl)-
1-phenyl-1H-pyrazol-4-yl)acrylic acid 
1H NMR (400 MHz, dmso) δ 13.74 (s, 1H), 
9.15 (s, 1H), 8.08 (s, 1H), 7.91 (d, J = 7.4 
Hz, 2H), 7.66 – 7.55 (m, 3H), 7.48 (dd, J = 
24.4, 17.1 Hz, 2H), 7.11 (d, J = 7.5 Hz, 2H), 
4.04 (d, J = 5.0 Hz, 2H), 1.82 – 1.67 (m, 
2H), 1.63 – 1.09 (m, 10H), 0.86 (t, 3H). 
13C NMR (101 MHz, dmso) δ 163.42, 
159.64, 154.96, 145.11, 138.56, 130.24, 
129.87, 129.36, 128.01, 122.75, 119.63, 
116.58, 114.96, 114.22, 101.06, 67.65, 
31.26, 28.76, 28.70, 28.66, 25.53, 22.11, 
13.98. 
py06  
(E)-3-(1-(4-chlorophenyl)-3-(4-
(octyloxy)phenyl)-1H-pyrazol-4-yl)-2-
cyanoacrylic acid 
1H NMR (400 MHz, dmso) δ 13.84 (s, 1H), 
9.16 (s, 1H), 8.06 (s, 1H), 7.95 (d, J = 7.2 
Hz, 2H), 7.64 (d, J = 7.4 Hz, 2H), 7.54 (d, J 
= 7.3 Hz, 2H), 7.10 (d, J = 7.2 Hz, 2H), 4.03 
(t, 2H), 1.77 – 1.67 (m, 2H), 1.59 – 1.22 (m, 
10H), 0.86 (t, 3H). 
13C NMR (101 MHz, dmso) δ 163.36, 
159.68, 155.04, 144.93, 137.35, 132.13, 
130.23, 129.76, 129.53, 122.59, 121.26, 
116.43, 114.95, 114.41, 101.36, 67.64, 
31.26, 28.76, 28.69, 28.65, 25.53, 22.11, 
13.98. 
py07 
 
1H NMR (400 MHz, dmso) δ 9.15 (s, 1H), 
8.08 (s, 1H), 7.92 (d, J = 8.0 Hz, 2H), 7.58 
(dd, J = 19.6, 8.1 Hz, 4H), 7.47 (d, J = 7.3 
Hz, 1H), 7.11 (d, J = 7.9 Hz, 2H), 4.04 (s, 
13C NMR (101 MHz, dmso) δ 207.84, 
163.43, 159.66, 154.98, 149.86, 145.12, 
138.57, 130.26, 129.89, 128.04, 122.77, 
119.66, 116.60, 114.98, 114.24, 101.11, 
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(E)-2-cyano-3-(3-(4-
(decyloxy)phenyl)-1-phenyl-1H-
pyrazol-4-yl)acrylic acid 
2H), 1.83 – 1.66 (m, 2H), 1.62 – 1.13 (m, 
14H), 0.85 (t, 3H). 
67.65, 31.33, 29.04, 28.98, 28.79, 28.73, 
28.66, 25.52, 22.13, 13.99. 
py08  
(E)-3-(1-(4-chlorophenyl)-3-(4-
(decyloxy)phenyl)-1H-pyrazol-4-yl)-2-
cyanoacrylic acid 
1H NMR (400 MHz, dmso) δ 9.16 (s, 1H), 
8.06 (s, 1H), 7.96 (d, J = 7.3 Hz, 2H), 7.65 
(d, J = 7.3 Hz, 2H), 7.54 (d, J = 7.0 Hz, 2H), 
7.10 (d, J = 7.1 Hz, 2H), 4.03 (t, 2H), 1.73 
(s, 2H), 1.45 – 1.12 (m, 14H), 0.85 (t, 3H). 
13C NMR (101 MHz, dmso) δ 163.37, 
159.69, 155.06, 144.95, 137.36, 132.14, 
130.24, 129.78, 129.56, 122.60, 121.29, 
116.45, 114.97, 114.42, 101.40, 67.65, 
31.32, 29.04, 28.98, 28.79, 28.72, 28.65, 
25.52, 22.12, 13.98. 
py09  
(E)-3-(3-(4-(benzyloxy)phenyl)-1-
phenyl-1H-pyrazol-4-yl)-2-
cyanoacrylic acid 
1H NMR (400 MHz, dmso) δ 13.73 (s, 1H), 
9.13 (s, 1H), 8.07 (s, 1H), 7.90 (d, J = 7.9 
Hz, 2H), 7.57 (d, J = 7.7 Hz, 4H), 7.51 – 
7.30 (m, 6H), 7.20 (d, J = 7.5 Hz, 2H), 5.19 
(s, 2H). 
13C NMR (101 MHz, dmso) δ 163.44, 
159.29, 154.89, 145.08, 138.53, 136.80, 
130.27, 129.85, 129.33, 128.48, 128.00, 
127.94, 127.80, 123.14, 119.61, 116.59, 
115.33, 114.24, 101.05, 69.39. 
py10  
2-((1-(4-chlorophenyl)-3-(4-
ethoxyphenyl)-1H-pyrazol-4-
yl)methylene)malononitrile 
1H NMR (400 MHz, dmso) δ 9.95 (s, 1H), 
9.30 (s, 1H), 7.94 (dd, J = 51.7, 8.7 Hz, 4H), 
7.61 (d, J = 8.7 Hz, 2H), 7.03 (d, J = 8.6 Hz, 
2H), 4.08 (q, J = 13.5, 6.6 Hz, 2H), 1.35 (t, J 
= 6.8 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 184.54, 
159.39, 152.58, 137.42, 135.17, 131.76, 
130.05, 129.60, 123.29, 122.12, 121.38, 
120.75, 114.89, 114.37, 63.17, 14.63. 
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py11  
2-((3-(4-butoxyphenyl)-1-phenyl-1H-
pyrazol-4-yl)methylene)malononitrile 
1H NMR (400 MHz, dmso) δ 9.17 (s, 1H), 
8.17 (s, 1H), 7.93 (d, J = 7.0 Hz, 2H), 7.60 
(t, J = 7.9 Hz, 4H), 7.47 (t, J = 6.9 Hz, 1H), 
7.10 (d, J = 7.1 Hz, 2H), 4.05 (t, J = 4.9 Hz, 
2H), 1.80 – 1.65 (m, 2H), 1.52 – 1.38 (m, 
2H), 0.95 (t, J = 6.5 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 159.77, 
154.70, 152.63, 138.36, 130.40, 130.14, 
129.88, 128.28, 122.38, 119.79, 114.96, 
114.37, 113.94, 78.07, 67.34, 30.68, 
18.75, 13.70. 
py12  
2-((3-(4-butoxyphenyl)-1-(4-
chlorophenyl)-1H-pyrazol-4-
yl)methylene)malononitrile 
1H NMR (400 MHz, dmso) δ 9.18 (s, 1H), 
8.15 (s, 1H), 7.96 (d, J = 8.6 Hz, 2H), 7.63 
(dd, J = 20.4, 8.6 Hz, 4H), 7.09 (d, J = 8.5 
Hz, 2H), 4.04 (t, J = 6.4 Hz, 2H), 1.78 – 
1.65 (m, 2H), 1.53 – 1.39 (m, 2H), 0.95 (t, J 
= 7.4 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 159.82, 
154.77, 152.48, 137.15, 132.43, 130.39, 
129.78, 122.22, 121.44, 114.95, 114.54, 
114.33, 113.81, 78.41, 67.34, 30.68, 
18.75, 13.71. 
py13  
2-((1-(4-chlorophenyl)-3-(4-
(hexyloxy)phenyl)-1H-pyrazol-4-
yl)methylene)malononitrile 
1H NMR (400 MHz, dmso) δ 9.17 (s, 1H), 
8.14 (s, 1H), 7.96 (d, J = 8.6 Hz, 2H), 7.76 – 
7.43 (m, 4H), 7.08 (d, J = 8.4 Hz, 2H), 4.03 
(t, J = 6.1 Hz, 2H), 1.96 – 1.56 (m, 2H), 
1.37 (d, J = 43.8 Hz, 6H), 0.88 (s, 3H). 
13C NMR (101 MHz, dmso) δ 160.22, 
155.16, 152.87, 137.54, 132.84, 130.79, 
130.66, 130.18, 122.61, 121.82, 115.34, 
114.93, 114.74, 114.21, 78.79, 68.05, 
31.43, 29.02, 25.62, 22.52, 14.36. 
py14 
 
1H NMR (400 MHz, dmso) δ 9.15 (s, 1H), 
8.14 (s, 1H), 7.92 (d, J = 7.5 Hz, 2H), 7.58 
(m, 4H), 7.46 (t, J = 6.9 Hz, 1H), 7.08 (d, J 
= 7.0 Hz, 2H), 4.02 (t, J = 5.5 Hz, 2H), 1.84 
13C NMR (101 MHz, dmso) δ 160.18, 
155.10, 152.96, 138.75, 130.79, 130.57, 
130.48, 130.27, 128.67, 122.77, 120.16, 
119.84, 115.34, 114.79, 114.76, 114.35, 
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2-((3-(4-(octyloxy)phenyl)-1-phenyl-
1H-pyrazol-4-
yl)methylene)malononitrile 
– 1.59 (m, 2H), 1.50 – 1.00 (m, 10H), 0.86 
(s, 3H). 
78.43, 68.04, 31.69, 29.18, 29.12, 29.06, 
25.95, 22.53, 14.40. 
py15  
2-((1-(4-chlorophenyl)-3-(4-
(octyloxy)phenyl)-1H-pyrazol-4-
yl)methylene)malononitrile 
1H NMR (400 MHz, dmso) δ 9.18 (s, 1H), 
8.15 (s, 1H), 7.96 (d, J = 8.5 Hz, 2H), 7.69 – 
7.56 (m, 3H), 7.08 (d, J = 8.4 Hz, 2H), 4.03 
(t, J = 6.1 Hz, 2H), 1.92 – 1.59 (m, 2H), 
1.59 – 1.09 (m, 10H), 0.85 (s, 3H). 
13C NMR (101 MHz, dmso) δ 160.23, 
155.18, 152.89, 137.57, 132.85, 130.80, 
130.70, 130.57, 130.19, 122.63, 121.85, 
121.49, 115.36, 114.95, 114.74, 114.21, 
78.82, 68.06, 31.68, 29.17, 29.11, 29.05, 
25.95, 22.53, 14.40. 
py16  
2-((3-(4-(decyloxy)phenyl)-1-phenyl-
1H-pyrazol-4-
yl)methylene)malononitrile 
1H NMR (400 MHz, dmso) δ 9.17 (s, 1H), 
8.16 (s, 1H), 7.96 – 7.89 (m, 2H), 7.65 – 
7.56 (m, 3H), 7.51 – 7.43 (m, 1H), 7.09 (m, 
2H), 4.04 (s, 3H), 1.74 (s, 2H), 1.53 – 1.08 
(m, 14H), 0.85 (t, J = 6.4 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 160.19, 
155.12, 153.04, 138.78, 130.81, 130.59, 
130.31, 128.71, 122.79, 120.21, 119.89, 
115.38, 114.79, 114.35, 79.71, 78.49, 
68.05, 31.73, 29.45, 29.40, 29.19, 29.13, 
29.04, 25.93, 22.54, 14.40. 
py17  
2-((1-(4-chlorophenyl)-3-(4-
(decyloxy)phenyl)-1H-pyrazol-4-
yl)methylene)malononitrile 
1H NMR (400 MHz, dmso) δ 9.20 (s, 1H), 
8.17 (s, 1H), 8.02 – 7.93 (m, 2H), 7.71 – 
7.64 (m, 2H), 7.64 – 7.58 (m, 2H), 7.09 (d, J 
= 8.6 Hz, 2H), 4.04 (t, J = 6.4 Hz, 2H), 1.86 
– 1.66 (m, 2H), 1.51 – 1.18 (m, 14H), 0.85 
(t, J = 6.3 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 160.24, 
155.21, 152.94, 137.60, 132.86, 130.82, 
130.59, 130.22, 122.65, 121.90, 121.54, 
115.39, 114.97, 114.75, 114.22, 78.86, 
68.06, 31.73, 29.45, 29.39, 29.19, 29.13, 
29.03, 25.93, 22.53, 14.40. 
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py18  
2-((3-(4-(benzyloxy)phenyl)-1-phenyl-
1H-pyrazol-4-
yl)methylene)malononitrile 
1H NMR (400 MHz, dmso) δ 9.18 (s, 1H), 
8.18 (s, 1H), 7.97 – 7.87 (m, 2H), 7.69 – 
7.55 (m, 4H), 7.52 – 7.33 (m, 6H), 7.25 – 
7.13 (m, 2H), 5.20 (s, 2H). 
13C NMR (101 MHz, dmso) δ 159.84, 
155.03, 153.06, 138.78, 137.24, 130.84, 
130.58, 130.30, 128.92, 128.71, 128.37, 
128.16, 123.19, 120.22, 115.77, 114.80, 
114.36, 78.55, 69.79. 
py19  
5-((1-(4-chlorophenyl)-3-(4-
ethoxyphenyl)-1H-pyrazol-4-
yl)methylene)pyrimidine-
2,4,6(1H,3H,5H)-trione 
1H NMR (400 MHz, dmso) δ 11.32 (d, J = 
9.1 Hz, 2H), 9.77 (s, 1H), 8.15 (s, 1H), 7.96 
(d, J = 8.1 Hz, 2H), 7.65 (d, J = 8.1 Hz, 2H), 
7.54 (d, J = 8.0 Hz, 2H), 7.13 (d, J = 7.9 Hz, 
2H), 4.13 (s, 2H), 1.38 (s, 3H). 
13C NMR (101 MHz, dmso) δ 164.04, 
163.10, 159.98, 158.39, 150.69, 146.59, 
146.19, 143.96, 137.83, 134.93, 132.55, 
131.29, 130.26, 123.19, 123.10, 121.73, 
115.71, 115.26, 114.87, 63.73, 15.06. 
py20 
 
5-((3-(4-butoxyphenyl)-1-phenyl-1H-
pyrazol-4-yl)methylene)pyrimidine-
2,4,6(1H,3H,5H)-trione 
1H NMR (400 MHz, dmso) δ 11.30 (d, J = 
10.0 Hz, 2H), 9.77 (s, 1H), 8.17 (s, 1H), 
7.91 (d, J = 7.8 Hz, 2H), 7.70 – 7.30 (m, 
5H), 7.13 (d, J = 8.6 Hz, 2H), 4.07 (t, J = 
6.5 Hz, 2H), 1.88 – 1.66 (m, 2H), 1.47 (dd, J 
= 14.9, 7.4 Hz, 2H), 0.95 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 164.09, 
163.15, 160.11, 158.31, 150.68, 149.18, 
144.20, 139.01, 134.84, 131.28, 130.34, 
128.44, 123.24, 120.05, 115.53, 115.29, 
114.55, 67.80, 31.14, 19.18, 14.14. 
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py21  
5-((3-(4-butoxyphenyl)-1-(4-
chlorophenyl)-1H-pyrazol-4-
yl)methylene)pyrimidine-
2,4,6(1H,3H,5H)-trione 
1H NMR (400 MHz, dmso) δ 11.31 (d, J = 
10.5 Hz, 2H), 9.76 (s, 1H), 8.15 (s, 1H), 
7.96 (d, J = 8.9 Hz, 2H), 7.65 (d, J = 8.8 Hz, 
2H), 7.53 (d, J = 8.6 Hz, 2H), 7.13 (d, J = 
8.7 Hz, 2H), 4.07 (t, J = 6.4 Hz, 2H), 1.88 – 
1.65 (m, 2H), 1.57 – 1.33 (m, 2H), 0.96 (t, J 
= 7.4 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 164.03, 
163.09, 160.15, 158.37, 150.68, 143.96, 
137.83, 134.91, 132.55, 131.26, 130.25, 
123.09, 121.71, 115.70, 115.29, 114.85, 
67.80, 31.14, 19.17, 14.14. 
py22  
5-((1-(4-chlorophenyl)-3-(4-
(hexyloxy)phenyl)-1H-pyrazol-4-
yl)methylene)pyrimidine-
2,4,6(1H,3H,5H)-trione 
1H NMR (400 MHz, dmso) δ 11.32 (d, J = 
10.5 Hz, 2H), 9.77 (s, 2H), 8.16 (s, 1H), 
7.97 (d, J = 7.3 Hz, 2H), 7.65 (d, J = 8.0 Hz, 
2H), 7.54 (d, J = 8.3 Hz, 2H), 7.13 (d, J = 
7.5 Hz, 2H), 4.06 (s, 2H), 1.75 (s, 2H), 1.57 
– 1.23 (m, 6H), 0.89 (s, 3H). 
13C NMR (101 MHz, dmso) δ 164.05, 
163.10, 160.15, 150.69, 146.33, 145.99, 
143.95, 137.84, 132.56, 131.28, 130.26, 
123.09, 121.74, 115.70, 115.30, 114.88, 
68.11, 31.44, 25.62, 22.52, 14.37. 
py23 
 
5-((3-(4-(octyloxy)phenyl)-1-phenyl-
1H-pyrazol-4-
1H NMR (400 MHz, dmso) δ 11.30 (d, J = 
10.4 Hz, 2H), 9.77 (s, 1H), 8.18 (s, 1H), 
7.91 (d, J = 7.4 Hz, 2H), 7.70 – 7.36 (m, 
5H), 7.12 (d, J = 8.1 Hz, 2H), 4.06 (d, J = 
5.8 Hz, 2H), 1.92 – 1.66 (m, 2H), 1.56 – 
1.12 (m, 10H), 0.86 (s, 3H). 
13C NMR (101 MHz, dmso) δ 164.08, 
163.15, 160.10, 158.29, 150.68, 144.19, 
139.01, 134.83, 131.27, 130.33, 128.44, 
128.42, 123.24, 120.04, 115.53, 115.27, 
114.56, 68.10, 31.68, 29.18, 29.11, 29.09, 
25.96, 22.52, 14.40. 
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yl)methylene)pyrimidine-
2,4,6(1H,3H,5H)-trione 
py24  
5-((1-(4-chlorophenyl)-3-(4-
(octyloxy)phenyl)-1H-pyrazol-4-
yl)methylene)pyrimidine-
2,4,6(1H,3H,5H)-trione 
1H NMR (400 MHz, dmso) δ 11.31 (d, J = 
10.4 Hz, 2H), 9.76 (s, 1H), 8.15 (s, 1H), 
7.95 (d, J = 8.9 Hz, 2H), 7.64 (d, J = 8.9 Hz, 
2H), 7.53 (d, J = 8.7 Hz, 2H), 7.12 (d, J = 
8.7 Hz, 2H), 4.05 (t, J = 6.5 Hz, 2H), 1.96 – 
1.63 (m, 2H), 1.43 (d, J = 7.8 Hz, 2H), 1.30 
(dd, J = 13.9, 8.0 Hz, 8H), 0.87 (t, J = 6.8 
Hz, 3H). 
13C NMR (101 MHz, dmso) δ 164.02, 
163.08, 160.14, 158.36, 150.67, 143.97, 
137.82, 134.90, 132.54, 131.25, 130.23, 
123.08, 121.69, 115.69, 115.28, 114.84, 
68.10, 31.67, 29.18, 29.11, 25.95, 22.52, 
14.39. 
py25  
5-((3-(4-(decyloxy)phenyl)-1-phenyl-
1H-pyrazol-4-
yl)methylene)pyrimidine-
2,4,6(1H,3H,5H)-trione 
1H NMR (400 MHz, dmso) δ 11.27 (s, 2H), 
9.74 (d, J = 5.1 Hz, 1H), 8.15 (d, J = 5.0 Hz, 
1H), 7.89 (d, J = 5.8 Hz, 2H), 7.63 – 7.34 
(m, 5H), 7.09 (d, J = 6.3 Hz, 2H), 4.01 (d, J 
= 5.6 Hz, 2H), 1.83 – 1.61 (m, 2H), 1.50 – 
1.03 (m, 16H), 0.82 (t, J = 5.2 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 164.07, 
163.14, 160.09, 158.28, 150.67, 144.21, 
139.01, 134.81, 131.25, 130.32, 128.41, 
123.24, 120.00, 115.53, 115.26, 114.51, 
68.09, 31.73, 29.46, 29.40, 29.22, 29.14, 
25.95, 22.53, 14.38. 
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py26  
5-((1-(4-chlorophenyl)-3-(4-
(decyloxy)phenyl)-1H-pyrazol-4-
yl)methylene)pyrimidine-
2,4,6(1H,3H,5H)-trione 
1H NMR (400 MHz, dmso) δ 11.31 (d, J = 
9.5 Hz, 2H), 9.76 (s, 1H), 8.16 (s, 1H), 8.03 
– 7.88 (m, 2H), 7.74 – 7.59 (m, 2H), 7.53 (d, 
J = 8.7 Hz, 2H), 7.27 – 7.01 (m, 2H), 4.05 
(t, J = 6.5 Hz, 2H), 1.88 – 1.61 (m, 2H), 
1.52 – 1.39 (m, 2H), 1.39 – 1.15 (m, 12H), 
0.85 (t, J = 6.9 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 164.03, 
163.09, 160.15, 158.37, 150.68, 143.97, 
137.83, 134.92, 132.56, 131.26, 130.25, 
123.09, 121.71, 115.70, 115.29, 114.86, 
68.11, 31.73, 29.45, 29.39, 29.20, 29.13, 
29.07, 25.94, 22.53, 14.39. 
py27  
5-((3-(4-(benzyloxy)phenyl)-1-phenyl-
1H-pyrazol-4-
yl)methylene)pyrimidine-
2,4,6(1H,3H,5H)-trione 
1H NMR (400 MHz, dmso) δ 11.31 (d, J = 
10.0 Hz, 2H), 9.78 (s, 1H), 8.18 (s, 1H), 
7.92 (d, J = 7.9 Hz, 2H), 7.68 – 7.28 (m, 
9H), 7.23 (d, J = 8.5 Hz, 2H), 5.22 (s, 2H). 
13C NMR (101 MHz, dmso) δ 164.09, 
163.15, 159.75, 158.23, 150.69, 144.15, 
139.02, 137.24, 134.85, 131.31, 130.35, 
128.92, 128.38, 128.25, 123.63, 120.06, 
115.67, 115.55, 114.60, 69.83. 
py28 
 
5-((1,3-diphenyl-1H-pyrazol-4-
yl)methylene)pyrimidine-
1H NMR (400 MHz, dmso) δ 11.34 (d, J = 
8.6 Hz, 2H), 9.80 (s, 1H), 8.17 (s, 1H), 7.93 
(d, J = 7.8 Hz, 2H), 7.72 – 7.52 (m, 7H), 
7.48 (d, J = 7.4 Hz, 1H). 
13C NMR (101 MHz, dmso) δ 164.05, 
163.13, 158.40, 150.70, 143.85, 138.98, 
134.93, 131.18, 130.36, 129.96, 129.85, 
129.36, 128.53, 120.10, 115.60, 114.86. 
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2,4,6(1H,3H,5H)-trione 
py29 
 
5-((1-(4-chlorophenyl)-3-(4-
ethoxyphenyl)-1H-pyrazol-4-
yl)methylene)-2-
thioxodihydropyrimidine-4,6(1H,5H)-
dione 
1H NMR (400 MHz, dmso) δ 12.44 (s, 2H), 
9.81 (s, 1H), 8.17 (s, 1H), 7.98 (d, J = 8.7 
Hz, 2H), 7.66 (d, J = 8.7 Hz, 2H), 7.55 (d, J 
= 8.5 Hz, 2H), 7.13 (d, J = 8.6 Hz, 2H), 4.13 
(d, J = 7.0 Hz, 2H), 1.38 (t, J = 6.9 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 178.80, 
162.33, 160.90, 160.07, 158.62, 145.01, 
137.74, 135.23, 132.70, 131.35, 130.28, 
122.94, 121.84, 116.12, 115.29, 115.02, 
63.75, 15.06. 
py30  
5-((3-(4-butoxyphenyl)-1-phenyl-1H-
pyrazol-4-yl)methylene)-2-
thioxodihydropyrimidine-4,6(1H,5H)-
dione 
1H NMR (400 MHz, dmso) δ 12.42 (s, 2H), 
9.81 (s, 1H), 8.19 (s, 1H), 7.93 (d, J = 7.9 
Hz, 2H), 7.64 – 7.52 (m, 4H), 7.48 (d, J = 
7.4 Hz, 1H), 7.14 (d, J = 8.7 Hz, 2H), 4.08 
(t, J = 6.5 Hz, 2H), 1.87 – 1.65 (m, 2H), 
1.48 (dd, J = 15.0, 7.4 Hz, 2H), 0.96 (t, J = 
7.4 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 178.77, 
162.36, 160.94, 160.20, 158.55, 138.92, 
135.13, 131.33, 130.36, 128.58, 123.08, 
120.13, 115.96, 115.32, 114.70, 67.81, 
31.14, 19.18, 14.14. 
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py31 
 
5-((3-(4-butoxyphenyl)-1-(4-
chlorophenyl)-1H-pyrazol-4-
yl)methylene)-2-
thioxodihydropyrimidine-4,6(1H,5H)-
dione 
1H NMR (400 MHz, dmso) δ 12.43 (s, 2H), 
9.80 (s, 1H), 8.16 (s, 1H), 8.08 – 7.85 (m, 
2H), 7.74 – 7.61 (m, 2H), 7.54 (d, J = 8.7 
Hz, 2H), 7.13 (d, J = 8.8 Hz, 2H), 4.07 (t, J 
= 6.5 Hz, 2H), 1.88 – 1.59 (m, 2H), 1.59 – 
1.33 (m, 2H), 0.96 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 178.79, 
162.31, 160.88, 160.24, 158.61, 137.73, 
135.21, 132.70, 131.32, 130.27, 122.93, 
121.81, 116.11, 115.33, 114.99, 67.82, 
31.13, 19.17, 14.14. 
py32 
 
5-((1-(4-chlorophenyl)-3-(4-
(hexyloxy)phenyl)-1H-pyrazol-4-
yl)methylene)-2-
thioxodihydropyrimidine-4,6(1H,5H)-
dione 
1H NMR (400 MHz, dmso) δ 12.43 (s, 2H), 
9.80 (s, 1H), 8.16 (s, 1H), 7.97 (d, J = 8.8 
Hz, 2H), 7.65 (d, J = 8.9 Hz, 2H), 7.54 (d, J 
= 8.6 Hz, 2H), 7.13 (d, J = 8.7 Hz, 2H), 4.06 
(t, J = 6.5 Hz, 2H), 1.92 – 1.63 (m, 2H), 
1.59 – 1.19 (m, 6H), 0.89 (t, J = 6.9 Hz, 
3H). 
13C NMR (101 MHz, dmso) δ 178.79, 
162.31, 160.88, 160.23, 158.59, 145.00, 
137.73, 135.20, 132.69, 131.32, 130.26, 
122.93, 121.80, 116.10, 115.32, 114.99, 
68.12, 31.44, 29.05, 25.62, 22.52, 14.37. 
py33 
 
1H NMR (400 MHz, dmso) δ 12.41 (s, 2H), 
9.80 (s, 1H), 8.19 (s, 1H), 7.92 (d, J = 7.9 
Hz, 2H), 7.60 (t, J = 7.8 Hz, 2H), 7.54 (d, J 
= 8.5 Hz, 2H), 7.47 (t, J = 7.4 Hz, 1H), 7.12 
(d, J = 8.5 Hz, 2H), 4.05 (t, J = 6.4 Hz, 2H), 
13C NMR (101 MHz, dmso) δ 178.76, 
162.35, 160.92, 160.18, 158.53, 145.27, 
138.91, 135.11, 131.31, 130.34, 128.56, 
123.07, 120.10, 115.95, 115.30, 114.66, 
68.11, 31.68, 29.18, 29.11, 29.09, 25.96, 
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5-((3-(4-(octyloxy)phenyl)-1-phenyl-
1H-pyrazol-4-yl)methylene)-2-
thioxodihydropyrimidine-4,6(1H,5H)-
dione 
1.86 – 1.65 (m, 2H), 1.48 – 1.38 (m, 2H), 
1.38 – 1.18 (m, 8H), 0.86 (t, J = 6.2 Hz, 
3H). 
22.52, 14.40. 
py34 
 
5-((1-(4-chlorophenyl)-3-(4-
(octyloxy)phenyl)-1H-pyrazol-4-
yl)methylene)-2-
thioxodihydropyrimidine-4,6(1H,5H)-
dione 
1H NMR (400 MHz, dmso) δ 12.43 (s, 2H), 
9.80 (s, 1H), 8.17 (s, 1H), 7.97 (d, J = 8.9 
Hz, 2H), 7.66 (d, J = 8.9 Hz, 2H), 7.55 (d, J 
= 8.7 Hz, 2H), 7.13 (d, J = 8.7 Hz, 2H), 4.06 
(t, J = 6.5 Hz, 2H), 1.87 – 1.63 (m, 2H), 
1.43 (d, J = 8.2 Hz, 2H), 1.39 – 1.15 (m, 
8H), 0.87 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 178.79, 
162.31, 160.88, 160.24, 158.60, 144.76, 
143.41, 135.23, 132.70, 131.32, 130.27, 
122.93, 121.82, 116.11, 115.33, 115.01, 
106.75, 68.12, 31.67, 29.17, 29.10, 25.95, 
22.52, 14.40. 
py35  
5-((3-(4-(decyloxy)phenyl)-1-phenyl-
1H-pyrazol-4-yl)methylene)-2-
thioxodihydropyrimidine-4,6(1H,5H)-
dione 
1H NMR (400 MHz, dmso) δ 12.42 (s, 2H), 
9.81 (s, 1H), 8.20 (s, 1H), 8.04 – 7.86 (m, 
2H), 7.65 – 7.52 (m, 4H), 7.48 (t, J = 7.4 
Hz, 1H), 7.13 (d, J = 8.8 Hz, 2H), 4.06 (t, J 
= 6.5 Hz, 2H), 1.98 – 1.62 (m, 2H), 1.52 – 
1.38 (m, 2H), 1.38 – 1.10 (m, 12H), 0.86 (t, 
J = 6.8 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 178.76, 
162.35, 160.93, 160.19, 158.53, 145.27, 
138.92, 135.12, 131.31, 130.35, 128.57, 
123.08, 120.10, 115.95, 115.30, 114.67, 
68.11, 31.73, 29.45, 29.40, 29.21, 29.14, 
29.08, 25.94, 22.53, 14.39. 
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py36 
 
5-((1-(4-chlorophenyl)-3-(4-
(decyloxy)phenyl)-1H-pyrazol-4-
yl)methylene)-2-
thioxodihydropyrimidine-4,6(1H,5H)-
dione 
1H NMR (400 MHz, dmso) δ 12.43 (s, 1H), 
9.80 (s, 1H), 8.17 (s, 1H), 8.00 – 7.94 (m, 
1H), 7.69 – 7.63 (m, 1H), 7.58 – 7.50 (m, 
1H), 7.13 (d, J = 8.8 Hz, 1H), 4.06 (t, J = 
6.5 Hz, 1H), 1.88 – 1.63 (m, 1H), 1.43 (d, J 
= 7.8 Hz, 1H), 1.39 – 1.17 (m, 6H), 0.86 (t, 
J = 6.9 Hz, 2H). 
13C NMR (101 MHz, dmso) δ 178.80, 
162.31, 160.88, 160.24, 158.60, 145.00, 
137.74, 135.23, 132.70, 131.32, 130.28, 
122.93, 121.82, 116.11, 115.33, 115.02, 
68.11, 31.73, 29.45, 29.39, 29.20, 29.13, 
29.07, 25.94, 22.53, 14.40. 
py37  
5-((3-(4-(benzyloxy)phenyl)-1-phenyl-
1H-pyrazol-4-yl)methylene)-2-
thioxodihydropyrimidine-4,6(1H,5H)-
dione 
1H NMR (400 MHz, dmso) δ 12.43 (s, 2H), 
9.81 (s, 1H), 8.18 (s, 1H), 7.93 (d, J = 6.1 
Hz, 2H), 7.76 – 7.28 (m, 10H), 7.24 (d, J = 
6.5 Hz, 2H), 5.22 (s, 2H). 
13C NMR (101 MHz, dmso) δ 178.78, 
162.37, 160.94, 159.84, 158.48, 145.21, 
138.92, 137.22, 135.15, 131.36, 130.37, 
128.92, 128.61, 128.38, 128.25, 123.46, 
120.15, 115.97, 115.70, 114.76, 69.84. 
py38 
 
5-((1,3-diphenyl-1H-pyrazol-4-
1H NMR (400 MHz, dmso) δ 12.44 (s, 2H), 
9.84 (s, 1H), 8.19 (s, 1H), 8.02 – 7.90 (m, 
2H), 7.70 – 7.54 (m, 7H), 7.49 (t, J = 7.4 
Hz, 1H). 
13C NMR (101 MHz, dmso) δ 178.78, 
162.32, 160.92, 158.65, 144.94, 138.90, 
135.23, 131.02, 130.39, 129.99, 129.96, 
129.39, 128.67, 120.19, 116.01, 115.01. 
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yl)methylene)-2-
thioxodihydropyrimidine-4,6(1H,5H)-
dione 
py39  
5-((3-(4-butoxyphenyl)-1-phenyl-1H-
pyrazol-4-yl)methylene)-1,3-
dimethylpyrimidine-2,4,6(1H,3H,5H)-
trione 
1H NMR (400 MHz, dmso) δ 9.72 (s, 1H), 
8.22 (s, 1H), 7.88 (d, J = 8.2 Hz, 2H), 7.60 – 
7.38 (m, 5H), 7.08 (d, J = 8.5 Hz, 2H), 4.03 
(t, J = 6.4 Hz, 2H), 3.22 (s, 3H), 3.17 (s, 
3H), 1.81 – 1.59 (m, 2H), 1.59 – 1.32 (m, 
2H), 0.93 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 162.74, 
161.68, 160.13, 158.45, 151.45, 145.17, 
138.90, 134.63, 131.25, 130.31, 128.44, 
123.13, 119.98, 115.57, 115.26, 114.04, 
67.80, 31.15, 28.93, 28.36, 19.18, 14.14. 
py40  
5-((3-(4-butoxyphenyl)-1-(4-
chlorophenyl)-1H-pyrazol-4-
yl)methylene)-1,3-dimethylpyrimidine-
2,4,6(1H,3H,5H)-trione 
1H NMR (400 MHz, dmso) δ 9.76 (s, 1H), 
8.23 (s, 1H), 7.96 (d, J = 8.7 Hz, 2H), 7.64 
(d, J = 8.8 Hz, 2H), 7.51 (d, J = 8.5 Hz, 2H), 
7.12 (d, J = 8.5 Hz, 2H), 4.07 (t, J = 6.4 Hz, 
2H), 3.26 (s, 3H), 3.21 (s, 3H), 1.93 – 1.61 
(m, 2H), 1.61 – 1.37 (m, 2H), 0.96 (t, J = 
7.4 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 162.73, 
161.67, 160.19, 158.53, 151.47, 144.91, 
137.72, 134.74, 132.58, 131.26, 130.24, 
122.99, 121.67, 115.75, 115.29, 109.98, 
67.81, 31.14, 28.96, 28.38, 19.18, 14.14. 
 
154 
 
py41  
1,3-dimethyl-5-((3-(4-
(octyloxy)phenyl)-1-phenyl-1H-
pyrazol-4-yl)methylene)pyrimidine-
2,4,6(1H,3H,5H)-trione 
1H NMR (400 MHz, dmso) δ 9.78 (s, 1H), 
8.27 (s, 1H), 7.93 (d, J = 7.7 Hz, 2H), 7.60 
(t, J = 7.9 Hz, 2H), 7.52 (d, J = 8.7 Hz, 2H), 
7.47 (d, J = 7.4 Hz, 1H), 7.12 (d, J = 8.7 Hz, 
2H), 4.06 (t, J = 6.5 Hz, 2H), 3.26 (s, 3H), 
3.21 (s, 3H), 1.88 – 1.66 (m, 2H), 1.43 (d, J 
= 7.7 Hz, 2H), 1.39 – 1.20 (m, 8H), 0.87 (t, 
J = 6.7 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 162.79, 
161.73, 160.15, 158.48, 151.50, 145.16, 
138.95, 134.70, 131.27, 130.34, 128.47, 
123.17, 120.06, 115.60, 115.30, 114.19, 
68.11, 31.68, 29.18, 29.11, 29.08, 28.95, 
28.38, 25.96, 22.53, 14.40. 
py42  
5-((1-(4-chlorophenyl)-3-(4-
(octyloxy)phenyl)-1H-pyrazol-4-
yl)methylene)-1,3-dimethylpyrimidine-
2,4,6(1H,3H,5H)-trione 
1H NMR (400 MHz, dmso) δ 9.77 (s, 1H), 
8.24 (s, 1H), 8.05 – 7.85 (m, 2H), 7.76 – 
7.58 (m, 2H), 7.51 (d, J = 8.6 Hz, 2H), 7.12 
(d, J = 8.7 Hz, 2H), 4.06 (t, J = 6.5 Hz, 2H), 
3.26 (s, 3H), 3.21 (s, 3H), 1.88 – 1.66 (m, 
2H), 1.51 – 1.39 (m, 2H), 1.39 – 1.20 (m, 
8H), 0.87 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 162.73, 
161.67, 160.18, 158.52, 151.47, 144.92, 
137.73, 134.73, 132.59, 131.25, 130.24, 
122.99, 121.67, 115.75, 115.29, 114.42, 
68.12, 67.63, 31.68, 29.18, 29.11, 28.95, 
28.38, 25.96, 22.53, 14.40. 
py43 
 
5-((3-(4-(decyloxy)phenyl)-1-phenyl-
1H-pyrazol-4-yl)methylene)-1,3-
1H NMR (400 MHz, dmso) δ 9.75 (s, 1H), 
8.24 (s, 1H), 7.98 – 7.81 (m, 2H), 7.51 (ddd, 
J = 26.9, 18.0, 7.5 Hz, 5H), 7.09 (d, J = 8.7 
Hz, 2H), 4.03 (t, J = 6.5 Hz, 2H), 3.23 (s, 
3H), 3.18 (s, 3H), 1.90 – 1.63 (m, 2H), 1.40 
(d, J = 8.1 Hz, 2H), 1.26 (t, J = 15.2 Hz, 
12H), 0.82 (t, J = 6.9 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 164.39, 
162.79, 161.75, 160.15, 151.50, 145.16, 
144.59, 140.16, 138.95, 131.27, 130.34, 
129.85, 128.46, 120.06, 115.60, 115.30, 
95.46, 68.11, 31.73, 29.46, 29.40, 29.21, 
29.14, 29.08, 28.38, 25.94, 22.53, 14.39. 
 
155 
 
dimethylpyrimidine-2,4,6(1H,3H,5H)-
trione 
py44  
5-((1-(4-chlorophenyl)-3-(4-
(decyloxy)phenyl)-1H-pyrazol-4-
yl)methylene)-1,3-dimethylpyrimidine-
2,4,6(1H,3H,5H)-trione 
1H NMR (400 MHz, dmso) δ 9.77 (s, 1H), 
8.24 (s, 1H), 8.07 – 7.87 (m, 2H), 7.72 – 
7.58 (m, 2H), 7.51 (d, J = 8.7 Hz, 2H), 7.12 
(d, J = 8.7 Hz, 2H), 4.06 (t, J = 6.4 Hz, 2H), 
3.27 (d, J = 4.8 Hz, 3H), 3.21 (s, 3H), 1.92 – 
1.63 (m, 2H), 1.50 – 1.39 (m, 2H), 1.29 (t, J 
= 15.2 Hz, 12H), 0.86 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 164.32, 
162.73, 161.68, 160.18, 151.47, 144.92, 
137.73, 134.74, 132.59, 131.25, 130.24, 
123.00, 121.67, 115.75, 115.29, 109.99, 
68.12, 31.73, 29.46, 29.40, 29.21, 29.14, 
29.08, 28.95, 28.38, 25.94, 22.53, 14.39. 
py45  
(E)-ethyl 3-(1-(4-chlorophenyl)-3-(4-
ethoxyphenyl)-1H-pyrazol-4-yl)-2-
cyanoacrylate 
1H NMR (400 MHz, dmso) δ 9.14 (s, 1H), 
8.21 – 7.83 (m, 4H), 7.83 – 7.43 (m, 5H), 
7.10 (d, J = 8.6 Hz, 2H), 4.11 (d, J = 6.9 Hz, 
2H), 1.36 (t, J = 6.1 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 162.88, 
159.81, 154.88, 142.00, 137.91, 132.31, 
130.61, 130.17, 129.54, 123.35, 121.54, 
117.29, 115.30, 114.96, 105.14, 63.68, 
15.06. 
py46 
 
(E)-ethyl 3-(1-(4-chlorophenyl)-3-(4-
(hexyloxy)phenyl)-1H-pyrazol-4-yl)-2-
1H NMR (400 MHz, dmso) δ 9.13 (s, 1H), 
8.00 (s, 1H), 7.96 (d, J = 8.4 Hz, 2H), 7.89 
(s, 1H), 7.70 (s, 1H), 7.64 (d, J = 8.5 Hz, 
2H), 7.55 (d, J = 8.1 Hz, 2H), 7.10 (d, J = 
8.2 Hz, 2H), 4.03 (s, 2H), 1.73 (s, 2H), 1.43 
(s, 2H), 1.32 (s, 4H), 0.88 (s, 3H). 
13C NMR (101 MHz, dmso) δ 162.87, 
159.98, 154.89, 142.01, 137.90, 132.31, 
130.59, 130.17, 129.52, 123.33, 121.52, 
117.30, 115.33, 114.95, 105.11, 68.06, 
31.43, 29.04, 25.62, 22.52, 14.36. 
 
156 
 
cyanoacrylate 
py47  
(E)-3-(1-(4-chlorophenyl)-3-(4-
ethoxyphenyl)-1H-pyrazol-4-yl)-2-
cyanoacrylamide 
1H NMR (400 MHz, dmso) δ 9.18 (s, 1H), 
8.10 (s, 1H), 7.97 (d, J = 7.4 Hz, 2H), 7.66 
(d, J = 7.6 Hz, 2H), 7.56 (d, J = 7.6 Hz, 2H), 
7.11 (d, J = 7.6 Hz, 2H), 4.29 (d, J = 6.8 Hz, 
2H), 4.11 (d, J = 6.5 Hz, 2H), 1.37 (d, J = 
5.8 Hz, 3H), 1.28 (t, J = 6.5 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 162.42, 
160.01, 156.80, 155.69, 146.13, 137.73, 
132.66, 130.73, 130.21, 122.93, 121.80, 
116.37, 115.37, 114.79, 100.36, 63.73, 
62.60, 15.04, 14.45. 
py48  
(E)-3-(1-(4-chlorophenyl)-3-(4-
(hexyloxy)phenyl)-1H-pyrazol-4-yl)-2-
cyanoacrylamide 
1H NMR (400 MHz, dmso) δ 9.18 (s, 1H), 
8.10 (s, 1H), 7.97 (d, J = 7.9 Hz, 2H), 7.66 
(d, J = 7.8 Hz, 2H), 7.55 (d, J = 7.6 Hz, 2H), 
7.12 (d, J = 7.7 Hz, 2H), 4.29 (d, J = 6.7 Hz, 
2H), 4.05 (s, 2H), 1.74 (s, 2H), 1.50 – 1.19 
(m, 9H), 0.88 (s, 3H). 
13C NMR (101 MHz, dmso) δ 162.42, 
160.17, 155.69, 146.13, 137.73, 132.66, 
130.72, 130.21, 122.91, 121.80, 116.38, 
115.41, 114.79, 109.99, 100.37, 68.09, 
62.61, 31.43, 29.02, 25.61, 22.52, 14.45, 
14.37. 
py49  
(Z)-5-((1-(4-chlorophenyl)-3-(4-
ethoxyphenyl)-1H-pyrazol-4-
yl)methylene)thiazolidine-2,4-dione 
1H NMR (400 MHz, dmso) δ 12.53 (s, 1H), 
8.68 (s, 1H), 8.04 (d, J = 8.6 Hz, 2H), 7.78 – 
7.41 (m, 5H), 7.09 (d, J = 8.4 Hz, 2H), 4.11 
(d, J = 6.8 Hz, 2H), 1.37 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 167.96, 
167.54, 159.65, 154.06, 138.02, 131.87, 
130.41, 129.90, 128.39, 123.70, 123.05, 
122.44, 121.30, 116.00, 115.26, 63.66, 
15.06. 
 
157 
 
py50  
(Z)-5-((1-(4-chlorophenyl)-3-(4-
(hexyloxy)phenyl)-1H-pyrazol-4-
yl)methylene)thiazolidine-2,4-dione 
1H NMR (400 MHz, dmso) δ 12.54 (s, 1H), 
8.69 (s, 1H), 8.06 (d, J = 8.7 Hz, 2H), 7.70 – 
7.41 (m, 5H), 7.10 (d, J = 8.5 Hz, 2H), 4.04 
(t, J = 6.2 Hz, 2H), 1.86 – 1.63 (m, 2H), 
1.44 (s, 2H), 1.33 (s, 4H), 0.89 (s, 3H). 
13C NMR (101 MHz, dmso) δ 168.00, 
159.82, 154.08, 140.67, 140.06, 138.04, 
134.92, 132.33, 131.88, 130.41, 129.92, 
128.43, 123.69, 122.43, 121.33, 116.02, 
115.31, 68.05, 31.43, 29.05, 25.62, 22.52, 
14.37. 
py51 
 
(Z)-5-((1,3-diphenyl-1H-pyrazol-4-
yl)methylene)thiazolidine-2,4-dione 
1H NMR (400 MHz, dmso) δ 12.54 (s, 1H), 
8.69 (s, 1H), 8.01 (d, J = 7.8 Hz, 2H), 7.70 – 
7.31 (m, 10H). 
13C NMR (101 MHz, dmso) δ 167.91, 
167.49, 154.00, 139.19, 131.76, 130.04, 
129.44, 129.38, 129.11, 128.43, 127.90, 
123.06, 122.47, 119.80, 115.92. 
py52  
(Z)-5-((1-(4-chlorophenyl)-3-(4-
ethoxyphenyl)-1H-pyrazol-4-
yl)methylene)-2-thioxothiazolidin-4-
one 
1H NMR (400 MHz, dmso) δ 13.72 (s, 1H), 
8.67 (s, 1H), 8.05 (d, J = 8.7 Hz, 2H), 7.58 
(d, J = 8.7 Hz, 2H), 7.52 (d, J = 8.5 Hz, 2H), 
7.34 (s, 1H), 7.07 (d, J = 8.5 Hz, 2H), 4.35 – 
3.87 (m, 2H), 1.36 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 195.45, 
169.46, 159.70, 154.31, 137.89, 131.96, 
130.46, 129.84, 128.75, 124.69, 123.51, 
122.18, 121.28, 116.13, 115.24, 63.66, 
15.06. 
 
158 
 
py53  
(Z)-5-((1-(4-chlorophenyl)-3-(4-
(hexyloxy)phenyl)-1H-pyrazol-4-
yl)methylene)-2-thioxothiazolidin-4-
one 
1H NMR (400 MHz, dmso) δ 13.73 (s, 1H), 
8.70 (s, 1H), 8.06 (d, J = 8.8 Hz, 2H), 7.70 – 
7.43 (m, 4H), 7.35 (s, 1H), 7.08 (d, J = 8.5 
Hz, 2H), 4.03 (t, J = 6.2 Hz, 2H), 1.83 – 
1.57 (m, 2H), 1.56 – 1.21 (m, 6H), 0.88 (s, 
3H). 
13C NMR (101 MHz, dmso) δ 195.46, 
169.46, 159.88, 154.34, 137.91, 131.97, 
130.46, 129.86, 128.81, 124.71, 123.50, 
122.21, 121.31, 116.14, 115.29, 68.04, 
31.45, 29.06, 25.63, 22.53, 14.37. 
py54  
(Z)-5-((1,3-diphenyl-1H-pyrazol-4-
yl)methylene)-2-thioxothiazolidin-4-
one 
1H NMR (400 MHz, dmso) δ 13.75 (s, 1H), 
8.75 (s, 1H), 8.13 – 7.96 (m, 2H), 7.68 – 
7.53 (m, 8H), 7.46 – 7.37 (m, 2H). 
13C NMR (101 MHz, dmso) δ 195.52, 
169.52, 154.30, 139.12, 131.61, 130.02, 
129.54, 129.41, 129.19, 128.91, 127.99, 
124.86, 122.20, 119.86, 116.10. 
py55  
(Z)-2-(5-((1-(4-chlorophenyl)-3-(4-
ethoxyphenyl)-1H-pyrazol-4-
yl)methylene)-2,4-dioxothiazolidin-3-
yl)acetic acid 
1H NMR (400 MHz, dmso) δ 13.47 (s, 1H), 
8.76 (s, 1H), 8.05 (d, J = 8.7 Hz, 2H), 7.68 
(s, 1H), 7.57 (dd, J = 26.7, 8.6 Hz, 4H), 7.09 
(d, J = 8.6 Hz, 2H), 4.35 (s, 2H), 4.10 (q, J = 
6.9 Hz, 2H), 1.36 (t, J = 6.9 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 168.00, 
166.61, 164.74, 159.29, 153.83, 137.53, 
131.57, 130.03, 129.48, 128.35, 124.12, 
123.13, 120.93, 119.57, 115.31, 114.84, 
63.24, 42.37, 14.63. 
 
159 
 
py56  
(Z)-2-(5-((1-(4-chlorophenyl)-3-(4-
(hexyloxy)phenyl)-1H-pyrazol-4-
yl)methylene)-2,4-dioxothiazolidin-3-
yl)acetic acid 
1H NMR (400 MHz, dmso) δ 8.78 (s, 1H), 
8.06 (d, J = 8.8 Hz, 2H), 7.69 (s, 1H), 7.63 (s, 
1H), 7.61 – 7.47 (m, 3H), 7.09 (d, J = 8.7 Hz, 
2H), 4.36 (s, 2H), 4.03 (t, J = 6.5 Hz, 2H), 
1.82 – 1.64 (m, 2H), 1.48 – 1.28 (m, 6H), 
0.88 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 168.01, 
166.62, 164.75, 159.47, 153.86, 137.55, 
131.59, 130.04, 129.50, 128.40, 124.15, 
123.13, 120.97, 119.59, 115.32, 114.90, 
67.64, 42.34, 31.03, 28.63, 25.21, 22.11, 
13.95. 
 
Table I-3. Structures, Names, 1H NMR and 13C NMR data for hydrazide derivatives (Chapter 5) 
No. structures 
NMR 
1H NMR 13C NMR 
zh01 
 
(E)-N'-benzylidene-4-
(cyclohexylmethoxy) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.70 (s, 1H), 8.41 
(s, 1H), 7.86 (d, J = 8.6 Hz, 2H), 7.69 (d, J = 6.4 
Hz, 2H), 7.42 (d, J = 7.3 Hz, 3H), 7.01 (d, J = 8.6 
Hz, 2H), 3.82 (d, J = 6.2 Hz, 2H), 1.90 – 1.50 (m, 
6H), 1.34 – 0.82 (m, 5H). 
13C NMR (101 MHz, dmso) δ 162.90, 
162.02, 147.49, 134.88, 130.36, 129.95, 
129.26, 127.41, 125.57, 114.57, 73.32, 37.44, 
29.62, 26.45, 25.67. 
zh02 
 
(E)-4-(cyclohexylmethoxy) -N'-(4-
1H NMR (400 MHz, dmso) δ 11.50 (s, 1H), 9.90 
(s, 1H), 8.30 (s, 1H), 7.84 (d, J = 7.5 Hz, 2H), 
7.51 (d, J = 7.9 Hz, 2H), 6.99 (d, J = 7.9 Hz, 2H), 
6.80 (d, J = 7.8 Hz, 2H), 3.81 (d, J = 6.0 Hz, 2H), 
13C NMR (101 MHz, dmso) δ 162.66, 
161.87, 159.71, 147.84, 129.82, 129.16, 
125.85, 125.81, 116.10, 114.51, 73.30, 37.44, 
29.62, 26.45, 25.68. 
 
160 
 
hydroxybenzylidene) 
benzohydrazide 
1.85 – 1.52 (m, 6H), 1.30 – 0.86 (m, 5H). 
zh03 
 
(E)-2-((2-(4-(cyclohexylmethoxy) 
benzoyl) hydrazono)methyl) 
benzoic acid 
1H NMR (400 MHz, dmso) δ 13.31 (s, 1H), 11.91 
(s, 1H), 9.14 (s, 1H), 8.03 (d, J = 7.5 Hz, 1H), 
7.96 – 7.74 (m, 3H), 7.60 (t, J = 7.3 Hz, 1H), 7.48 
(t, J = 7.4 Hz, 1H), 7.00 (d, J = 8.7 Hz, 2H), 3.82 
(d, J = 6.2 Hz, 2H), 1.94 – 1.50 (m, 6H), 1.32 – 
0.92 (m, 5H). 
13C NMR (101 MHz, dmso) δ 168.55, 
163.02, 162.06, 146.20, 135.18, 132.36, 
131.02, 130.70, 130.07, 129.85, 126.98, 
125.47, 114.50, 73.32, 37.45, 29.62, 26.45, 
25.67. 
zh04  
(E)-4-(cyclohexylmethoxy) -N'-(4-
nitrobenzylidene) benzohydrazide 
1H NMR (400 MHz, dmso) δ 12.02 (s, 1H), 8.53 
(s, 1H), 8.29 (d, J = 7.8 Hz, 2H), 7.97 (d, J = 6.1 
Hz, 2H), 7.91 (d, J = 7.4 Hz, 2H), 7.05 (d, J = 7.9 
Hz, 2H), 3.85 (d, J = 4.3 Hz, 2H), 1.99 – 1.44 (m, 
6H), 1.15 (m, 5H). 
13C NMR (101 MHz, dmso) δ 163.13, 
162.24, 148.12, 144.90, 141.25, 130.13, 
128.28, 125.21, 124.49, 114.61, 73.35, 37.44, 
29.61, 26.44, 25.67. 
zh05 
 
(E)-4-((2-(4-(cyclohexylmethoxy) 
benzoyl) hydrazono)methyl) 
benzoic acid 
1H NMR (400 MHz, dmso) δ 12.72 (s, 1H), 11.84 
(s, 1H), 8.46 (s, 1H), 8.05 – 7.90 (m, 2H), 7.90 – 
7.43 (m, 3H), 6.97 (t, J = 18.8 Hz, 2H), 3.74 (dd, 
J = 6.2 Hz, 2H), 1.92 – 1.41 (m, 6H), 1.41 – 0.68 
(m, 5H). 
13C NMR (101 MHz, dmso) δ 167.33, 
163.03, 162.13, 146.23, 138.96, 131.95, 
130.19, 130.04, 127.38, 125.41, 114.57, 
73.33, 40.54, 40.33, 40.12, 39.92, 39.71, 
39.50, 39.29, 37.44, 29.60, 26.44, 25.67. 
zh06  
(E)-4-(cyclohexylmethoxy) -N'-(4-
(trifluoromethyl) benzylidene) 
1H NMR (400 MHz, dmso) δ 11.90 (s, 1H), 8.48 
(s, 1H), 7.97 – 7.71 (m, 5H), 7.02 (d, J = 8.5 Hz, 
2H), 3.83 (d, J = 6.1 Hz, 2H), 2.01 – 1.47 (m, 
6H), 1.39 – 0.84 (m, 5H). 
13C NMR (101 MHz, dmso) δ 163.09, 
162.17, 145.66, 138.88, 130.07, 127.96, 
126.17, 126.13, 125.34, 123.20, 114.62, 
73.34, 37.44, 29.61, 26.45, 25.67. 
 
161 
 
benzohydrazide 
zh07 
 
(E)-4-(cyclohexylmethoxy) -N'-(4-
hydroxy-3-methylbenzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.46 (s, 1H), 9.80 
(s, 2H), 8.25 (s, 1H), 7.84 (d, J = 8.4 Hz, 2H), 
7.42 (s, 1H), 7.31 (d, J = 7.9 Hz, 1H), 7.00 (d, J = 
8.5 Hz, 2H), 6.80 (d, J = 8.2 Hz, 1H), 3.82 (d, J = 
6.1 Hz, 2H), 2.12 (s, 3H), 1.92 – 1.48 (m, 6H), 
1.35 – 0.84 (m, 5H). 
13C NMR (101 MHz, dmso) δ 162.62, 
161.85, 157.92, 147.97, 129.82, 129.71, 
126.84, 125.85, 125.66, 124.87, 115.22, 
114.51, 73.30, 68.37, 37.45, 29.62, 26.46, 
25.76, 25.68, 16.36. 
zh08 
 
(E)-4-(cyclohexylmethoxy)-N'-(4-
hydroxy-3-methoxybenzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.51 (s, 1H), 9.51 
(s, 1H), 8.29 (s, 1H), 7.84 (d, J = 8.6 Hz, 2H), 
7.27 (s, 1H), 7.01 (t, J = 10.5 Hz, 3H), 6.80 (d, J 
= 8.0 Hz, 1H), 3.87 – 3.62 (m, 5H), 1.90 – 1.47 
(m, 6H), 1.32 – 0.81 (m, 5H). 
13C NMR (101 MHz, dmso) δ 162.67, 
161.88, 149.26, 148.43, 148.07, 129.83, 
126.27, 122.43, 115.82, 114.53, 109.20, 
73.30, 55.93, 37.44, 29.62, 26.45, 25.68, 
19.00. 
zh09 
 
(E)-4-(cyclohexylmethoxy)-N'-(3-
ethoxy-4-hydroxybenzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.50 (s, 1H), 9.40 
(s, 1H), 8.29 (s, 1H), 7.85 (d, J = 8.8 Hz, 2H), 
7.25 (s, 1H), 7.01 (dd, J = 16.7, 8.4 Hz, 3H), 6.82 
(d, J = 8.1 Hz, 1H), 4.02 (q, J = 6.8 Hz, 2H), 3.81 
(d, J = 6.2 Hz, 2H), 1.94 – 1.47 (m, 6H), 1.32 (t, J 
= 6.9 Hz, 3H), 1.24 – 0.84 (m, 5H). 
13C NMR (101 MHz, dmso) δ 162.72, 
161.89, 149.54, 148.16, 147.59, 129.83, 
126.29, 125.87, 122.35, 115.95, 114.52, 
110.70, 73.32, 64.29, 37.45, 29.62, 26.45, 
25.67, 15.16. 
zh10  
(E)-N'-(3-chloro-4-
hydroxybenzylidene)-4-
1H NMR (400 MHz, dmso) δ 11.63 (s, 1H), 10.69 
(s, 1H), 8.27 (s, 1H), 7.84 (d, J = 8.3 Hz, 2H), 
7.66 (s, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.00 (d, J = 
8.4 Hz, 3H), 3.82 (d, J = 6.1 Hz, 2H), 1.79 – 1.57 
(m, 6H), 1.24 – 0.96 (m, 5H). 
13C NMR (101 MHz, dmso) δ 162.78, 
161.96, 155.13, 146.29, 129.89, 128.64, 
127.56, 127.17, 125.63, 120.68, 117.27, 
114.54, 109.99, 73.31, 37.44, 29.62, 26.45, 
25.67. 
 
162 
 
(cyclohexylmethoxy) 
benzohydrazide 
zh11 
 
(E)-4-(cyclohexylmethoxy)-N'-(4-
hydroxy-3-nitrobenzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.75 (s, 1H), 11.45 
(s, 1H), 8.36 (s, 1H), 8.15 (s, 1H), 7.86 (t, J = 9.6 
Hz, 3H), 7.18 (d, J = 8.7 Hz, 1H), 7.01 (d, J = 7.9 
Hz, 2H), 3.82 (d, J = 6.1 Hz, 2H), 1.90 – 1.45 (m, 
6H), 1.32 – 0.82 (m, 5H). 
13C NMR (101 MHz, dmso) δ 162.88, 
162.04, 153.60, 145.37, 137.51, 133.26, 
129.97, 126.41, 125.49, 124.24, 120.07, 
114.56, 73.31, 37.43, 29.61, 26.45, 25.67. 
zh12 
 
(E)-N'-(3-chloro-4-hydroxy-5-
methoxybenzylidene)-4-
(cyclohexylmethoxy) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.66 (s, 1H), 9.93 
(s, 1H), 8.27 (s, 1H), 7.85 (d, J = 8.7 Hz, 2H), 
7.24 (s, 2H), 7.01 (d, J = 8.7 Hz, 2H), 3.86 (s, 
3H), 3.82 (d, J = 6.2 Hz, 2H), 1.85 – 1.50 (m, 
6H), 1.30 – 0.94 (m, 5H). 
13C NMR (101 MHz, dmso) δ 162.81, 
161.98, 149.33, 146.57, 145.01, 129.92, 
126.53, 125.64, 121.89, 120.38, 114.55, 
107.90, 73.31, 56.63, 37.44, 29.62, 26.45, 
25.68. 
zh13 
 
(E)-N'-(3-bromo-4-hydroxy-5-
methoxybenzylidene)-4-
(cyclohexylmethoxy) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.64 (s, 1H), 9.93 
(s, 1H), 8.27 (s, 1H), 7.85 (d, J = 8.7 Hz, 2H), 
7.37 (s, 1H), 7.28 (s, 1H), 7.00 (d, J = 8.7 Hz, 
2H), 3.86 (s, 3H), 3.81 (d, J = 6.2 Hz, 2H), 1.92 – 
1.48 (m, 6H), 1.32 – 0.88 (m, 5H). 
13C NMR (101 MHz, dmso) δ 162.84, 
161.98, 149.05, 146.46, 146.06, 129.91, 
127.25, 125.70, 124.64, 114.55, 109.77, 
108.60, 73.33, 56.65, 37.44, 29.62, 26.45, 
25.67. 
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zh14 
 
(E)-4-(cyclohexylmethoxy)-N'-(4-
hydroxy-3-iodo-5-
methoxybenzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.61 (s, 1H), 9.98 
(s, 1H), 8.24 (s, 1H), 7.84 (d, J = 8.7 Hz, 2H), 
7.55 (s, 1H), 7.28 (s, 1H), 7.00 (d, J = 8.7 Hz, 
2H), 3.84 (s, 3H), 3.82 (d, J = 6.3 Hz, 2H), 1.83 – 
1.54 (m, 6H), 1.28 – 0.92 (m, 5H). 
13C NMR (101 MHz, dmso) δ 162.83, 
161.97, 148.58, 147.71, 146.37, 130.35, 
129.90, 128.22, 125.72, 114.56, 109.45, 
84.88, 73.33, 56.54, 37.45, 29.62, 26.45, 
25.67. 
zh15 
 
(E)-N'-(4-chloro-3-
nitrobenzylidene)-4-
(cyclohexylmethoxy) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 12.01 (s, 1H), 8.48 
(s, 1H), 8.36 (s, 1H), 8.03 (d, J = 7.6 Hz, 1H), 
7.90 (d, J = 8.1 Hz, 2H), 7.84 (d, J = 8.3 Hz, 1H), 
7.05 (d, J = 8.4 Hz, 2H), 3.85 (d, J = 5.9 Hz, 2H), 
1.99 – 1.48 (m, 6H), 1.39 – 0.81 (m, 5H). 
13C NMR (101 MHz, dmso) δ 163.10, 
162.21, 148.33, 143.92, 135.60, 132.60, 
131.84, 130.12, 125.96, 125.19, 123.83, 
114.60, 73.34, 37.43, 29.61, 26.45, 25.67. 
zh16 
 
(E)-4-(cyclohexylmethoxy)-N'-(4-
fluorobenzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.72 (s, 1H), 8.40 
(s, 1H), 7.86 (d, J = 8.5 Hz, 2H), 7.79 – 7.69 (m, 
2H), 7.26 (t, J = 8.7 Hz, 2H), 7.01 (d, J = 8.6 Hz, 
2H), 3.82 (d, J = 6.2 Hz, 2H), 1.92 – 1.52 (m, 
6H), 1.32 – 0.88 (m, 5H). 
13C NMR (101 MHz, dmso) δ 162.90, 
162.03, 146.34, 131.51, 131.08, 129.94, 
129.59, 129.51, 125.52, 116.62, 116.43, 
116.21, 114.57, 73.31, 37.43, 29.61, 26.45, 
25.67. 
zh17 
 
1H NMR (400 MHz, dmso) δ 11.83 (s, 1H), 8.39 
(s, 1H), 7.87 (d, J = 8.4 Hz, 2H), 7.74 (s, 1H), 
7.64 (s, 1H), 7.45 (d, J = 4.3 Hz, 2H), 7.01 (d, J = 
13C NMR (101 MHz, dmso) δ 163.02, 
162.12, 145.73, 137.16, 134.06, 131.17, 
130.02, 126.58, 126.14, 125.39, 114.59, 
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(E)-N'-(3-chlorobenzylidene)-4-
(cyclohexylmethoxy) 
benzohydrazide 
8.6 Hz, 2H), 3.82 (d, J = 6.2 Hz, 2H), 1.85 – 1.48 
(m, 6H), 1.26 – 0.94 (m, 5H). 
73.33, 37.44, 29.61, 26.45, 25.67. 
zh18 
 
(E)-N'-(4-chloro-3-
fluorobenzylidene)-4-
(cyclohexylmethoxy) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.88 (s, 1H), 8.39 
(s, 1H), 7.86 (d, J = 8.5 Hz, 2H), 7.76 – 7.43 (m, 
3H), 7.01 (d, J = 8.8 Hz, 2H), 3.82 (d, J = 6.3 Hz, 
2H), 1.99 – 1.45 (m, 6H), 1.37 – 0.72 (m, 5H). 
13C NMR (101 MHz, dmso) δ 163.01, 
162.15, 159.08, 156.63, 144.99, 136.34, 
136.27, 131.56, 130.04, 125.31, 124.48, 
121.11, 115.03, 114.81, 114.58, 73.33, 37.43, 
29.61, 26.45, 25.67. 
zh19  
(E)-4-(cyclohexylmethoxy)-N'-
(3,4,5-trimethoxybenzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.70 (s, 1H), 8.35 
(s, 1H), 7.86 (d, J = 8.6 Hz, 2H), 7.09 – 6.83 (m, 
4H), 3.80 (s, 6H), 3.67 (s, 2H), 1.90 – 1.47 (m, 
6H), 1.32 – 0.73 (m, 5H). 
13C NMR (101 MHz, dmso) δ 162.92, 
162.00, 153.60, 147.54, 139.44, 130.42, 
129.95, 125.64, 114.57, 104.54, 73.32, 60.53, 
56.33, 37.43, 29.61, 26.45, 25.67. 
zh20  
(E)-4-(cyclohexylmethoxy)-N'-(2-
hydroxy-3-methoxy-5-
nitrobenzylidene) benzohydrazide 
1H NMR (400 MHz, dmso) δ 12.14 (s, 2H), 8.69 
(s, 1H), 8.22 (s, 1H), 7.89 (d, J = 8.2 Hz, 2H), 
7.75 (s, 1H), 7.03 (d, J = 8.3 Hz, 2H), 3.92 (s, 
3H), 3.83 (d, J = 6.1 Hz, 2H), 1.94 – 1.47 (m, 
6H), 1.35 – 0.73 (m, 5H). 
13C NMR (101 MHz, dmso) δ 162.83, 
162.31, 153.25, 148.54, 144.65, 139.92, 
130.11, 124.76, 119.52, 116.57, 114.68, 
107.50, 73.36, 56.84, 37.43, 29.61, 26.45, 
25.67. 
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zh21  
(E)-4-(cyclohexylmethoxy)-N'-(4-
hydroxy-3-methoxy-5-
nitrobenzylidene) benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.78 (s, 1H), 10.91 
(s, 1H), 8.35 (s, 1H), 7.86 (d, J = 8.7 Hz, 2H), 
7.72 (s, 1H), 7.55 (s, 1H), 7.01 (d, J = 8.7 Hz, 
2H), 3.92 (s, 3H), 3.82 (d, J = 6.2 Hz, 2H), 1.90 – 
1.54 (m, 6H), 1.32 – 0.88 (m, 5H). 
13C NMR (101 MHz, dmso) δ 162.92, 
162.04, 150.20, 145.75, 144.37, 137.58, 
129.98, 125.64, 125.51, 116.27, 114.57, 
112.41, 109.99, 73.32, 57.06, 37.43, 29.61, 
26.45, 25.67. 
zh22 
 
(E)-4-(cyclohexylmethoxy)-N'-(2-
hydroxy-3-methoxybenzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.94 (s, 1H), 11.07 
(s, 1H), 8.59 (s, 1H), 7.88 (d, J = 8.6 Hz, 2H), 
7.18 – 6.95 (m, 4H), 6.83 (t, J = 7.9 Hz, 1H), 3.83 
(d, J = 6.2 Hz, 2H), 3.78 (s, 3H), 1.89 – 1.48 (m, 
6H), 1.37 – 0.82 (m, 5H). 
13C NMR (101 MHz, dmso) δ 162.57, 
162.20, 148.33, 148.07, 147.55, 129.99, 
124.97, 121.32, 119.40, 119.33, 114.66, 
114.09, 73.35, 56.21, 37.44, 29.61, 26.45, 
25.67. 
zh23 
 
(E)-N'-(5-chloro-2-
hydroxybenzylidene)-4-
(cyclohexylmethoxy) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 12.05 (s, 1H), 11.35 
(s, 1H), 8.56 (s, 1H), 7.89 (d, J = 6.5 Hz, 2H), 
7.62 (s, 1H), 7.43 – 7.18 (m, 1H), 7.12 – 6.94 (m, 
2H), 6.92 (dd, J = 8.7, 2.7 Hz, 1H), 3.82 (dd, J = 
5.9, 2.8 Hz, 2H), 1.90 – 1.48 (m, 6H), 1.41 – 0.90 
(m, 5H). 
13C NMR (101 MHz, dmso) δ 162.73, 
162.26, 156.43, 145.71, 131.00, 130.06, 
128.12, 124.84, 123.33, 121.13, 118.62, 
114.64, 73.34, 37.43, 29.61, 26.44, 25.67. 
 
166 
 
zh24 
 
(E)-N'-(5-bromo-2-
hydroxybenzylidene)-4-
(cyclohexylmethoxy) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 12.05 (s, 1H), 11.35 
(s, 1H), 8.56 (s, 1H), 7.88 (d, J = 8.5 Hz, 2H), 
7.74 (s, 1H), 7.39 (dd, J = 8.7, 2.1 Hz, 1H), 7.02 
(d, J = 8.7 Hz, 2H), 6.87 (d, J = 8.7 Hz, 1H), 3.82 
(d, J = 6.2 Hz, 2H), 1.98 – 1.50 (m, 6H), 1.35 – 
0.88 (m, 5H). 
13C NMR (101 MHz, dmso) δ 162.73, 
162.25, 156.82, 145.51, 133.81, 130.94, 
130.06, 124.85, 121.76, 119.08, 114.65, 
110.81, 73.34, 37.43, 29.61, 26.45, 25.67. 
zh25  
(E)-N'-benzylidene-4-
propoxybenzohydrazide 
1H NMR (400 MHz, dmso) δ 11.70 (s, 1H), 8.41 
(s, 1H), 7.87 (d, J = 8.7 Hz, 2H), 7.69 (d, J = 6.4 
Hz, 2H), 7.42 (d, J = 7.3 Hz, 3H), 7.02 (d, J = 8.7 
Hz, 2H), 3.97 (t, J = 6.6 Hz, 2H), 1.72 (dd, J = 
14.1, 6.9 Hz, 2H), 0.95 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 162.93, 
161.88, 147.50, 134.87, 130.37, 129.96, 
129.27, 127.41, 125.62, 114.56, 69.62, 22.38, 
10.79. 
zh26  
(E)-N'-(4-hydroxybenzylidene)-4-
propoxybenzohydrazide 
1H NMR (400 MHz, dmso) δ 11.51 (s, 1H), 9.90 
(s, 1H), 8.30 (s, 1H), 7.85 (d, J = 7.0 Hz, 2H), 
7.51 (d, J = 7.4 Hz, 2H), 7.00 (d, J = 7.3 Hz, 2H), 
6.80 (d, J = 7.2 Hz, 2H), 3.95 (dd, J = 8.5, 4.3 Hz, 
2H), 1.71 (d, J = 6.9 Hz, 2H), 0.94 (t, J = 7.4 Hz, 
3H). 
13C NMR (101 MHz, dmso) δ 162.70, 
161.74, 159.71, 147.86, 129.84, 129.17, 
125.84, 116.10, 114.49, 69.58, 22.38, 10.79. 
zh27  
(E)-4-((2-(4-propoxybenzoyl) 
hydrazono) methyl) benzoic acid 
1H NMR (400 MHz, dmso) δ 13.07 (s, 1H), 11.86 
(s, 1H), 8.46 (s, 1H), 7.97 (d, J = 7.9 Hz, 2H), 
7.88 (d, J = 8.5 Hz, 2H), 7.80 (d, J = 7.7 Hz, 2H), 
7.02 (d, J = 8.7 Hz, 2H), 3.97 (t, J = 6.5 Hz, 2H), 
1.71 (dd, J = 14.0, 7.0 Hz, 2H), 0.95 (t, J = 7.4 
13C NMR (101 MHz, dmso) δ 167.35, 
163.04, 161.99, 161.48, 146.23, 138.94, 
137.89, 133.47, 131.95, 130.21, 130.06, 
128.95, 127.41, 125.43, 114.57, 69.63, 22.37, 
10.78. 
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Hz, 3H). 
zh28 
 
(E)-N'-(3-chloro-4-
hydroxybenzylidene)-4-
propoxybenzohydrazide 
1H NMR (400 MHz, dmso) δ 11.51 (s, 1H), 9.44 
(s, 1H), 8.28 (s, 1H), 7.84 (d, J = 8.6 Hz, 2H), 
7.25 (s, 1H), 7.01 (t, J = 9.5 Hz, 3H), 6.81 (d, J = 
8.1 Hz, 1H), 4.03 (dd, J = 13.6, 6.7 Hz, 2H), 3.96 
(t, J = 6.5 Hz, 2H), 1.71 (dd, J = 14.0, 6.9 Hz, 
2H), 1.33 (t, J = 6.8 Hz, 3H), 0.95 (t, J = 7.4 Hz, 
3H). 
13C NMR (101 MHz, dmso) δ 162.69, 
161.74, 149.49, 148.10, 147.58, 129.84, 
126.24, 125.86, 122.34, 115.91, 114.50, 
110.55, 69.59, 64.23, 22.38, 15.17, 10.79. 
zh29 
 
(E)-N'-(4-hydroxy-3-
nitrobenzylidene)-4-
propoxybenzohydrazide 
1H NMR (400 MHz, dmso) δ 11.75 (s, 1H), 11.48 
(s, 1H), 8.34 (d, J = 8.0 Hz, 1H), 8.15 (s, 1H), 
7.85 (d, J = 6.7 Hz, 3H), 7.17 (d, J = 10.9 Hz, 
1H), 7.01 (d, J = 6.5 Hz, 2H), 3.97 (dd, J = 6.3, 
3.5 Hz, 2H), 1.71 (dd, J = 11.2, 6.8 Hz, 2H), 0.95 
(t, J = 7.3, 3.0 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 161.90, 
160.24, 153.61, 145.38, 137.50, 133.26, 
129.97, 126.39, 125.54, 124.24, 120.08, 
114.54, 69.61, 22.37, 10.78. 
zh30  
(E)-N'-(3-chloro-4-hydroxy-5-
methoxybenzylidene)-4-
propoxybenzohydrazide 
1H NMR (400 MHz, dmso) δ 11.64 (s, 1H), 9.88 
(s, 1H), 8.28 (s, 1H), 7.85 (d, J = 7.7 Hz, 2H), 
7.24 (s, 2H), 7.01 (d, J = 7.9 Hz, 2H), 3.97 (t, J = 
6.1 Hz, 2H), 3.86 (s, 3H), 1.72 (dd, J = 13.6, 6.9 
Hz, 2H), 0.95 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 162.85, 
161.84, 149.36, 146.61, 145.03, 129.92, 
126.56, 125.74, 121.87, 120.42, 114.53, 
108.01, 69.63, 56.65, 22.38, 10.77. 
 
168 
 
zh31  
(E)-N'-(3-bromo-4-hydroxy-5-
methoxybenzylidene)-4-
propoxybenzohydrazide 
1H NMR (400 MHz, dmso) δ 11.67 (s, 1H), 9.97 
(s, 1H), 8.26 (s, 1H), 7.85 (d, J = 8.8 Hz, 2H), 
7.38 (s, 1H), 7.28 (s, 1H), 7.01 (d, J = 8.8 Hz, 
2H), 3.97 (t, J = 6.6 Hz, 2H), 3.86 (s, 3H), 1.71 
(dd, J = 14.1, 6.9 Hz, 2H), 0.95 (t, J = 7.4 Hz, 
3H). 
13C NMR (101 MHz, dmso) δ 162.84, 
161.83, 149.02, 146.45, 146.03, 129.93, 
127.21, 125.68, 124.66, 114.52, 109.74, 
108.50, 69.61, 56.63, 22.37, 10.79. 
zh32  
(E)-N'-(4-hydroxy-3-iodo-5-
methoxybenzylidene)-4-
propoxybenzohydrazide 
1H NMR (400 MHz, dmso) δ 11.65 (s, 1H), 10.03 
(s, 1H), 8.24 (s, 1H), 7.84 (d, J = 8.8 Hz, 2H), 
7.55 (s, 1H), 7.28 (s, 1H), 7.01 (d, J = 8.8 Hz, 
2H), 3.97 (t, J = 6.6 Hz, 2H), 3.84 (s, 3H), 1.71 
(d, J = 7.3 Hz, 2H), 0.95 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 162.83, 
161.82, 148.56, 147.67, 146.34, 130.37, 
129.92, 128.17, 125.69, 114.52, 109.34, 
84.90, 69.61, 56.51, 22.37, 10.79. 
zh33  
(E)-4-(pentyloxy)-N'-(3,4,5-
trimethoxybenzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.69 (s, 1H), 8.35 
(s, 1H), 7.86 (d, J = 7.5 Hz, 2H), 7.18 – 6.77 (m, 
4H), 4.00 (t, J = 5.7 Hz, 2H), 3.80 (s, 6H), 3.67 (s, 
3H), 1.92 – 1.54 (m, 2H), 1.54 – 1.19 (m, 4H), 
0.86 (t, J = 6.2 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 162.96, 
161.87, 153.60, 147.57, 139.49, 130.42, 
129.94, 125.70, 114.53, 104.57, 68.14, 60.52, 
56.33, 28.69, 28.09, 22.32, 14.34. 
zh34 
 
1H NMR (400 MHz, dmso) δ 11.74 (s, 1H), 8.45 
(s, 1H), 7.90 (d, J = 8.6 Hz, 2H), 7.72 (d, J = 6.4 
Hz, 2H), 7.45 (d, J = 7.3 Hz, 3H), 7.05 (d, J = 8.7 
13C NMR (101 MHz, dmso) δ 162.91, 
161.89, 147.48, 134.88, 130.35, 129.96, 
129.26, 127.41, 125.61, 114.54, 68.14, 
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(E)-N'-benzylidene-4-(pentyloxy) 
benzohydrazide 
Hz, 2H), 4.04 (t, J = 6.5 Hz, 2H), 1.84 – 1.57 (m, 
2H), 1.53 – 1.24 (m, 4H), 0.90 (t, J = 7.0 Hz, 3H). 
28.70, 28.09, 22.33, 14.37. 
zh35  
(E)-N'-(4-nitrobenzylidene)-4-
(pentyloxy) benzohydrazide 
1H NMR (400 MHz, dmso) δ 12.01 (s, 1H), 8.52 
(s, 1H), 8.28 (d, J = 8.5 Hz, 2H), 7.94 (dd, J = 
20.3, 7.7 Hz, 4H), 7.05 (d, J = 8.6 Hz, 2H), 4.03 
(t, J = 6.4 Hz, 2H), 1.92 – 1.57 (m, 2H), 1.48 – 
1.23 (m, 4H), 0.89 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 163.16, 
162.09, 148.11, 144.89, 141.24, 130.13, 
128.27, 125.24, 124.47, 114.57, 68.17, 28.69, 
28.08, 22.32, 14.33. 
zh36  
(E)-4-((2-(4-(pentyloxy) benzoyl) 
hydrazono)methyl) benzoic acid 
1H NMR (400 MHz, dmso) δ 13.04 (s, 1H), 11.86 
(s, 1H), 8.46 (s, 1H), 7.98 (d, J = 8.0 Hz, 2H), 
7.88 (d, J = 8.4 Hz, 2H), 7.80 (d, J = 7.5 Hz, 2H), 
7.01 (d, J = 8.6 Hz, 2H), 3.99 (t, J = 6.5 Hz, 2H), 
1.81 – 1.56 (m, 2H), 1.56 – 1.12 (m, 4H), 0.85 (t, 
J = 6.9 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 167.35, 
163.04, 162.00, 146.22, 138.95, 131.94, 
130.21, 130.05, 127.40, 125.41, 114.56, 
68.14, 28.70, 28.08, 22.33, 14.35. 
zh37 
 
(E)-4-(pentyloxy)-N'-(4-
(trifluoromethyl) benzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.94 (s, 1H), 8.51 
(s, 1H), 8.03 – 7.85 (m, 4H), 7.80 (d, J = 8.0 Hz, 
2H), 7.05 (d, J = 8.6 Hz, 2H), 4.03 (t, J = 6.5 Hz, 
2H), 1.93 – 1.68 (m, 2H), 1.50 – 1.24 (m, 4H), 
0.89 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 163.15, 
162.01, 145.63, 138.91, 130.06, 129.74, 
127.93, 126.13, 126.09, 126.05, 125.89, 
125.44, 123.19, 114.55, 68.14, 28.69, 28.08, 
22.32, 14.33. 
zh38  
(E)-N'-(4-hydroxy-3-
methoxybenzylidene)-4-
1H NMR (400 MHz, dmso) δ 11.52 (s, 1H), 9.52 
(s, 1H), 8.30 (s, 1H), 7.85 (d, J = 8.7 Hz, 2H), 
7.27 (s, 1H), 7.09 – 6.94 (m, 3H), 6.80 (d, J = 8.1 
Hz, 1H), 4.00 (t, J = 6.5 Hz, 2H), 3.79 (s, 3H), 
1.87 – 1.56 (m, 2H), 1.48 – 1.21 (m, 4H), 0.86 (t, 
13C NMR (101 MHz, dmso) δ 162.70, 
161.75, 149.27, 148.43, 148.09, 129.84, 
126.27, 125.85, 122.45, 115.82, 114.50, 
109.19, 68.11, 55.93, 28.70, 28.09, 22.33, 
14.37. 
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(pentyloxy) benzohydrazide J = 6.9 Hz, 3H). 
zh39 
 
(E)-N'-(3-ethoxy-4-
hydroxybenzylidene)-4-
(pentyloxy) benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.50 (s, 1H), 9.42 
(s, 1H), 8.28 (s, 1H), 7.84 (d, J = 8.5 Hz, 2H), 
7.25 (s, 1H), 7.14 – 6.90 (m, 3H), 6.81 (d, J = 7.9 
Hz, 1H), 4.01 (dd, J = 14.4, 7.6 Hz, 4H), 1.89 – 
1.52 (m, 2H), 1.52 – 1.15 (m, 6H), 0.86 (t, J = 6.8 
Hz, 3H). 
13C NMR (101 MHz, dmso) δ 162.70, 
161.74, 149.50, 148.12, 147.59, 129.83, 
126.26, 125.88, 122.33, 115.93, 114.50, 
110.62, 68.12, 64.26, 28.70, 28.09, 22.32, 
15.17, 14.35. 
zh40 
 
(E)-N'-(4-hydroxy-3-
nitrobenzylidene)-4-(pentyloxy) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.80 (s, 1H), 11.49 
(s, 1H), 8.40 (s, 1H), 8.19 (s, 1H), 7.91 (t, J = 9.5 
Hz, 3H), 7.22 (d, J = 8.7 Hz, 1H), 7.05 (d, J = 8.3 
Hz, 2H), 4.04 (t, J = 6.4 Hz, 2H), 1.87 – 1.61 (m, 
2H), 1.50 – 1.25 (m, 4H), 0.90 (t, J = 6.7 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 162.90, 
161.91, 153.59, 145.38, 137.51, 133.26, 
129.97, 126.40, 125.52, 124.24, 120.08, 
114.54, 68.14, 28.69, 28.09, 22.33, 14.37. 
zh41  
(E)-N'-(4-fluorobenzylidene)-4-
(pentyloxy) benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.72 (s, 2H), 8.41 
(s, 1H), 7.86 (d, J = 8.4 Hz, 2H), 7.74 (d, J = 5.5 
Hz, 2H), 7.26 (t, J = 8.6 Hz, 2H), 7.01 (d, J = 8.5 
Hz, 2H), 4.00 (t, J = 6.5 Hz, 2H), 1.87 – 1.57 (m, 
2H), 1.50 – 1.14 (m, 4H), 0.86 (t, J = 6.9 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 164.67, 
162.92, 162.20, 161.90, 146.34, 131.48, 
129.95, 129.59, 129.50, 125.57, 116.43, 
116.21, 114.54, 68.13, 28.70, 28.09, 22.32, 
14.36. 
zh42 
 
(E)-2-((2-(4-
(pentyloxy)benzoyl)hydrazono) 
methyl) benzoic acid 
1H NMR (400 MHz, dmso) δ 13.34 (s, 1H), 11.96 
(s, 1H), 9.18 (s, 1H), 8.07 (d, J = 7.6 Hz, 1H), 
7.99 – 7.81 (m, 3H), 7.63 (t, J = 7.5 Hz, 1H), 7.51 
(t, J = 7.4 Hz, 1H), 7.03 (d, J = 8.7 Hz, 2H), 4.03 
(t, J = 6.5 Hz, 2H), 1.86 – 1.51 (m, 2H), 1.49 – 
1.20 (m, 4H), 0.88 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 168.55, 
163.05, 161.93, 146.21, 135.21, 132.37, 
130.97, 130.72, 130.08, 129.84, 127.00, 
125.51, 114.47, 68.13, 28.70, 28.09, 22.32, 
14.35. 
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zh43  
(E)-N'-(2-hydroxy-3-methoxy-5-
nitrobenzylidene)-4-(pentyloxy) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 12.17 (s, 2H), 8.72 
(s, 1H), 8.24 (s, 1H), 7.92 (d, J = 8.5 Hz, 2H), 
7.77 (d, J = 2.2 Hz, 1H), 7.06 (d, J = 8.7 Hz, 2H), 
4.04 (t, J = 6.5 Hz, 2H), 3.95 (s, 3H), 1.83 – 1.57 
(m, 2H), 1.48 – 1.21 (m, 4H), 0.89 (t, J = 7.0 Hz, 
3H). 
13C NMR (101 MHz, dmso) δ 162.82, 
162.17, 153.25, 148.52, 144.63, 139.90, 
130.11, 124.77, 119.49, 116.56, 114.63, 
107.46, 68.18, 56.81, 28.69, 28.08, 22.33, 
14.36. 
zh44  
(E)-N'-(4-hydroxy-3-methoxy-5-
nitrobenzylidene)-4-(pentyloxy) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.82 (s, 1H), 10.92 
(s, 1H), 8.38 (s, 1H), 7.89 (d, J = 8.6 Hz, 2H), 
7.75 (s, 1H), 7.58 (s, 1H), 7.04 (d, J = 8.6 Hz, 
2H), 4.03 (t, J = 6.5 Hz, 2H), 3.95 (s, 3H), 1.88 – 
1.63 (m, 2H), 1.52 – 1.19 (m, 4H), 0.89 (t, J = 6.9 
Hz, 3H). 
13C NMR (101 MHz, dmso) δ 162.94, 
161.91, 150.20, 145.75, 144.39, 137.55, 
129.99, 125.64, 125.55, 116.27, 114.53, 
112.41, 68.14, 57.04, 28.69, 28.09, 22.33, 
14.35. 
zh45  
(E)-N'-(2-hydroxybenzylidene)-4-
(pentyloxy) benzohydrazide 
1H NMR (400 MHz, dmso) δ 12.01 (s, 1H), 11.39 
(s, 1H), 8.62 (s, 1H), 7.92 (d, J = 8.5 Hz, 2H), 
7.52 (d, J = 7.6 Hz, 1H), 7.28 (d, J = 7.7 Hz, 1H), 
7.06 (d, J = 8.3 Hz, 2H), 6.92 (t, J = 8.8 Hz, 2H), 
4.04 (t, J = 6.4 Hz, 2H), 1.93 – 1.57 (m, 2H), 1.37 
(td, J = 14.1, 6.7 Hz, 4H), 0.89 (t, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 162.61, 
162.08, 157.86, 148.15, 131.63, 130.00, 
124.95, 119.72, 119.11, 116.82, 114.63, 
68.17, 28.70, 28.09, 22.33, 14.36. 
zh46 
 
(E)-N'-(4-bromo-3-
1H NMR (400 MHz, dmso) δ 11.99 (s, 1H), 8.42 
(s, 1H), 8.27 (s, 1H), 7.90 (dd, J = 24.1, 8.1 Hz, 
4H), 7.00 (d, J = 7.9 Hz, 2H), 3.98 (t, J = 6.4 Hz, 
2H), 1.87 – 1.57 (m, 2H), 1.47 – 1.21 (m, 4H), 
13C NMR (101 MHz, dmso) δ 163.09, 
162.08, 150.36, 143.98, 136.07, 135.63, 
131.67, 130.12, 125.18, 123.67, 114.54, 
114.23, 68.15, 28.70, 28.08, 22.34, 14.35. 
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nitrobenzylidene)-4-(pentyloxy) 
benzohydrazide 
0.85 (t, J = 6.5 Hz, 3H). 
zh47  
(E)-N'-(4-nitrobenzylidene)-4-
(octyloxy) benzohydrazide 
1H NMR (400 MHz, dmso) δ 12.04 (s, 1H), 8.54 
(s, 1H), 8.31 (d, J = 8.7 Hz, 2H), 7.99 (d, J = 7.9 
Hz, 2H), 7.92 (d, J = 8.6 Hz, 2H), 7.07 (d, J = 8.8 
Hz, 2H), 4.05 (t, J = 6.5 Hz, 2H), 1.89 – 1.61 (m, 
2H), 1.41 (d, J = 7.6 Hz, 2H), 1.28 (d, J = 9.5 Hz, 
8H), 0.86 (t, J = 6.7 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 163.11, 
162.11, 148.14, 144.95, 141.24, 130.14, 
128.30, 125.23, 124.53, 114.61, 68.19, 31.68, 
29.17, 29.11, 28.99, 25.91, 22.53, 14.42. 
zh48  
(E)-4-((2-(4-(octyloxy)benzoyl) 
hydrazono) methyl) benzoic acid 
1H NMR (400 MHz, dmso) δ 13.10 (s, 1H), 11.89 
(s, 1H), 8.49 (s, 1H), 8.01 (d, J = 8.0 Hz, 2H), 
7.91 (d, J = 8.5 Hz, 2H), 7.83 (d, J = 7.5 Hz, 2H), 
7.05 (d, J = 8.7 Hz, 2H), 4.03 (t, J = 6.4 Hz, 2H), 
1.86 – 1.59 (m, 2H), 1.48 – 1.36 (m, 2H), 1.36 – 
1.16 (m, 8H), 0.85 (t, J = 6.6 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 167.34, 
163.02, 162.00, 146.21, 138.95, 131.95, 
130.21, 130.05, 127.40, 125.41, 114.56, 
68.16, 31.68, 29.18, 29.12, 29.00, 25.91, 
22.53, 14.41. 
zh49 
 
(E)-4-(octyloxy)-N'-(4-
(trifluoromethyl) benzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.93 (s, 2H), 8.51 
(s, 1H), 7.91 (d, J = 8.8 Hz, 4H), 7.81 (d, J = 7.9 
Hz, 2H), 7.05 (d, J = 8.5 Hz, 2H), 4.04 (t, J = 6.3 
Hz, 2H), 1.88 – 1.62 (m, 2H), 1.49 – 1.36 (m, 
2H), 1.36 – 1.17 (m, 8H), 0.86 (s, 3H). 
13C NMR (101 MHz, dmso) δ 163.08, 
162.02, 145.66, 138.89, 130.07, 129.77, 
127.96, 126.17, 126.13, 125.37, 114.59, 
68.17, 31.68, 29.17, 29.11, 29.00, 25.91, 
22.53, 14.41. 
zh50 
 
(E)-N'-(4-hydroxy-3-
1H NMR (400 MHz, dmso) δ 11.55 (s, 1H), 9.55 
(s, 1H), 8.33 (s, 1H), 7.88 (d, J = 8.7 Hz, 2H), 
7.30 (s, 1H), 7.15 – 6.95 (m, 3H), 6.84 (d, J = 8.1 
Hz, 1H), 4.03 (t, J = 6.5 Hz, 2H), 3.83 (s, 3H), 
13C NMR (101 MHz, dmso) δ 162.68, 
161.75, 149.27, 148.43, 148.08, 129.84, 
126.26, 125.84, 122.44, 115.82, 114.49, 
109.19, 68.12, 55.93, 31.68, 29.18, 29.12, 
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methoxybenzylidene)-4-(octyloxy) 
benzohydrazide 
1.84 – 1.59 (m, 2H), 1.41 (s, 2H), 1.26 (s, 8H), 
0.86 (t, J = 6.6 Hz, 3H). 
29.01, 25.92, 22.54, 14.41. 
zh51 
 
(E)-N'-(3-ethoxy-4-
hydroxybenzylidene)-4-(octyloxy) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.54 (s, 1H), 9.46 
(s, 1H), 8.31 (s, 1H), 7.88 (d, J = 8.6 Hz, 2H), 
7.29 (s, 1H), 7.04 (t, J = 11.4 Hz, 3H), 6.85 (d, J = 
8.0 Hz, 1H), 4.18 – 3.86 (m, 4H), 1.81 – 1.63 (m, 
2H), 1.48 – 1.15 (m, 12H), 0.85 (d, J = 6.4 Hz, 
3H). 
13C NMR (101 MHz, dmso) δ 162.70, 
161.75, 149.50, 148.12, 147.59, 129.83, 
126.26, 125.85, 122.33, 115.93, 114.50, 
110.63, 68.13, 64.26, 31.67, 29.16, 29.10, 
29.00, 25.91, 22.52, 15.16, 14.39. 
zh52 
 
(E)-N'-(4-hydroxy-3-
nitrobenzylidene)-4-(octyloxy) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.79 (s, 1H), 11.50 
(s, 1H), 8.39 (s, 1H), 8.19 (s, 1H), 7.90 (t, J = 9.6 
Hz, 3H), 7.21 (d, J = 8.7 Hz, 1H), 7.04 (d, J = 8.4 
Hz, 2H), 4.03 (t, J = 6.4 Hz, 2H), 1.83 – 1.65 (m, 
2H), 1.52 – 1.14 (m, 10H), 0.86 (t, J = 6.4 Hz, 
3H). 
13C NMR (101 MHz, dmso) δ 162.90, 
161.91, 153.61, 145.37, 137.50, 133.26, 
129.97, 126.40, 125.52, 124.24, 120.08, 
114.54, 68.14, 31.68, 29.17, 29.11, 29.00, 
25.91, 22.53, 14.41. 
zh53  
(E)-N'-(4-fluorobenzylidene)-4-
(octyloxy) benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.75 (s, 1H), 8.44 
(s, 1H), 7.90 (d, J = 8.2 Hz, 2H), 7.78 (s, 2H), 
7.29 (t, J = 8.5 Hz, 2H), 7.04 (d, J = 8.3 Hz, 2H), 
4.03 (t, J = 6.3 Hz, 2H), 1.81 – 1.63 (m, 2H), 1.48 
– 1.11 (m, 10H), 0.85 (d, J = 6.5 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 164.67, 
162.90, 162.20, 161.90, 146.32, 131.52, 
129.94, 129.59, 129.50, 125.57, 116.42, 
116.20, 114.53, 68.14, 31.68, 29.18, 29.12, 
29.01, 25.92, 22.53, 14.40. 
zh54  
(E)-2-((2-(4-(octyloxy)benzoyl) 
hydrazono) methyl) benzoic acid 
1H NMR (400 MHz, dmso) δ 13.28 (s, 1H), 11.96 
(s, 1H), 9.19 (s, 1H), 8.08 (d, J = 7.5 Hz, 1H), 
7.92 (dd, J = 11.6, 8.5 Hz, 3H), 7.64 (t, J = 7.4 
Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 7.04 (d, J = 8.8 
Hz, 2H), 4.03 (t, J = 6.5 Hz, 2H), 1.81 – 1.63 (m, 
13C NMR (101 MHz, dmso) δ 168.54, 
163.03, 161.93, 146.20, 135.21, 132.37, 
130.96, 130.71, 130.08, 129.84, 126.99, 
125.51, 114.47, 68.14, 31.67, 29.17, 29.11, 
29.01, 25.91, 22.52, 14.39. 
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2H), 1.48 – 1.15 (m, 10H), 0.86 (t, J = 6.7 Hz, 
3H). 
zh55  
(E)-N'-(2-hydroxy-3-methoxy-5-
nitrobenzylidene)-4-(octyloxy) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 12.15 (s, 2H), 8.69 
(s, 1H), 8.23 (s, 1H), 7.89 (d, J = 8.4 Hz, 2H), 
7.75 (d, J = 1.7 Hz, 1H), 7.03 (d, J = 8.5 Hz, 2H), 
4.01 (t, J = 6.4 Hz, 2H), 3.92 (s, 3H), 1.85 – 1.61 
(m, 2H), 1.47 – 1.34 (m, 2H), 1.34 – 1.10 (m, 
8H), 0.83 (t, J = 6.4 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 162.84, 
162.18, 153.27, 148.54, 144.61, 139.90, 
130.12, 124.78, 119.53, 116.53, 114.65, 
107.48, 68.19, 56.83, 31.68, 29.17, 29.11, 
28.99, 25.91, 22.53, 14.42. 
zh56  
(E)-N'-(4-hydroxy-3-methoxy-5-
nitrobenzylidene)-4-(octyloxy) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.82 (s, 1H), 10.90 
(s, 1H), 8.39 (s, 1H), 7.89 (d, J = 8.7 Hz, 2H), 
7.75 (s, 1H), 7.58 (s, 1H), 7.04 (d, J = 8.7 Hz, 
2H), 4.03 (t, J = 6.5 Hz, 2H), 3.96 (s, 3H), 1.89 – 
1.61 (m, 2H), 1.48 – 1.14 (m, 8H), 0.86 (t, J = 6.6 
Hz, 2H). 
13C NMR (101 MHz, dmso) δ 162.93, 
161.92, 150.20, 145.74, 144.39, 137.56, 
129.98, 125.63, 125.54, 116.27, 114.53, 
112.40, 68.15, 57.05, 31.68, 29.18, 29.12, 
29.00, 25.91, 22.53, 14.41. 
zh57  
(E)-N'-(2-hydroxybenzylidene)-4-
(octyloxy) benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.98 (s, 1H), 11.36 
(s, 1H), 8.58 (s, 1H), 7.88 (d, J = 8.6 Hz, 2H), 
7.49 (d, J = 7.5 Hz, 1H), 7.25 (d, J = 7.3 Hz, 1H), 
7.02 (d, J = 8.7 Hz, 2H), 6.89 (t, J = 8.5 Hz, 2H), 
4.00 (t, J = 6.5 Hz, 2H), 1.77 – 1.56 (m, 2H), 1.43 
– 1.12 (m, 10H), 0.82 (t, J = 6.7 Hz, 3H). 
13C NMR (101 MHz, dmso) δ 162.61, 
162.08, 157.86, 148.15, 131.64, 130.00, 
124.93, 119.72, 119.11, 116.82, 114.63, 
68.17, 31.68, 29.17, 29.12, 29.00, 25.91, 
22.53, 14.41. 
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zh58 
 
(E)-N'-(4-bromo-3-
nitrobenzylidene)-4-(octyloxy) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 12.00 (s, 1H), 8.43 
(s, 1H), 8.28 (s, 1H), 7.99 – 7.74 (m, 3H), 7.01 (d, 
J = 8.6 Hz, 2H), 4.00 (t, J = 6.4 Hz, 2H), 1.79 – 
1.57 (m, 2H), 1.47 – 1.14 (m, 10H), 0.82 (t, J = 
6.6 Hz, 2H). 
13C NMR (101 MHz, dmso) δ 163.10, 
162.09, 150.42, 144.01, 136.07, 135.66, 
131.66, 130.13, 125.19, 123.70, 114.58, 
114.23, 68.18, 31.69, 29.18, 29.12, 28.99, 
25.91, 22.54, 14.42. 
zh59  
(E)-4-(benzyloxy)-N'-(4-
nitrobenzylidene) benzohydrazide 
1H NMR (400 MHz, dmso) δ 12.05 (s, 1H), 8.54 
(s, 1H), 8.30 (d, J = 8.5 Hz, 2H), 7.98 (d, J = 7.7 
Hz, 2H), 7.93 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 7.5 
Hz, 2H), 7.41 (t, J = 7.4 Hz, 2H), 7.35 (d, J = 7.1 
Hz, 1H), 7.16 (d, J = 8.6 Hz, 2H), 5.21 (s, 2H). 
13C NMR (101 MHz, dmso) δ 163.16, 
161.70, 148.15, 145.01, 141.22, 137.00, 
130.15, 128.92, 128.42, 128.30, 128.23, 
125.66, 124.51, 115.03, 69.85. 
zh60  
(E)-4-((2-(4-(benzyloxy) benzoyl) 
hydrazono) methyl) benzoic acid 
1H NMR (400 MHz, dmso) δ 12.97 (s, 1H), 11.91 
(s, 1H), 8.49 (s, 1H), 8.01 (d, J = 8.1 Hz, 2H), 
7.92 (d, J = 8.5 Hz, 2H), 7.84 (d, J = 7.8 Hz, 2H), 
7.48 (d, J = 7.2 Hz, 2H), 7.41 (t, J = 7.4 Hz, 2H), 
7.34 (t, J = 7.2 Hz, 1H), 7.15 (d, J = 8.7 Hz, 2H), 
5.20 (s, 2H). 
13C NMR (101 MHz, dmso) δ 167.35, 
163.04, 161.60, 146.30, 138.92, 137.02, 
131.98, 130.22, 130.06, 128.91, 128.41, 
128.24, 127.42, 125.84, 115.01, 69.83. 
zh61 
 
(E)-4-(benzyloxy)-N'-(4-
(trifluoromethyl) benzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.95 (s, 1H), 8.53 
(s, 1H), 7.94 (s, 4H), 7.79 (d, J = 6.9 Hz, 2H), 
7.50 – 7.25 (m, 4H), 7.16 (d, J = 7.9 Hz, 2H), 
5.20 (s, 2H). 
13C NMR (101 MHz, dmso) δ 163.14, 
161.64, 145.76, 138.86, 137.01, 130.09, 
129.82, 128.88, 128.37, 128.18, 127.95, 
126.10, 125.84, 123.17, 114.99, 69.84. 
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zh62 
 
(E)-4-(benzyloxy)-N'-(4-hydroxy-
3-methoxybenzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.59 (s, 1H), 9.57 
(s, 1H), 8.33 (s, 1H), 7.90 (d, J = 8.8 Hz, 2H), 
7.56 – 7.25 (m, 6H), 7.23 – 6.98 (m, 3H), 6.85 (d, 
J = 8.1 Hz, 1H), 5.20 (s, 2H), 3.83 (s, 3H). 
13C NMR (101 MHz, dmso) δ 162.75, 
161.35, 149.30, 148.45, 148.20, 137.05, 
129.87, 128.91, 128.39, 128.21, 126.25, 
122.51, 115.83, 114.94, 109.20, 69.79, 55.92. 
zh63 
 
(E)-4-(benzyloxy)-N'-(4-hydroxy-
3-nitrobenzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.77 (s, 1H), 11.41 
(s, 1H), 8.36 (s, 1H), 8.16 (s, 1H), 7.87 (t, J = 7.4 
Hz, 3H), 7.37 (m, 5H), 7.18 (d, J = 8.7 Hz, 1H), 
7.11 (d, J = 8.6 Hz, 2H), 5.17 (s, 2H). 
13C NMR (101 MHz, dmso) δ 162.90, 
161.50, 153.63, 145.45, 137.51, 137.03, 
133.27, 129.98, 128.91, 128.41, 128.23, 
126.37, 125.94, 124.28, 120.09, 114.97, 
69.81. 
zh64 
 
(E)-4-(benzyloxy)-N'-(4-
fluorobenzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.77 (s, 1H), 8.44 
(s, 1H), 7.91 (d, J = 8.5 Hz, 2H), 7.85 – 7.70 (m, 
2H), 7.47 (d, J = 7.1 Hz, 2H), 7.41 (t, J = 7.3 Hz, 
2H), 7.35 (d, J = 7.1 Hz, 1H), 7.30 (t, J = 8.8 Hz, 
2H), 7.15 (d, J = 8.6 Hz, 2H), 5.20 (s, 2H). 
13C NMR (101 MHz, dmso) δ 164.68, 
162.92, 162.22, 161.49, 146.41, 137.04, 
131.47, 129.96, 129.61, 129.53, 128.91, 
128.40, 128.23, 126.00, 116.43, 116.22, 
114.97, 69.81. 
zh65  
(E)-2-((2-(4-(benzyloxy)benzoyl) 
hydrazono) methyl) benzoic acid 
1H NMR (400 MHz, dmso) δ 13.31 (s, 1H), 11.93 
(s, 1H), 9.15 (s, 1H), 8.04 (d, J = 7.6 Hz, 1H), 
7.98 – 7.74 (m, 3H), 7.60 (d, J = 7.5 Hz, 1H), 
7.53 – 7.26 (m, 6H), 7.11 (d, J = 8.8 Hz, 2H), 5.17 
(s, 2H). 
13C NMR (101 MHz, dmso) δ 168.54, 
163.05, 161.52, 146.30, 137.05, 135.18, 
132.39, 130.99, 130.72, 130.09, 129.88, 
128.91, 128.40, 128.23, 127.01, 125.94, 
114.91, 69.83. 
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zh66  
(E)-4-(benzyloxy)-N'-(2-hydroxy-
3-methoxy-5-nitrobenzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 12.14 (s, 2H), 8.68 
(s, 1H), 8.21 (s, 1H), 7.90 (d, J = 8.5 Hz, 2H), 
7.73 (d, J = 2.2 Hz, 1H), 7.44 (d, J = 7.1 Hz, 2H), 
7.37 (t, J = 7.3 Hz, 2H), 7.32 (d, J = 7.1 Hz, 1H), 
7.12 (d, J = 8.7 Hz, 2H), 5.17 (s, 2H), 3.92 (s, 
3H). 
13C NMR (101 MHz, dmso) δ 162.82, 
161.77, 153.25, 148.52, 144.68, 139.88, 
136.97, 130.12, 128.91, 128.42, 128.24, 
125.20, 119.48, 116.55, 115.05, 107.45, 
69.85, 56.80. 
zh67  
(E)-4-(benzyloxy)-N'-(4-hydroxy-
3-methoxy-5-nitrobenzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.83 (s, 1H), 10.89 
(s, 2H), 8.38 (s, 1H), 7.90 (d, J = 8.6 Hz, 2H), 
7.75 (s, 1H), 7.58 (s, 1H), 7.47 (d, J = 7.4 Hz, 
2H), 7.41 (t, J = 7.4 Hz, 2H), 7.35 (d, J = 7.0 Hz, 
1H), 7.14 (d, J = 8.6 Hz, 2H), 5.20 (s, 2H), 3.95 
(s, 3H). 
13C NMR (101 MHz, dmso) δ 162.94, 
161.50, 150.20, 145.83, 144.41, 137.57, 
137.03, 129.99, 128.91, 128.41, 128.22, 
125.96, 125.60, 116.31, 114.97, 112.39, 
69.80, 57.05. 
zh68 
 
(E)-4-(benzyloxy)-N'-(2-
hydroxybenzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.99 (s, 1H), 11.35 
(s, 1H), 8.58 (s, 1H), 7.90 (d, J = 8.1 Hz, 2H), 
7.50 (d, J = 7.5 Hz, 1H), 7.45 (d, J = 7.3 Hz, 1H), 
7.38 (t, J = 7.2 Hz, 1H), 7.32 (d, J = 6.9 Hz, 1H), 
7.25 (d, J = 7.7 Hz, 1H), 7.13 (d, J = 8.3 Hz, 2H), 
6.90 (d, J = 8.7 Hz, 2H), 5.17 (s, 2H). 
13C NMR (101 MHz, dmso) δ 162.61, 
161.67, 157.85, 148.18, 137.00, 131.67, 
130.01, 128.92, 128.43, 128.26, 125.38, 
119.74, 119.12, 116.83, 115.06, 69.85. 
zh69 
 
(E)-4-(benzyloxy)-N'-(4-bromo-3-
1H NMR (400 MHz, dmso) δ 12.05 (s, 1H), 8.46 
(s, 1H), 8.32 (s, 1H), 7.99 (d, J = 8.3 Hz, 1H), 
7.96 – 7.82 (m, 3H), 7.48 (d, J = 8.0 Hz, 2H), 
7.41 (t, J = 7.6 Hz, 2H), 7.38 – 7.29 (m, 1H), 7.15 
13C NMR (101 MHz, dmso) δ 163.11, 
161.67, 150.43, 144.12, 136.99, 136.04, 
135.66, 131.67, 130.13, 128.92, 128.42, 
128.24, 125.62, 123.73, 115.02, 114.27, 
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nitrobenzylidene) benzohydrazide (d, J = 8.4 Hz, 2H), 5.20 (s, 2H). 69.83. 
zh70  
(E)-4-((2-(4-((4-
bromobenzyl)oxy)benzoyl) 
hydrazono) methyl) benzoic acid 
1H NMR (400 MHz, dmso) δ 13.07 (s, 1H), 11.90 
(s, 1H), 8.48 (s, 1H), 8.00 (d, J = 8.0 Hz, 2H), 
7.91 (d, J = 8.5 Hz, 2H), 7.83 (d, J = 7.7 Hz, 2H), 
7.60 (d, J = 8.3 Hz, 2H), 7.43 (d, J = 8.3 Hz, 2H), 
7.14 (d, J = 8.7 Hz, 2H), 5.19 (s, 2H). 
13C NMR (101 MHz, dmso) δ 167.34, 
163.00, 161.37, 146.32, 138.91, 136.51, 
131.97, 131.84, 130.34, 130.22, 130.07, 
127.43, 125.98, 121.53, 115.03, 68.99. 
zh71  
(E)-4-((4-bromobenzyl)oxy)-N'-
(4-(trifluoromethyl)benzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.92 (s, 1H), 8.47 
(s, 1H), 7.89 (d, J = 7.9 Hz, 3H), 7.78 (d, J = 8.0 
Hz, 2H), 7.57 (d, J = 8.3 Hz, 1H), 7.40 (d, J = 8.3 
Hz, 1H), 7.11 (d, J = 8.7 Hz, 1H), 5.16 (s, 2H). 
13C NMR (101 MHz, dmso) δ 163.06, 
161.40, 145.76, 138.84, 136.50, 131.84, 
130.33, 130.09, 127.98, 126.17, 126.13, 
125.90, 123.19, 121.53, 115.03, 68.99. 
zh72  
(E)-2-((2-(4-((4-bromobenzyl) 
oxy) benzoyl) hydrazono) methyl) 
benzoic acid 
1H NMR (400 MHz, dmso) δ 13.12 (s, 1H), 11.97 
(s, 1H), 9.18 (s, 1H), 8.07 (d, J = 7.6 Hz, 1H), 
8.00 – 7.82 (m, 3H), 7.71 – 7.56 (m, 3H), 7.52 (t, 
J = 7.4 Hz, 1H), 7.44 (d, J = 8.4 Hz, 2H), 7.13 (d, 
J = 8.8 Hz, 2H), 5.19 (s, 2H). 
13C NMR (101 MHz, dmso) δ 168.54, 
163.01, 161.29, 146.32, 136.55, 135.16, 
132.39, 131.84, 130.99, 130.72, 130.32, 
130.10, 129.88, 127.00, 126.07, 121.52, 
114.93, 68.99. 
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zh73  
(E)-4-((4-bromobenzyl)oxy)-N'-
(2-hydroxy-3-methoxy-5-
nitrobenzylidene) benzohydrazide 
1H NMR (400 MHz, dmso) δ 12.18 (s, 1H), 12.06 
(s, 1H), 8.72 (s, 1H), 8.26 (d, J = 1.8 Hz, 1H), 
7.94 (d, J = 8.5 Hz, 2H), 7.78 (d, J = 2.2 Hz, 1H), 
7.61 (d, J = 8.2 Hz, 2H), 7.44 (d, J = 8.2 Hz, 2H), 
7.15 (d, J = 8.6 Hz, 2H), 5.19 (s, 2H), 3.96 (s, 
3H). 
13C NMR (101 MHz, dmso) δ 162.81, 
161.55, 153.26, 148.54, 144.66, 139.90, 
136.48, 131.84, 130.35, 130.14, 125.36, 
121.55, 119.53, 116.51, 115.09, 107.50, 
69.02, 56.83. 
zh74  
(E)-4-((4-bromobenzyl)oxy)-N'-
(4-hydroxy-3-methoxy-5-
nitrobenzylidene) benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.83 (s, 1H), 10.93 
(s, 1H), 8.38 (s, 1H), 7.90 (d, J = 8.6 Hz, 2H), 
7.75 (s, 1H), 7.60 (t, J = 7.2 Hz, 3H), 7.43 (d, J = 
8.2 Hz, 2H), 7.14 (d, J = 8.6 Hz, 2H), 5.19 (s, 
2H), 3.95 (s, 3H). 
13C NMR (101 MHz, dmso) δ 162.90, 
161.27, 150.20, 145.85, 144.40, 137.58, 
136.53, 131.84, 130.32, 130.00, 126.10, 
125.59, 121.52, 116.31, 115.00, 112.39, 
68.96, 57.06. 
zh75  
(E)-4-((4-bromobenzyl)oxy)-N'-
(2-hydroxybenzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 12.02 (s, 1H), 11.37 
(s, 1H), 8.62 (s, 1H), 7.93 (d, J = 8.6 Hz, 2H), 
7.61 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 7.2 Hz, 1H), 
7.44 (d, J = 8.3 Hz, 2H), 7.30 (t, J = 7.7 Hz, 1H), 
7.15 (d, J = 8.7 Hz, 2H), 6.99 – 6.85 (m, 2H), 
5.19 (s, 2H). 
13C NMR (101 MHz, dmso) δ 162.58, 
161.45, 157.85, 148.19, 136.49, 131.84, 
131.68, 130.35, 130.03, 129.97, 125.52, 
121.55, 119.74, 119.11, 116.83, 115.08, 
69.01. 
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zh76  
(E)-4-((2-(4-(3-phenylpropoxy) 
benzoyl) hydrazono) methyl) 
benzoic acid 
1H NMR (400 MHz, dmso) δ 13.10 (s, 1H), 11.90 
(s, 1H), 8.49 (s, 1H), 8.01 (d, J = 8.1 Hz, 2H), 
7.91 (d, J = 8.6 Hz, 2H), 7.84 (d, J = 7.6 Hz, 2H), 
7.35 – 7.13 (m, 5H), 7.07 (d, J = 8.7 Hz, 2H), 
4.05 (t, J = 6.3 Hz, 2H), 2.75 (t, J = 7.6 Hz, 2H), 
2.17 – 1.90 (m, 2H). 
13C NMR (101 MHz, dmso) δ 167.35, 
163.05, 161.92, 146.23, 141.70, 138.94, 
131.96, 130.22, 130.08, 128.79, 127.42, 
126.31, 125.56, 114.62, 67.38, 31.83, 30.70. 
zh77  
(E)-4-(3-phenylpropoxy)-N'-(4-
(trifluoromethyl) benzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.95 (s, 1H), 8.51 
(s, 1H), 7.93 (t, J = 8.4 Hz, 3H), 7.81 (d, J = 8.1 
Hz, 2H), 7.35 – 7.12 (m, 4H), 7.07 (d, J = 8.7 Hz, 
2H), 4.05 (t, J = 6.3 Hz, 2H), 2.90 – 2.61 (m, 2H), 
2.19 – 1.86 (m, 2H). 
13C NMR (101 MHz, dmso) δ 163.10, 
161.95, 145.68, 141.70, 138.87, 130.10, 
128.79, 128.78, 127.97, 126.31, 126.17, 
126.13, 125.90, 125.50, 123.20, 114.63, 
67.39, 31.83, 30.69. 
zh78  
(E)-2-((2-(4-(3-phenylpropoxy) 
benzoyl) hydrazono) methyl) 
benzoic acid 
1H NMR (400 MHz, dmso) δ 13.35 (s, 1H), 11.97 
(s, 1H), 9.19 (s, 1H), 8.08 (d, J = 7.5 Hz, 1H), 
7.92 (dd, J = 13.2, 8.3 Hz, 2H), 7.64 (t, J = 7.5 
Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 7.36 – 7.13 (m, 
3H), 7.05 (d, J = 8.7 Hz, 1H), 4.05 (t, J = 6.3 Hz, 
1H), 2.85 – 2.63 (m, 1H), 2.23 – 1.90 (m, 1H). 
13C NMR (101 MHz, dmso) δ 168.55, 
163.07, 161.84, 146.23, 141.71, 135.20, 
132.39, 130.98, 130.72, 130.11, 129.86, 
128.78, 127.00, 126.30, 125.65, 114.52, 
67.37, 31.84, 30.71. 
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zh79  
(E)-N'-(2-hydroxy-3-methoxy-5-
nitrobenzylidene)-4-(3-
phenylpropoxy) benzohydrazide 
1H NMR (400 MHz, dmso) δ 12.18 (s, 2H), 8.73 
(s, 1H), 8.26 (s, 1H), 7.93 (d, J = 8.4 Hz, 2H), 
7.78 (d, J = 1.8 Hz, 1H), 7.29 (t, J = 7.3 Hz, 2H), 
7.24 (d, J = 7.2 Hz, 2H), 7.19 (t, J = 7.2 Hz, 1H), 
7.07 (d, J = 8.6 Hz, 2H), 4.05 (t, J = 6.2 Hz, 2H), 
3.96 (s, 3H), 2.75 (t, J = 7.6 Hz, 2H), 2.14 – 1.95 
(m, 2H). 
13C NMR (101 MHz, dmso) δ 162.84, 
162.09, 153.25, 148.53, 144.62, 141.70, 
139.90, 130.15, 128.79, 128.78, 126.31, 
124.92, 119.53, 116.53, 114.68, 107.48, 
67.42, 56.83, 31.83, 30.69. 
zh80  
(E)-N'-(4-hydroxy-3-methoxy-5-
nitrobenzylidene)-4-(3-
phenylpropoxy) benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.83 (s, 1H), 10.93 
(s, 1H), 8.39 (s, 1H), 7.90 (d, J = 8.7 Hz, 2H), 
7.75 (s, 1H), 7.58 (s, 1H), 7.34 – 7.14 (m, 5H), 
7.05 (d, J = 8.7 Hz, 2H), 4.04 (t, J = 6.3 Hz, 2H), 
3.95 (s, 3H), 2.75 (t, J = 7.7 Hz, 2H), 2.10 – 1.83 
(m, 2H). 
13C NMR (101 MHz, dmso) δ 162.96, 
161.83, 150.19, 145.78, 144.40, 141.70, 
137.55, 130.02, 128.78, 126.30, 125.68, 
125.63, 116.30, 114.57, 112.39, 67.36, 57.04, 
31.83, 30.69. 
zh81  
(E)-N'-(4-bromo-3-
nitrobenzylidene)-4-(3-
phenylpropoxy) benzohydrazide 
1H NMR (400 MHz, dmso) δ 12.05 (s, 1H), 8.47 
(s, 1H), 8.32 (s, 1H), 8.04 – 7.84 (m, 3H), 7.36 – 
7.14 (m, 4H), 7.07 (d, J = 8.2 Hz, 2H), 4.05 (t, J = 
6.1 Hz, 2H), 2.75 (t, J = 7.5 Hz, 2H), 2.05 (dd, J = 
13.9, 6.7 Hz, 2H). 
13C NMR (101 MHz, dmso) δ 163.19, 
161.98, 160.19, 150.43, 144.02, 141.70, 
136.10, 135.65, 131.65, 130.16, 128.78, 
126.31, 125.43, 123.69, 114.62, 114.20, 
67.40, 31.83, 30.69. 
zh82 
 
1H NMR (400 MHz, dmso) δ 11.88 (s, 1H), 8.53 
(s, 1H), 7.94 (d, J = 7.4 Hz, 2H), 7.82 (d, J = 8.1 
Hz, 2H), 7.56 (d, J = 8.6 Hz, 1H), 7.50 (d, J = 1.7 
13C NMR (101 MHz, dmso) δ 163.11, 
152.19, 148.40, 145.74, 138.87, 130.10, 
127.96, 126.15, 125.50, 121.75, 113.20, 
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(E)-3,4-bis(pentyloxy)-N'-(4-
(trifluoromethyl)benzylidene) 
benzohydrazide 
Hz, 1H), 7.09 (d, J = 8.5 Hz, 1H), 4.03 (q, J = 6.0 
Hz, 4H), 1.83 – 1.61 (m, 4H), 1.52 – 1.23 (m, 
8H), 0.90 (t, J = 7.0 Hz, 6H). 
112.81, 68.97, 68.69, 28.87, 28.74, 28.22, 
28.19, 22.32, 14.40. 
zh83 
 
(E)-N'-(3-ethoxy-4-
hydroxybenzylidene)-3,4-
bis(pentyloxy) benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.48 (s, 2H), 9.44 
(s, 1H), 8.34 (s, 1H), 7.56 – 7.45 (m, 2H), 7.28 (s, 
1H), 7.06 (d, J = 8.3 Hz, 2H), 6.85 (d, J = 8.1 Hz, 
1H), 4.22 – 3.84 (m, 7H), 1.88 – 1.56 (m, 5H), 
1.48 – 1.21 (m, 11H), 0.90 (t, J = 6.9 Hz, 6H). 
13C NMR (101 MHz, dmso) δ 162.72, 
149.55, 148.25, 147.58, 126.26, 122.31, 
121.55, 118.08, 115.97, 113.28, 112.93, 
110.79, 69.04, 68.73, 64.31, 28.89, 28.76, 
28.22, 28.18, 22.31, 15.17, 14.37. 
zh84 
 
(E)-N'-(3-chloro-4-
hydroxybenzylidene)-3,4-
bis(pentyloxy) benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.62 (s, 2H), 10.73 
(s, 1H), 8.33 (s, 1H), 7.70 (s, 1H), 7.58 – 7.41 (m, 
3H), 7.06 (t, J = 7.7 Hz, 2H), 4.17 – 3.91 (m, 4H), 
1.85 – 1.61 (m, 4H), 1.54 – 1.21 (m, 8H), 0.90 (t, 
J = 7.0 Hz, 6H). 
13C NMR (101 MHz, dmso) δ 162.82, 
155.11, 151.97, 148.37, 146.38, 128.64, 
127.55, 127.19, 125.82, 121.56, 120.68, 
117.26, 113.16, 112.79, 68.95, 68.67, 28.89, 
28.75, 28.23, 28.19, 22.34, 22.33, 14.40. 
zh85  
(E)-N'-(2-hydroxy-3-methoxy-5-
nitrobenzylidene)-3,4-
bis(pentyloxy) benzohydrazide 
1H NMR (400 MHz, dmso) δ 12.11 (s, 2H), 8.74 
(s, 1H), 8.26 (s, 1H), 7.79 (d, J = 2.4 Hz, 1H), 
7.57 (d, J = 8.1 Hz, 1H), 7.51 (s, 1H), 7.09 (d, J = 
8.5 Hz, 1H), 4.03 (q, J = 6.1 Hz, 4H), 3.96 (s, 
3H), 1.92 – 1.61 (m, 4H), 1.52 – 1.21 (m, 8H), 
0.90 (t, J = 7.0 Hz, 6H). 
13C NMR (101 MHz, dmso) δ 162.89, 
153.23, 152.34, 148.56, 148.42, 144.53, 
139.92, 124.90, 121.83, 119.58, 116.43, 
113.15, 112.82, 107.50, 68.96, 68.69, 56.84, 
28.86, 28.73, 28.22, 28.18, 22.34, 22.32, 
14.41. 
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zh86 
 
(E)-3,4,5-tris(benzyloxy)-N'-(4-
nitrobenzylidene) benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.79 (s, 1H), 11.51 
(s, 1H), 8.44 (s, 1H), 8.21 (s, 1H), 7.94 (d, J = 8.1 
Hz, 1H), 7.58 – 7.09 (m, 18H), 5.21 (s, 4H), 5.03 
(s, 2H). 
13C NMR (101 MHz, dmso) δ 162.86, 
153.75, 152.51, 146.13, 140.54, 137.81, 
137.55, 137.19, 133.35, 128.89, 128.62, 
128.51, 128.40, 128.33, 128.13, 126.23, 
124.34, 120.13, 107.33, 74.71, 70.90. 
zh87  
(E)-4-((2-(3,4,5-tris(benzyloxy) 
benzoyl) hydrazono) methyl) 
benzoic acid 
1H NMR (400 MHz, dmso) δ 13.13 (s, 1H), 11.93 
(s, 1H), 8.56 (s, 1H), 8.04 (d, J = 7.5 Hz, 2H), 
7.87 (d, J = 7.2 Hz, 2H), 7.61 – 7.01 (m, 17H), 
5.22 (s, 4H), 5.04 (s, 2H). 
13C NMR (101 MHz, dmso) δ 167.36, 
163.03, 152.55, 146.96, 140.66, 138.77, 
137.82, 137.19, 132.18, 130.25, 128.89, 
128.63, 128.51, 128.40, 128.32, 128.14, 
127.52, 109.99, 107.41, 74.74, 70.93. 
zh88  
(E)-3,4,5-tris(benzyloxy)-N'-(4-
(trifluoromethyl) benzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.94 (s, 1H), 8.56 
(s, 1H), 7.96 (d, J = 7.7 Hz, 2H), 7.83 (d, J = 7.9 
Hz, 2H), 7.61 – 7.17 (m, 16H), 5.22 (s, 4H), 5.04 
(s, 2H). 
13C NMR (101 MHz, dmso) δ 163.05, 
152.54, 146.39, 140.68, 138.71, 137.81, 
137.19, 128.89, 128.78, 128.62, 128.51, 
128.40, 128.33, 128.13, 128.07, 126.21, 
126.17, 125.89, 123.18, 107.43, 74.73, 
70.93. 
zh89 
 
1H NMR (400 MHz, dmso) δ 13.39 (s, 1H), 11.97 
(s, 1H), 9.23 (s, 1H), 8.09 (d, J = 7.6 Hz, 1H), 
7.92 (d, J = 7.7 Hz, 1H), 7.76 – 7.08 (m, 17H), 
5.22 (s, 4H), 5.04 (s, 2H). 
13C NMR (101 MHz, dmso) δ 168.55, 
163.02, 152.50, 146.80, 140.57, 137.84, 
137.23, 135.10, 132.45, 131.03, 130.76, 
130.04, 128.88, 128.62, 128.51, 128.39, 
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(E)-2-((2-(3,4,5-tris(benzyloxy) 
benzoyl) hydrazono) methyl) 
benzoic acid 
128.32, 128.15, 127.17, 107.46, 74.72, 
70.93. 
zh90  
(E)-3,4,5-tris(benzyloxy)-N'-(4-
fluorobenzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.77 (s, 1H), 8.49 
(s, 1H), 7.94 – 7.73 (m, 2H), 7.60 – 7.14 (m, 
19H), 5.22 (s, 4H), 5.04 (s, 2H). 
13C NMR (101 MHz, dmso) δ 164.79, 
162.85, 162.33, 152.52, 147.06, 140.53, 
137.82, 137.20, 131.36, 131.33, 129.72, 
129.64, 128.97, 128.89, 128.62, 128.51, 
128.40, 128.32, 128.13, 116.49, 116.27, 
107.31, 74.72, 70.89. 
zh91  
(E)-3,4,5-tris(benzyloxy)-N'-
(3,4,5-trimethoxybenzylidene) 
benzohydrazide 
1H NMR (400 MHz, dmso) δ 11.72 (s, 1H), 8.43 
(s, 1H), 7.40 (ddd, J = 50.0, 33.3, 5.9 Hz, 15H), 
7.04 (s, 2H), 5.21 (s, 4H), 5.03 (s, 2H), 3.84 (s, 
6H), 3.72 (s, 3H). 
13C NMR (101 MHz, dmso) δ 162.87, 
153.64, 152.50, 148.39, 140.50, 139.67, 
137.82, 137.20, 130.21, 129.09, 128.89, 
128.63, 128.52, 128.40, 128.33, 128.12, 
107.32, 104.71, 74.72, 70.89, 60.56, 56.38. 
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Appendix II. Calculated formula weight (F.W.), Calculated molecular weight for 
protonated compounds (MH)+, and experimental results by High Performance 
mass spectrum (HPMS) (Found) 
Table II-1. Calculated F.W., (MH)+ and HPMS of  2-cyano-3-phenylacrylic acid 
derivatives (Chapter 3)  
V Possible Protonated Structures 
Calculated 
F.W. 
Calculated 
(MH)+ 
Found 
v01 
 
346.1529 347.1601 347.1597 
v02 
 
360.1685 361.1758 361.1758 
v03 
 
374.1842 375.1914 375.1909 
v04 
 
299.1270 300.1343 300.1340 
 
186 
 
v05 
 
313.1426 314.1499 314.1489 
v06 
 
327.1583 328.1656 328.1650 
v07 
 
287.1521 288.1594 288.1593 
v08 
 
301.1678 302.1751 302.1757 
v9 
 
315.1834 316.1907 316.1911 
v10 
 
268.1576 269.1648 269.1651 
 
187 
 
v11 
 
286.1681 287.1754 287.1759 
v12 
 
409.0889 410.0961 410.0968 
v13 
 
362.0630 363.0703 363.0711 
v14 
 
423.1040 424.1118 424.1112 
v15 
 
355.1890 356.1969 356.1964 
v16 
 
395.0732 396.0805 396.0804 
 
188 
 
v17 
 
437.1202 438.1274 438.1270 
v18 
 
390.0943 391.1016 391.1011 
v19 
 
577.2767 578.2839 578.2838 
v20 
 
530.2508 531.2581 531.2580 
v21 
 
303.1471 304.1543 304.1553 
v22 
 
256.1212 257.1285 257.1298 
 
189 
 
v23 
 
331.1784 332.1856 332.1871 
v24 
 
284.1525 285.1598 285.1604 
v25 
 
303.1471 304.1543 304.1550 
v26 
 
387.2410 388.2482 388.2498 
v27 
 
359.2097 360.2169 360.2177 
v28 
 
358.2256 359.2329 359.2328 
 
190 
 
v29 
 
340.2151 341.2224 341.2222 
v30 
 
402.2155 403.2227 403.2237 
v31 
 
302.1630 303.1703 303.1703 
v32 
 
272.1525 273.1598 273.1604 
v33 
 
345.1940 346.2013 346.2021 
v34 
 
290.1630 291.1703 291.1711 
 
191 
 
v35 
 
240.1263 241.1335 241.1343 
v36 
 
254.1419 255.1482 255.1490 
v37 
 
275.1158 276.1230 276.1228 
v38 
 
274.1317 275.1390 275.1383 
v39 
 
343.1784 344.1856 344.1856 
v40 
 
296.1525 297.1598 297.1607 
 
192 
 
v41 
 
314.1630 315.1703 315.1703 
v42 
 
317.1627 318.1700 318.1696 
v43 
 
270.1368 271.1441 271.1437 
v44 
 
265.1314 266.1387 266.1378 
v45 
 
289.1314 290.1387 290.1388 
v46 
 
337.1314 338.1387 338.1389 
 
193 
 
v47 
 
290.1055 291.1128 291.1132 
v48 
 
308.1161 309.1234 309.1241 
v49 
 
352.1059 353.1132 353.1140 
v50 
 
284.1525 285.1598 285.1602 
v51 
 
300.1474 301.1547 301.1550 
v52 
 
317.1376 318.1448 318.1454 
 
194 
 
v53 
 
549.2454 550.2526 550.2512 
v54 
 
486.3094 487.3166 487.3164 
v55 
 
514.3407 515.3479 515.3479 
v56 
 
485.3254 486.3326 486.3233 
v57 
 
347.1733 348.1805 348.1811 
v58 
 
326.1994 327.2067 327.2065 
 
195 
 
Table II-2. Calculated F.W., (MH)+ and HPMS of 1, 3-Diphenylpyrazole 
derivatives (Chapter 4) 
 
Structures of Pyrazole 
compounds.  
Calculated 
F.W. 
Calculate
d (MH) + 
Found 
py01 
 
393.0880 394.0953 394.0926 
py02 
 
387.1583 388.1656 388.1641 
py03 
 
421.1193 422.1266 422.1235 
py04 
 
449.1506 450.1579 450.1558 
py05 
 
443.2209 444.2282 444.2252 
py06 
 
477.1819 478.1892 478.1861 
 
196 
 
py07 
 
471.2522 472.2595 472.2576 
py08 
 
505.2132 506.2205 506.2177 
py09 
 
421.1426 422.1499 422.1486 
py10 
 
374.0934 375.1007 377.0881 
py11 
 
368.1637 369.1710 369.1681 
py12 
 
402.1427 403.1320 403.1326 
py13 
 
430.1560 431.1633 431.1640 
 
197 
 
py14 
 
424.2263 425.2336 425.2339 
py15 
 
458.1873 459.1946 459.1956 
py16 
 
452.2576 453.2649 453.2655 
py17 
 
486.2186 487.2259 487.2265 
py18 
 
402.1481 403.1553 403.1553 
py19 
 
436.0938 437.1011 437.1001 
 
198 
 
py20 
 
430.1641 431.1714 431.1715 
py21 
 
464.1251 465.1324 465.1315 
py22 
 
492.1564 439.1637 439.1632 
py23 
 
486.2267 487.2340 487.2333 
py24 
 
520.1877 521.1950 521.1949 
py25 
 
514.2580 515.2653 515.2645 
 
199 
 
py26 
 
548.2190 549.2263 549.2259 
py27 
 
464.1485 465.1557 465.1553 
py28 
 
358.1066 359.1139 359.1134 
py29 
 
452.0710 453.0783 453.0781 
py30 
 
446.1413 447.1485 447.1478 
py31 
 
480.1023 481.1096 481.1095 
 
200 
 
py32 
 
508.1336 509.1409 509.1403 
py33 
 
502.2039 503.2111 503.2107 
py34 
 
536.1649 537.1722 537.1714 
py35 
 
530.2352 531.2424 531.2419 
py36 
 
564.1962 565.2035 565.2029 
py37 
 
480.1256 481.1329 481.1339 
 
201 
 
py38 
 
374.0837 375.0910 379.0907 
py39 
 
458.1954 459.2027 459.2026 
py40 
 
492.1564 493.1637 493.1651 
py41 
 
514.2580 515.2653 515.2655 
py42 
 
548.2190 549.2263 549.2252 
py43 
 
542.2893 543.2966 543.2964 
 
202 
 
py44 
 
576.2503 577.2576 577.2578 
py45 
 
392.1040 393.1113 393.1117 
py46 
 
448.1666 449.1739 449.1740 
py47 
 
421.1193 422.1266 422.1269 
py48 
 
477.1819 478.1892 478.1889 
py49 
 
425.0601 426.0674 426.0674 
 
203 
 
py50 
 
481.1227 482.1300 482.1303 
py51 
 
347.0728 348.0801 348.0803 
py52 
 
441.0372 442.0445 442.0448 
py53 
 
497.0998 498.1071 498.1072 
py54 
 
363.0500 364.0573 364.0579 
py55 
 
483.0656 484.0728 484.0728 
 
204 
 
py56 
 
539.1282 540.1354 540.1352 
 
 
Table II-3. Calculated F.W., (MH)+ and HPMS of hydrazide derivatives. 
(Chapter 5) 
No. Hydrazide structures 
Calculated 
F.W. 
Calculated 
(MH)+ 
Found 
zh01 
 
336.1383 337.1911 337.1913 
zh02 
 
352.1787 353.1860 353.1863 
zh03 
 
380.1736 381.1809 381.1805 
zh04 
 
381.1689 382.1761 382.1759 
zh05 
 
380.1736 381.1809 381.1804 
 
205 
 
zh06 
 
404.1712 405.1784 405.1781 
zh07 
 
366.1943 367.2016 367.2012 
zh08 
 
382.1893 383.1965 383.1953 
zh09 
 
396.2046 397.2122 397.2115 
zh10 
 
386.1397 387.1470 387.1462 
zh11 
 
397.1638 398.1710 398.1710 
zh12 
 
416.1503 417.1576 417.1574 
zh13 
 
460.0998 461.1070 461.1068 
 
206 
 
zh14 
 
508.0859 509.0932 509.0928 
zh15 
 
445.1299 416.1372 416.1360 
zh16 
 
345.1744 355.1816 355.1816 
zh17 
 
370.1448 371.1521 371.1521 
zh18 
 
388.1354 389.1427 389.1425 
zh19 
 
426.2155 427.2227 427.2223 
zh20 
 
427.1743 428.1816 428.1817 
 
207 
 
zh21 
 
427.1743 428.1816 428.1614 
zh22 
 
382.1893 383.1965 383.1963 
zh23 
 
386.1397 387.1470 387.1471 
zh24 
 
430.0892 431.0965 431.0961 
zh25 
 
282.1368 283.1441 283.1441 
zh26 
 
298.1317 299.1390 299.1390 
zh27 
 
326.1267 327.1339 327.1339 
zh28 
 
342.1580 343.1652 343.1644 
 
208 
 
zh29 
 
343.1168 344.1241 344.1230 
zh30 
 
362.1033 363.1106 363.1096 
zh31 
 
406.0528 407.0601 407.0584 
zh32 
 
454.0390 455.0462 455.0451 
zh33 
 
400.1998 401.2071 401.2068 
zh34 
 
310.1681 311.1754 311.1745 
zh35 
 
355.1532 356.1605 356.1596 
zh36 
 
354.1580 355.1652 355.1655 
 
209 
 
zh37 
 
378.1555 379.1628 379.1623 
zh38 
 
356.1736 357.1809 357.1811 
zh39 
 
370.1893 371.1965 371.1965 
zh40 
 
371.1481 372.1554 372.1553 
zh41 
 
328.1587 329.1660 329.1656 
zh42 
 
354.1580 355.1652 355.1654 
zh43 
 
401.1587 402.1660 402.1655 
zh44 
 
401.1587 402.1660 402.1655 
 
210 
 
zh45 
 
326.1630 327.1703 327.1701 
zh46 
 
433.0637 434.0710 434.0704 
zh47 
 
397.2002 398.2074 398.2070 
zh48 
 
396.2049 397.2122 397.2123 
zh49 
 
420.2025 421.2097 421.2095 
zh50 
 
398.2206 399.2278 399.2274 
zh51 
 
412.2362 413.2435 413.2436 
zh52 
 
413.1951 414.2023 414.2023 
 
211 
 
zh53 
 
370.2057 371.2129 371.2130 
zh54 
 
396.2049 397.2122 397.2121 
zh55 
 
443.2056 444.2129 444.2130 
zh56 
 
443.2056 444.2129 444.2130 
zh57 
 
368.2100 369.2173 369.2178 
zh58 
 
475.1107 476.1179 476.1194 
zh59 
 
375.1219 376.1292 376.1300 
zh60 
 
374.1267 375.1339 375.1348 
 
212 
 
zh61 
 
398.1242 399.1315 399.1518 
zh62 
 
376.1423 377.1496 377.1496 
zh63 
 
391.1168 392.1241 392.1238 
zh64 
 
348.1274 349.1347 349.1344 
zh65 
 
374.1267 375.1339 375.1339 
zh66 
 
421.1274 422.1347 422.1346 
zh67 
 
421.1274 422.1347 422.1346 
zh68 
 
346.1317 347.1390 347.1394 
 
213 
 
zh69 
 
453.0324 454.0397 454.0394 
zh70 
 
452.0372 453.0444 453.0442 
zh71 
 
476.0347 477.0420 477.0428 
zh72 
 
452.0372 453.0444 453.0463 
zh73 
 
499.0379 500.0452 500.0466 
zh74 
 
499.0379 500.0452 500.0472 
zh75 
 
424.0423 425.0495 425.0509 
 
214 
 
zh76 
 
402.1580 403.1652 403.1657 
zh77 
 
426.1555 427.1628 427.1637 
zh78 
 
402.1580 403.1652 403.1659 
zh79 
 
449.1587 450.1660 450.1673 
zh80 
 
449.1587 450.1660 450.1670 
zh81 
 
481.0637 482.0710 482.0707 
zh82 
 
464.2287 465.2360 465.2360 
 
215 
 
zh83 
 
456.2624 457.2697 457.2700 
zh84 
 
446.1972 447.2045 447.2046 
zh85 
 
487.2319 488.2391 604.2069 
zh86 
 
587.2056 588.2129 604.2077 
zh87 
 
586.2104 587.2177 587.2176 
zh88 
 
610.2079 611.2152 611.2150 
zh89 
 
586.2104 587.2177 587.2178 
 
216 
 
zh90 
 
560.2111 561.2184 561.2184 
zh91 
 
632.2523 633.2595 633.2590 
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